qkkoiqzmmoekmsucamsizckosibihcpmoswgwavi length 6 402294 page 402294 <!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><meta name="generator" content="Gatsby 5.12.11"/><meta data-react-helmet="true" name="application-name" content="COVID-19 Treatment Guidelines"/><meta data-react-helmet="true" property="og:title" content="Immunocompromised | COVID-19 Treatment Guidelines"/><meta data-react-helmet="true" name="twitter:title" content="Immunocompromised | COVID-19 Treatment Guidelines"/><meta data-react-helmet="true" id="desc" name="description" content="Read about the management of COVID-19 in people who are immunocompromised."/><meta data-react-helmet="true" name="theme-color" content="#065fa9"/><meta data-react-helmet="true" property="og:url" content="https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/"/><meta data-react-helmet="true" name="twitter:url" content="https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/"/><meta data-react-helmet="true" property="og:image" content="https://files.covid19treatmentguidelines.nih.gov/images/social.jpg"/><meta data-react-helmet="true" name="twitter:image" content="https://files.covid19treatmentguidelines.nih.gov/images/social.jpg"/><meta data-react-helmet="true" property="og:description" content="Read about the management of COVID-19 in people who are immunocompromised."/><meta data-react-helmet="true" name="twitter:description" content="Read about the management of COVID-19 in people who are immunocompromised."/><meta data-react-helmet="true" property="og:site_name" content="COVID-19 Treatment Guidelines"/><meta data-react-helmet="true" name="twitter:card" content="summary_large_image"/><meta data-react-helmet="true" name="twitter:site" content="@NIHCOVIDTxGuide"/><meta data-react-helmet="true" property="og:type" content="website"/><style data-href="/styles.aeb6d5f5e1e3e0b710f1.css" data-identity="gatsby-global-css">@font-face{font-display:swap;font-family:Public Sans;font-style:normal;font-weight:400;src:url(/static/public-sans-v7-latin-regular-4063c1d7b1b3a9f07cf6a6241fe86cf6.woff2) format("woff2"),url(/static/public-sans-v7-latin-regular-8615d05e4495612b2aa5bd21d93fd88b.woff) format("woff"),url(/static/public-sans-v7-latin-regular-a992ed78cde8e532eaba1ee25101714b.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}@font-face{font-display:swap;font-family:Public Sans;font-style:normal;font-weight:500;src:url(/static/public-sans-v7-latin-500-14db0e1ccdf5be8a7b17a335f1172ba0.woff2) format("woff2"),url(/static/public-sans-v7-latin-500-2218db3d172414494b44edb022f6a22a.woff) format("woff"),url(/static/public-sans-v7-latin-500-7ebb54f4a9b6bdd03a1cc70b1d338387.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}@font-face{font-display:swap;font-family:Public Sans;font-style:normal;font-weight:700;src:url(/static/public-sans-v7-latin-700-1428a70e32a54a579dd6bcef986e327b.woff2) format("woff2"),url(/static/public-sans-v7-latin-700-6a4027198768af70fc24c4b6d382488d.woff) format("woff"),url(/static/public-sans-v7-latin-700-f616bc4693482ca3bea97c6211ce2148.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}@font-face{font-display:swap;font-family:Public Sans;font-style:italic;font-weight:400;src:url(/static/public-sans-v7-latin-italic-4b4ac60fbb9489e287e60525f27580d9.woff2) format("woff2"),url(/static/public-sans-v7-latin-italic-7f14bb09ba9146193452d3ab19d8c5e4.woff) format("woff"),url(/static/public-sans-v7-latin-italic-e0631ce1dda5b1fe6a9347391b37f428.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}@font-face{font-display:swap;font-family:Public Sans;font-style:italic;font-weight:500;src:url(/static/public-sans-v7-latin-500italic-ccaf87bfe99e2b91026d535008d79d3c.woff2) format("woff2"),url(/static/public-sans-v7-latin-500italic-025b9e66ebde66bce17b7b35c26113ef.woff) format("woff"),url(/static/public-sans-v7-latin-500italic-726a99280a91f46ef6910a33c51c4229.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}@font-face{font-display:swap;font-family:Public Sans;font-style:italic;font-weight:700;src:url(/static/public-sans-v7-latin-700italic-ee88dc5a7fb9e0ad1fdfbe6c8711fa3b.woff2) format("woff2"),url(/static/public-sans-v7-latin-700italic-33a906b61a67315f7581c1ee20824267.woff) format("woff"),url(/static/public-sans-v7-latin-700italic-6c807988cc34ef0a5ea4ab622cfabe6e.ttf) format("truetype");unicode-range:u+00??,u+0131,u+0152-0153,u+02bb-02bc,u+02c6,u+02da,u+02dc,u+2000-206f,u+2074,u+20ac,u+2122,u+2191,u+2193,u+2212,u+2215,u+feff,u+fffd}
/*!
 * Bootstrap v4.5.3 (https://getbootstrap.com/)
 * Copyright 2011-2020 The Bootstrap Authors
 * Copyright 2011-2020 Twitter, Inc.
 * Licensed under MIT (https://github.com/twbs/bootstrap/blob/main/LICENSE)
 */:root{--blue:#007bff;--indigo:#6610f2;--purple:#6f42c1;--pink:#e83e8c;--red:#dc3545;--orange:#fd7e14;--yellow:#ffc107;--green:#28a745;--teal:#20c997;--cyan:#17a2b8;--white:#fff;--gray:#6c757d;--gray-dark:#343a40;--primary:#007bff;--secondary:#6c757d;--success:#28a745;--info:#17a2b8;--warning:#ffc107;--danger:#dc3545;--light:#f8f9fa;--dark:#343a40;--breakpoint-xs:0;--breakpoint-sm:576px;--breakpoint-md:768px;--breakpoint-lg:992px;--breakpoint-xl:1200px;--font-family-sans-serif:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,"Helvetica Neue",Arial,"Noto Sans",sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol","Noto Color Emoji";--font-family-monospace:SFMono-Regular,Menlo,Monaco,Consolas,"Liberation Mono","Courier New",monospace}*,:after,:before{box-sizing:border-box}html{-webkit-text-size-adjust:100%;-webkit-tap-highlight-color:transparent;font-family:sans-serif;line-height:1.15}article,aside,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}body{background-color:#fff;color:#212529;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji;font-size:1rem;font-weight:400;line-height:1.5;margin:0;text-align:left}[tabindex="-1"]:focus:not(:focus-visible){outline:0!important}hr{box-sizing:content-box;height:0;overflow:visible}h1,h2,h3,h4,h5,h6{margin-bottom:.5rem;margin-top:0}p{margin-bottom:1rem;margin-top:0}abbr[data-original-title],abbr[title]{border-bottom:0;cursor:help;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted;-webkit-text-decoration-skip-ink:none;text-decoration-skip-ink:none}address{font-style:normal;line-height:inherit}address,dl,ol,ul{margin-bottom:1rem}dl,ol,ul{margin-top:0}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}dt{font-weight:700}dd{margin-bottom:.5rem;margin-left:0}blockquote{margin:0 0 1rem}b,strong{font-weight:bolder}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}a{background-color:transparent;color:#007bff;text-decoration:none}a:hover{color:#0056b3;text-decoration:underline}a:not([href]):not([class]),a:not([href]):not([class]):hover{color:inherit;text-decoration:none}code,kbd,pre,samp{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}pre{-ms-overflow-style:scrollbar;margin-bottom:1rem;margin-top:0;overflow:auto}figure{margin:0 0 1rem}img{border-style:none}img,svg{vertical-align:middle}svg{overflow:hidden}caption{caption-side:bottom;color:#6c757d;padding-bottom:.75rem;padding-top:.75rem;text-align:left}th{text-align:inherit;text-align:-webkit-match-parent}label{display:inline-block;margin-bottom:.5rem}button{border-radius:0}button:focus{outline:1px dotted;outline:5px auto -webkit-focus-ring-color}button,input,optgroup,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit;margin:0}button,input{overflow:visible}button,select{text-transform:none}[role=button]{cursor:pointer}select{word-wrap:normal}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]:not(:disabled),[type=reset]:not(:disabled),[type=submit]:not(:disabled),button:not(:disabled){cursor:pointer}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}input[type=checkbox],input[type=radio]{box-sizing:border-box;padding:0}textarea{overflow:auto;resize:vertical}fieldset{border:0;margin:0;min-width:0;padding:0}legend{color:inherit;display:block;font-size:1.5rem;line-height:inherit;margin-bottom:.5rem;max-width:100%;padding:0;white-space:normal;width:100%}progress{vertical-align:baseline}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:none;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}output{display:inline-block}summary{cursor:pointer;display:list-item}template{display:none}[hidden]{display:none!important}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-weight:500;line-height:1.2;margin-bottom:.5rem}.h1,h1{font-size:2.5rem}.h2,h2{font-size:2rem}.h3,h3{font-size:1.75rem}.h4,h4{font-size:1.5rem}.h5,h5{font-size:1.25rem}.h6,h6{font-size:1rem}.lead{font-size:1.25rem;font-weight:300}.display-1{font-size:6rem}.display-1,.display-2{font-weight:300;line-height:1.2}.display-2{font-size:5.5rem}.display-3{font-size:4.5rem}.display-3,.display-4{font-weight:300;line-height:1.2}.display-4{font-size:3.5rem}hr{border:0;border-top:1px solid rgba(0,0,0,.1);margin-bottom:1rem;margin-top:1rem}.small,small{font-size:80%;font-weight:400}.mark,mark{background-color:#fcf8e3;padding:.2em}.list-inline,.list-unstyled{list-style:none;padding-left:0}.list-inline-item{display:inline-block}.list-inline-item:not(:last-child){margin-right:.5rem}.initialism{font-size:90%;text-transform:uppercase}.blockquote{font-size:1.25rem;margin-bottom:1rem}.blockquote-footer{color:#6c757d;display:block;font-size:80%}.blockquote-footer:before{content:"\2014\00A0"}.img-fluid,.img-thumbnail{height:auto;max-width:100%}.img-thumbnail{background-color:#fff;border:1px solid #dee2e6;border-radius:.25rem;padding:.25rem}.figure{display:inline-block}.figure-img{line-height:1;margin-bottom:.5rem}.figure-caption{color:#6c757d;font-size:90%}code{word-wrap:break-word;color:#e83e8c;font-size:87.5%}a>code{color:inherit}kbd{background-color:#212529;border-radius:.2rem;color:#fff;font-size:87.5%;padding:.2rem .4rem}kbd kbd{font-size:100%;font-weight:700;padding:0}pre{color:#212529;display:block;font-size:87.5%}pre code{color:inherit;font-size:inherit;word-break:normal}.pre-scrollable{max-height:340px;overflow-y:scroll}.container,.container-fluid,.container-lg,.container-md,.container-sm,.container-xl{margin-left:auto;margin-right:auto;padding-left:15px;padding-right:15px;width:100%}@media (min-width:576px){.container,.container-sm{max-width:540px}}@media (min-width:768px){.container,.container-md,.container-sm{max-width:720px}}@media (min-width:992px){.container,.container-lg,.container-md,.container-sm{max-width:960px}}@media (min-width:1200px){.container,.container-lg,.container-md,.container-sm,.container-xl{max-width:1140px}}.row{display:flex;flex-wrap:wrap;margin-left:-15px;margin-right:-15px}.no-gutters{margin-left:0;margin-right:0}.no-gutters>.col,.no-gutters>[class*=col-]{padding-left:0;padding-right:0}.col,.col-1,.col-10,.col-11,.col-12,.col-2,.col-3,.col-4,.col-5,.col-6,.col-7,.col-8,.col-9,.col-auto,.col-lg,.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-lg-auto,.col-md,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-md-auto,.col-sm,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-sm-auto,.col-xl,.col-xl-1,.col-xl-10,.col-xl-11,.col-xl-12,.col-xl-2,.col-xl-3,.col-xl-4,.col-xl-5,.col-xl-6,.col-xl-7,.col-xl-8,.col-xl-9,.col-xl-auto{padding-left:15px;padding-right:15px;position:relative;width:100%}.col{flex-basis:0;flex-grow:1;max-width:100%}.row-cols-1>*{flex:0 0 100%;max-width:100%}.row-cols-2>*{flex:0 0 50%;max-width:50%}.row-cols-3>*{flex:0 0 33.333333%;max-width:33.333333%}.row-cols-4>*{flex:0 0 25%;max-width:25%}.row-cols-5>*{flex:0 0 20%;max-width:20%}.row-cols-6>*{flex:0 0 16.666667%;max-width:16.666667%}.col-auto{flex:0 0 auto;max-width:100%;width:auto}.col-1{flex:0 0 8.333333%;max-width:8.333333%}.col-2{flex:0 0 16.666667%;max-width:16.666667%}.col-3{flex:0 0 25%;max-width:25%}.col-4{flex:0 0 33.333333%;max-width:33.333333%}.col-5{flex:0 0 41.666667%;max-width:41.666667%}.col-6{flex:0 0 50%;max-width:50%}.col-7{flex:0 0 58.333333%;max-width:58.333333%}.col-8{flex:0 0 66.666667%;max-width:66.666667%}.col-9{flex:0 0 75%;max-width:75%}.col-10{flex:0 0 83.333333%;max-width:83.333333%}.col-11{flex:0 0 91.666667%;max-width:91.666667%}.col-12{flex:0 0 100%;max-width:100%}.order-first{order:-1}.order-last{order:13}.order-0{order:0}.order-1{order:1}.order-2{order:2}.order-3{order:3}.order-4{order:4}.order-5{order:5}.order-6{order:6}.order-7{order:7}.order-8{order:8}.order-9{order:9}.order-10{order:10}.order-11{order:11}.order-12{order:12}.offset-1{margin-left:8.333333%}.offset-2{margin-left:16.666667%}.offset-3{margin-left:25%}.offset-4{margin-left:33.333333%}.offset-5{margin-left:41.666667%}.offset-6{margin-left:50%}.offset-7{margin-left:58.333333%}.offset-8{margin-left:66.666667%}.offset-9{margin-left:75%}.offset-10{margin-left:83.333333%}.offset-11{margin-left:91.666667%}@media (min-width:576px){.col-sm{flex-basis:0;flex-grow:1;max-width:100%}.row-cols-sm-1>*{flex:0 0 100%;max-width:100%}.row-cols-sm-2>*{flex:0 0 50%;max-width:50%}.row-cols-sm-3>*{flex:0 0 33.333333%;max-width:33.333333%}.row-cols-sm-4>*{flex:0 0 25%;max-width:25%}.row-cols-sm-5>*{flex:0 0 20%;max-width:20%}.row-cols-sm-6>*{flex:0 0 16.666667%;max-width:16.666667%}.col-sm-auto{flex:0 0 auto;max-width:100%;width:auto}.col-sm-1{flex:0 0 8.333333%;max-width:8.333333%}.col-sm-2{flex:0 0 16.666667%;max-width:16.666667%}.col-sm-3{flex:0 0 25%;max-width:25%}.col-sm-4{flex:0 0 33.333333%;max-width:33.333333%}.col-sm-5{flex:0 0 41.666667%;max-width:41.666667%}.col-sm-6{flex:0 0 50%;max-width:50%}.col-sm-7{flex:0 0 58.333333%;max-width:58.333333%}.col-sm-8{flex:0 0 66.666667%;max-width:66.666667%}.col-sm-9{flex:0 0 75%;max-width:75%}.col-sm-10{flex:0 0 83.333333%;max-width:83.333333%}.col-sm-11{flex:0 0 91.666667%;max-width:91.666667%}.col-sm-12{flex:0 0 100%;max-width:100%}.order-sm-first{order:-1}.order-sm-last{order:13}.order-sm-0{order:0}.order-sm-1{order:1}.order-sm-2{order:2}.order-sm-3{order:3}.order-sm-4{order:4}.order-sm-5{order:5}.order-sm-6{order:6}.order-sm-7{order:7}.order-sm-8{order:8}.order-sm-9{order:9}.order-sm-10{order:10}.order-sm-11{order:11}.order-sm-12{order:12}.offset-sm-0{margin-left:0}.offset-sm-1{margin-left:8.333333%}.offset-sm-2{margin-left:16.666667%}.offset-sm-3{margin-left:25%}.offset-sm-4{margin-left:33.333333%}.offset-sm-5{margin-left:41.666667%}.offset-sm-6{margin-left:50%}.offset-sm-7{margin-left:58.333333%}.offset-sm-8{margin-left:66.666667%}.offset-sm-9{margin-left:75%}.offset-sm-10{margin-left:83.333333%}.offset-sm-11{margin-left:91.666667%}}@media (min-width:768px){.col-md{flex-basis:0;flex-grow:1;max-width:100%}.row-cols-md-1>*{flex:0 0 100%;max-width:100%}.row-cols-md-2>*{flex:0 0 50%;max-width:50%}.row-cols-md-3>*{flex:0 0 33.333333%;max-width:33.333333%}.row-cols-md-4>*{flex:0 0 25%;max-width:25%}.row-cols-md-5>*{flex:0 0 20%;max-width:20%}.row-cols-md-6>*{flex:0 0 16.666667%;max-width:16.666667%}.col-md-auto{flex:0 0 auto;max-width:100%;width:auto}.col-md-1{flex:0 0 8.333333%;max-width:8.333333%}.col-md-2{flex:0 0 16.666667%;max-width:16.666667%}.col-md-3{flex:0 0 25%;max-width:25%}.col-md-4{flex:0 0 33.333333%;max-width:33.333333%}.col-md-5{flex:0 0 41.666667%;max-width:41.666667%}.col-md-6{flex:0 0 50%;max-width:50%}.col-md-7{flex:0 0 58.333333%;max-width:58.333333%}.col-md-8{flex:0 0 66.666667%;max-width:66.666667%}.col-md-9{flex:0 0 75%;max-width:75%}.col-md-10{flex:0 0 83.333333%;max-width:83.333333%}.col-md-11{flex:0 0 91.666667%;max-width:91.666667%}.col-md-12{flex:0 0 100%;max-width:100%}.order-md-first{order:-1}.order-md-last{order:13}.order-md-0{order:0}.order-md-1{order:1}.order-md-2{order:2}.order-md-3{order:3}.order-md-4{order:4}.order-md-5{order:5}.order-md-6{order:6}.order-md-7{order:7}.order-md-8{order:8}.order-md-9{order:9}.order-md-10{order:10}.order-md-11{order:11}.order-md-12{order:12}.offset-md-0{margin-left:0}.offset-md-1{margin-left:8.333333%}.offset-md-2{margin-left:16.666667%}.offset-md-3{margin-left:25%}.offset-md-4{margin-left:33.333333%}.offset-md-5{margin-left:41.666667%}.offset-md-6{margin-left:50%}.offset-md-7{margin-left:58.333333%}.offset-md-8{margin-left:66.666667%}.offset-md-9{margin-left:75%}.offset-md-10{margin-left:83.333333%}.offset-md-11{margin-left:91.666667%}}@media (min-width:992px){.col-lg{flex-basis:0;flex-grow:1;max-width:100%}.row-cols-lg-1>*{flex:0 0 100%;max-width:100%}.row-cols-lg-2>*{flex:0 0 50%;max-width:50%}.row-cols-lg-3>*{flex:0 0 33.333333%;max-width:33.333333%}.row-cols-lg-4>*{flex:0 0 25%;max-width:25%}.row-cols-lg-5>*{flex:0 0 20%;max-width:20%}.row-cols-lg-6>*{flex:0 0 16.666667%;max-width:16.666667%}.col-lg-auto{flex:0 0 auto;max-width:100%;width:auto}.col-lg-1{flex:0 0 8.333333%;max-width:8.333333%}.col-lg-2{flex:0 0 16.666667%;max-width:16.666667%}.col-lg-3{flex:0 0 25%;max-width:25%}.col-lg-4{flex:0 0 33.333333%;max-width:33.333333%}.col-lg-5{flex:0 0 41.666667%;max-width:41.666667%}.col-lg-6{flex:0 0 50%;max-width:50%}.col-lg-7{flex:0 0 58.333333%;max-width:58.333333%}.col-lg-8{flex:0 0 66.666667%;max-width:66.666667%}.col-lg-9{flex:0 0 75%;max-width:75%}.col-lg-10{flex:0 0 83.333333%;max-width:83.333333%}.col-lg-11{flex:0 0 91.666667%;max-width:91.666667%}.col-lg-12{flex:0 0 100%;max-width:100%}.order-lg-first{order:-1}.order-lg-last{order:13}.order-lg-0{order:0}.order-lg-1{order:1}.order-lg-2{order:2}.order-lg-3{order:3}.order-lg-4{order:4}.order-lg-5{order:5}.order-lg-6{order:6}.order-lg-7{order:7}.order-lg-8{order:8}.order-lg-9{order:9}.order-lg-10{order:10}.order-lg-11{order:11}.order-lg-12{order:12}.offset-lg-0{margin-left:0}.offset-lg-1{margin-left:8.333333%}.offset-lg-2{margin-left:16.666667%}.offset-lg-3{margin-left:25%}.offset-lg-4{margin-left:33.333333%}.offset-lg-5{margin-left:41.666667%}.offset-lg-6{margin-left:50%}.offset-lg-7{margin-left:58.333333%}.offset-lg-8{margin-left:66.666667%}.offset-lg-9{margin-left:75%}.offset-lg-10{margin-left:83.333333%}.offset-lg-11{margin-left:91.666667%}}@media (min-width:1200px){.col-xl{flex-basis:0;flex-grow:1;max-width:100%}.row-cols-xl-1>*{flex:0 0 100%;max-width:100%}.row-cols-xl-2>*{flex:0 0 50%;max-width:50%}.row-cols-xl-3>*{flex:0 0 33.333333%;max-width:33.333333%}.row-cols-xl-4>*{flex:0 0 25%;max-width:25%}.row-cols-xl-5>*{flex:0 0 20%;max-width:20%}.row-cols-xl-6>*{flex:0 0 16.666667%;max-width:16.666667%}.col-xl-auto{flex:0 0 auto;max-width:100%;width:auto}.col-xl-1{flex:0 0 8.333333%;max-width:8.333333%}.col-xl-2{flex:0 0 16.666667%;max-width:16.666667%}.col-xl-3{flex:0 0 25%;max-width:25%}.col-xl-4{flex:0 0 33.333333%;max-width:33.333333%}.col-xl-5{flex:0 0 41.666667%;max-width:41.666667%}.col-xl-6{flex:0 0 50%;max-width:50%}.col-xl-7{flex:0 0 58.333333%;max-width:58.333333%}.col-xl-8{flex:0 0 66.666667%;max-width:66.666667%}.col-xl-9{flex:0 0 75%;max-width:75%}.col-xl-10{flex:0 0 83.333333%;max-width:83.333333%}.col-xl-11{flex:0 0 91.666667%;max-width:91.666667%}.col-xl-12{flex:0 0 100%;max-width:100%}.order-xl-first{order:-1}.order-xl-last{order:13}.order-xl-0{order:0}.order-xl-1{order:1}.order-xl-2{order:2}.order-xl-3{order:3}.order-xl-4{order:4}.order-xl-5{order:5}.order-xl-6{order:6}.order-xl-7{order:7}.order-xl-8{order:8}.order-xl-9{order:9}.order-xl-10{order:10}.order-xl-11{order:11}.order-xl-12{order:12}.offset-xl-0{margin-left:0}.offset-xl-1{margin-left:8.333333%}.offset-xl-2{margin-left:16.666667%}.offset-xl-3{margin-left:25%}.offset-xl-4{margin-left:33.333333%}.offset-xl-5{margin-left:41.666667%}.offset-xl-6{margin-left:50%}.offset-xl-7{margin-left:58.333333%}.offset-xl-8{margin-left:66.666667%}.offset-xl-9{margin-left:75%}.offset-xl-10{margin-left:83.333333%}.offset-xl-11{margin-left:91.666667%}}.table{color:#212529;margin-bottom:1rem;width:100%}.table td,.table th{border-top:1px solid #dee2e6;padding:.75rem;vertical-align:top}.table thead th{border-bottom:2px solid #dee2e6;vertical-align:bottom}.table tbody+tbody{border-top:2px solid #dee2e6}.table-sm td,.table-sm th{padding:.3rem}.table-bordered,.table-bordered td,.table-bordered th{border:1px solid #dee2e6}.table-bordered thead td,.table-bordered thead th{border-bottom-width:2px}.table-borderless tbody+tbody,.table-borderless td,.table-borderless th,.table-borderless thead th{border:0}.table-striped tbody tr:nth-of-type(odd){background-color:rgba(0,0,0,.05)}.table-hover tbody tr:hover{background-color:rgba(0,0,0,.075);color:#212529}.table-primary,.table-primary>td,.table-primary>th{background-color:#b8daff}.table-primary tbody+tbody,.table-primary td,.table-primary th,.table-primary thead th{border-color:#7abaff}.table-hover .table-primary:hover,.table-hover .table-primary:hover>td,.table-hover .table-primary:hover>th{background-color:#9fcdff}.table-secondary,.table-secondary>td,.table-secondary>th{background-color:#d6d8db}.table-secondary tbody+tbody,.table-secondary td,.table-secondary th,.table-secondary thead th{border-color:#b3b7bb}.table-hover .table-secondary:hover,.table-hover .table-secondary:hover>td,.table-hover .table-secondary:hover>th{background-color:#c8cbcf}.table-success,.table-success>td,.table-success>th{background-color:#c3e6cb}.table-success tbody+tbody,.table-success td,.table-success th,.table-success thead th{border-color:#8fd19e}.table-hover .table-success:hover,.table-hover .table-success:hover>td,.table-hover .table-success:hover>th{background-color:#b1dfbb}.table-info,.table-info>td,.table-info>th{background-color:#bee5eb}.table-info tbody+tbody,.table-info td,.table-info th,.table-info thead th{border-color:#86cfda}.table-hover .table-info:hover,.table-hover .table-info:hover>td,.table-hover .table-info:hover>th{background-color:#abdde5}.table-warning,.table-warning>td,.table-warning>th{background-color:#ffeeba}.table-warning tbody+tbody,.table-warning td,.table-warning th,.table-warning thead th{border-color:#ffdf7e}.table-hover .table-warning:hover,.table-hover .table-warning:hover>td,.table-hover .table-warning:hover>th{background-color:#ffe8a1}.table-danger,.table-danger>td,.table-danger>th{background-color:#f5c6cb}.table-danger tbody+tbody,.table-danger td,.table-danger th,.table-danger thead th{border-color:#ed969e}.table-hover .table-danger:hover,.table-hover .table-danger:hover>td,.table-hover .table-danger:hover>th{background-color:#f1b0b7}.table-light,.table-light>td,.table-light>th{background-color:#fdfdfe}.table-light tbody+tbody,.table-light td,.table-light th,.table-light thead th{border-color:#fbfcfc}.table-hover .table-light:hover,.table-hover .table-light:hover>td,.table-hover .table-light:hover>th{background-color:#ececf6}.table-dark,.table-dark>td,.table-dark>th{background-color:#c6c8ca}.table-dark tbody+tbody,.table-dark td,.table-dark th,.table-dark thead th{border-color:#95999c}.table-hover .table-dark:hover,.table-hover .table-dark:hover>td,.table-hover .table-dark:hover>th{background-color:#b9bbbe}.table-active,.table-active>td,.table-active>th,.table-hover .table-active:hover,.table-hover .table-active:hover>td,.table-hover .table-active:hover>th{background-color:rgba(0,0,0,.075)}.table .thead-dark th{background-color:#343a40;border-color:#454d55;color:#fff}.table .thead-light th{background-color:#e9ecef;border-color:#dee2e6;color:#495057}.table-dark{background-color:#343a40;color:#fff}.table-dark td,.table-dark th,.table-dark thead th{border-color:#454d55}.table-dark.table-bordered{border:0}.table-dark.table-striped tbody tr:nth-of-type(odd){background-color:hsla(0,0%,100%,.05)}.table-dark.table-hover tbody tr:hover{background-color:hsla(0,0%,100%,.075);color:#fff}@media (max-width:575.98px){.table-responsive-sm{-webkit-overflow-scrolling:touch;display:block;overflow-x:auto;width:100%}.table-responsive-sm>.table-bordered{border:0}}@media (max-width:767.98px){.table-responsive-md{-webkit-overflow-scrolling:touch;display:block;overflow-x:auto;width:100%}.table-responsive-md>.table-bordered{border:0}}@media (max-width:991.98px){.table-responsive-lg{-webkit-overflow-scrolling:touch;display:block;overflow-x:auto;width:100%}.table-responsive-lg>.table-bordered{border:0}}@media (max-width:1199.98px){.table-responsive-xl{-webkit-overflow-scrolling:touch;display:block;overflow-x:auto;width:100%}.table-responsive-xl>.table-bordered{border:0}}.table-responsive{-webkit-overflow-scrolling:touch;display:block;overflow-x:auto;width:100%}.table-responsive>.table-bordered{border:0}.form-control{background-clip:padding-box;background-color:#fff;border:1px solid #ced4da;border-radius:.25rem;color:#495057;display:block;font-size:1rem;font-weight:400;height:calc(1.5em + .75rem + 2px);line-height:1.5;padding:.375rem .75rem;transition:border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:100%}@media (prefers-reduced-motion:reduce){.form-control{transition:none}}.form-control::-ms-expand{background-color:transparent;border:0}.form-control:-moz-focusring{color:transparent;text-shadow:0 0 0 #495057}.form-control:focus{background-color:#fff;border-color:#80bdff;box-shadow:0 0 0 .2rem rgba(0,123,255,.25);color:#495057;outline:0}.form-control::placeholder{color:#6c757d;opacity:1}.form-control:disabled,.form-control[readonly]{background-color:#e9ecef;opacity:1}input[type=date].form-control,input[type=datetime-local].form-control,input[type=month].form-control,input[type=time].form-control{-webkit-appearance:none;appearance:none}select.form-control:focus::-ms-value{background-color:#fff;color:#495057}.form-control-file,.form-control-range{display:block;width:100%}.col-form-label{font-size:inherit;line-height:1.5;margin-bottom:0;padding-bottom:calc(.375rem + 1px);padding-top:calc(.375rem + 1px)}.col-form-label-lg{font-size:1.25rem;line-height:1.5;padding-bottom:calc(.5rem + 1px);padding-top:calc(.5rem + 1px)}.col-form-label-sm{font-size:.875rem;line-height:1.5;padding-bottom:calc(.25rem + 1px);padding-top:calc(.25rem + 1px)}.form-control-plaintext{background-color:transparent;border:solid transparent;border-width:1px 0;color:#212529;display:block;font-size:1rem;line-height:1.5;margin-bottom:0;padding:.375rem 0;width:100%}.form-control-plaintext.form-control-lg,.form-control-plaintext.form-control-sm{padding-left:0;padding-right:0}.form-control-sm{border-radius:.2rem;font-size:.875rem;height:calc(1.5em + .5rem + 2px);line-height:1.5;padding:.25rem .5rem}.form-control-lg{border-radius:.3rem;font-size:1.25rem;height:calc(1.5em + 1rem + 2px);line-height:1.5;padding:.5rem 1rem}select.form-control[multiple],select.form-control[size],textarea.form-control{height:auto}.form-group{margin-bottom:1rem}.form-text{display:block;margin-top:.25rem}.form-row{display:flex;flex-wrap:wrap;margin-left:-5px;margin-right:-5px}.form-row>.col,.form-row>[class*=col-]{padding-left:5px;padding-right:5px}.form-check{display:block;padding-left:1.25rem;position:relative}.form-check-input{margin-left:-1.25rem;margin-top:.3rem;position:absolute}.form-check-input:disabled~.form-check-label,.form-check-input[disabled]~.form-check-label{color:#6c757d}.form-check-label{margin-bottom:0}.form-check-inline{align-items:center;display:inline-flex;margin-right:.75rem;padding-left:0}.form-check-inline .form-check-input{margin-left:0;margin-right:.3125rem;margin-top:0;position:static}.valid-feedback{color:#28a745;display:none;font-size:80%;margin-top:.25rem;width:100%}.valid-tooltip{background-color:rgba(40,167,69,.9);border-radius:.25rem;color:#fff;display:none;font-size:.875rem;left:0;line-height:1.5;margin-top:.1rem;max-width:100%;padding:.25rem .5rem;position:absolute;top:100%;z-index:5}.is-valid~.valid-feedback,.is-valid~.valid-tooltip,.was-validated :valid~.valid-feedback,.was-validated :valid~.valid-tooltip{display:block}.form-control.is-valid,.was-validated .form-control:valid{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='8' height='8' viewBox='0 0 8 8'%3E%3Cpath fill='%2328a745' d='M2.3 6.73.6 4.53c-.4-1.04.46-1.4 1.1-.8l1.1 1.4 3.4-3.8c.6-.63 1.6-.27 1.2.7l-4 4.6c-.43.5-.8.4-1.1.1z'/%3E%3C/svg%3E");background-position:right calc(.375em + .1875rem) center;background-repeat:no-repeat;background-size:calc(.75em + .375rem) calc(.75em + .375rem);border-color:#28a745;padding-right:calc(1.5em + .75rem)}.form-control.is-valid:focus,.was-validated .form-control:valid:focus{border-color:#28a745;box-shadow:0 0 0 .2rem rgba(40,167,69,.25)}.was-validated textarea.form-control:valid,textarea.form-control.is-valid{background-position:top calc(.375em + .1875rem) right calc(.375em + .1875rem);padding-right:calc(1.5em + .75rem)}.custom-select.is-valid,.was-validated .custom-select:valid{background:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='4' height='5' viewBox='0 0 4 5'%3E%3Cpath fill='%23343a40' d='M2 0 0 2h4zm0 5L0 3h4z'/%3E%3C/svg%3E") no-repeat right .75rem center/8px 10px,url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='8' height='8' viewBox='0 0 8 8'%3E%3Cpath fill='%2328a745' d='M2.3 6.73.6 4.53c-.4-1.04.46-1.4 1.1-.8l1.1 1.4 3.4-3.8c.6-.63 1.6-.27 1.2.7l-4 4.6c-.43.5-.8.4-1.1.1z'/%3E%3C/svg%3E") #fff no-repeat center right 1.75rem/calc(.75em + .375rem) calc(.75em + .375rem);border-color:#28a745;padding-right:calc(.75em + 2.3125rem)}.custom-select.is-valid:focus,.was-validated .custom-select:valid:focus{border-color:#28a745;box-shadow:0 0 0 .2rem rgba(40,167,69,.25)}.form-check-input.is-valid~.form-check-label,.was-validated .form-check-input:valid~.form-check-label{color:#28a745}.form-check-input.is-valid~.valid-feedback,.form-check-input.is-valid~.valid-tooltip,.was-validated .form-check-input:valid~.valid-feedback,.was-validated .form-check-input:valid~.valid-tooltip{display:block}.custom-control-input.is-valid~.custom-control-label,.was-validated .custom-control-input:valid~.custom-control-label{color:#28a745}.custom-control-input.is-valid~.custom-control-label:before,.was-validated .custom-control-input:valid~.custom-control-label:before{border-color:#28a745}.custom-control-input.is-valid:checked~.custom-control-label:before,.was-validated .custom-control-input:valid:checked~.custom-control-label:before{background-color:#34ce57;border-color:#34ce57}.custom-control-input.is-valid:focus~.custom-control-label:before,.was-validated .custom-control-input:valid:focus~.custom-control-label:before{box-shadow:0 0 0 .2rem rgba(40,167,69,.25)}.custom-control-input.is-valid:focus:not(:checked)~.custom-control-label:before,.was-validated .custom-control-input:valid:focus:not(:checked)~.custom-control-label:before{border-color:#28a745}.custom-file-input.is-valid~.custom-file-label,.was-validated .custom-file-input:valid~.custom-file-label{border-color:#28a745}.custom-file-input.is-valid:focus~.custom-file-label,.was-validated .custom-file-input:valid:focus~.custom-file-label{border-color:#28a745;box-shadow:0 0 0 .2rem rgba(40,167,69,.25)}.invalid-feedback{color:#dc3545;display:none;font-size:80%;margin-top:.25rem;width:100%}.invalid-tooltip{background-color:rgba(220,53,69,.9);border-radius:.25rem;color:#fff;display:none;font-size:.875rem;left:0;line-height:1.5;margin-top:.1rem;max-width:100%;padding:.25rem .5rem;position:absolute;top:100%;z-index:5}.is-invalid~.invalid-feedback,.is-invalid~.invalid-tooltip,.was-validated :invalid~.invalid-feedback,.was-validated :invalid~.invalid-tooltip{display:block}.form-control.is-invalid,.was-validated .form-control:invalid{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='12' height='12' fill='none' stroke='%23dc3545' viewBox='0 0 12 12'%3E%3Ccircle cx='6' cy='6' r='4.5'/%3E%3Cpath stroke-linejoin='round' d='M5.8 3.6h.4L6 6.5z'/%3E%3Ccircle cx='6' cy='8.2' r='.6' fill='%23dc3545' stroke='none'/%3E%3C/svg%3E");background-position:right calc(.375em + .1875rem) center;background-repeat:no-repeat;background-size:calc(.75em + .375rem) calc(.75em + .375rem);border-color:#dc3545;padding-right:calc(1.5em + .75rem)}.form-control.is-invalid:focus,.was-validated .form-control:invalid:focus{border-color:#dc3545;box-shadow:0 0 0 .2rem rgba(220,53,69,.25)}.was-validated textarea.form-control:invalid,textarea.form-control.is-invalid{background-position:top calc(.375em + .1875rem) right calc(.375em + .1875rem);padding-right:calc(1.5em + .75rem)}.custom-select.is-invalid,.was-validated .custom-select:invalid{background:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='4' height='5' viewBox='0 0 4 5'%3E%3Cpath fill='%23343a40' d='M2 0 0 2h4zm0 5L0 3h4z'/%3E%3C/svg%3E") no-repeat right .75rem center/8px 10px,url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='12' height='12' fill='none' stroke='%23dc3545' viewBox='0 0 12 12'%3E%3Ccircle cx='6' cy='6' r='4.5'/%3E%3Cpath stroke-linejoin='round' d='M5.8 3.6h.4L6 6.5z'/%3E%3Ccircle cx='6' cy='8.2' r='.6' fill='%23dc3545' stroke='none'/%3E%3C/svg%3E") #fff no-repeat center right 1.75rem/calc(.75em + .375rem) calc(.75em + .375rem);border-color:#dc3545;padding-right:calc(.75em + 2.3125rem)}.custom-select.is-invalid:focus,.was-validated .custom-select:invalid:focus{border-color:#dc3545;box-shadow:0 0 0 .2rem rgba(220,53,69,.25)}.form-check-input.is-invalid~.form-check-label,.was-validated .form-check-input:invalid~.form-check-label{color:#dc3545}.form-check-input.is-invalid~.invalid-feedback,.form-check-input.is-invalid~.invalid-tooltip,.was-validated .form-check-input:invalid~.invalid-feedback,.was-validated .form-check-input:invalid~.invalid-tooltip{display:block}.custom-control-input.is-invalid~.custom-control-label,.was-validated .custom-control-input:invalid~.custom-control-label{color:#dc3545}.custom-control-input.is-invalid~.custom-control-label:before,.was-validated .custom-control-input:invalid~.custom-control-label:before{border-color:#dc3545}.custom-control-input.is-invalid:checked~.custom-control-label:before,.was-validated .custom-control-input:invalid:checked~.custom-control-label:before{background-color:#e4606d;border-color:#e4606d}.custom-control-input.is-invalid:focus~.custom-control-label:before,.was-validated .custom-control-input:invalid:focus~.custom-control-label:before{box-shadow:0 0 0 .2rem rgba(220,53,69,.25)}.custom-control-input.is-invalid:focus:not(:checked)~.custom-control-label:before,.was-validated .custom-control-input:invalid:focus:not(:checked)~.custom-control-label:before{border-color:#dc3545}.custom-file-input.is-invalid~.custom-file-label,.was-validated .custom-file-input:invalid~.custom-file-label{border-color:#dc3545}.custom-file-input.is-invalid:focus~.custom-file-label,.was-validated .custom-file-input:invalid:focus~.custom-file-label{border-color:#dc3545;box-shadow:0 0 0 .2rem rgba(220,53,69,.25)}.form-inline{align-items:center;display:flex;flex-flow:row wrap}.form-inline .form-check{width:100%}@media (min-width:576px){.form-inline label{justify-content:center}.form-inline .form-group,.form-inline label{align-items:center;display:flex;margin-bottom:0}.form-inline .form-group{flex:0 0 auto;flex-flow:row wrap}.form-inline .form-control{display:inline-block;vertical-align:middle;width:auto}.form-inline .form-control-plaintext{display:inline-block}.form-inline .custom-select,.form-inline .input-group{width:auto}.form-inline .form-check{align-items:center;display:flex;justify-content:center;padding-left:0;width:auto}.form-inline .form-check-input{flex-shrink:0;margin-left:0;margin-right:.25rem;margin-top:0;position:relative}.form-inline .custom-control{align-items:center;justify-content:center}.form-inline .custom-control-label{margin-bottom:0}}.btn{background-color:transparent;border:1px solid transparent;border-radius:.25rem;color:#212529;display:inline-block;font-size:1rem;font-weight:400;line-height:1.5;padding:.375rem .75rem;text-align:center;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;-webkit-user-select:none;user-select:none;vertical-align:middle}@media (prefers-reduced-motion:reduce){.btn{transition:none}}.btn:hover{color:#212529;text-decoration:none}.btn.focus,.btn:focus{box-shadow:0 0 0 .2rem rgba(0,123,255,.25);outline:0}.btn.disabled,.btn:disabled{opacity:.65}.btn:not(:disabled):not(.disabled){cursor:pointer}a.btn.disabled,fieldset:disabled a.btn{pointer-events:none}.btn-primary{background-color:#007bff;border-color:#007bff;color:#fff}.btn-primary.focus,.btn-primary:focus,.btn-primary:hover{background-color:#0069d9;border-color:#0062cc;color:#fff}.btn-primary.focus,.btn-primary:focus{box-shadow:0 0 0 .2rem rgba(38,143,255,.5)}.btn-primary.disabled,.btn-primary:disabled{background-color:#007bff;border-color:#007bff;color:#fff}.btn-primary:not(:disabled):not(.disabled).active,.btn-primary:not(:disabled):not(.disabled):active,.show>.btn-primary.dropdown-toggle{background-color:#0062cc;border-color:#005cbf;color:#fff}.btn-primary:not(:disabled):not(.disabled).active:focus,.btn-primary:not(:disabled):not(.disabled):active:focus,.show>.btn-primary.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(38,143,255,.5)}.btn-secondary{background-color:#6c757d;border-color:#6c757d;color:#fff}.btn-secondary.focus,.btn-secondary:focus,.btn-secondary:hover{background-color:#5a6268;border-color:#545b62;color:#fff}.btn-secondary.focus,.btn-secondary:focus{box-shadow:0 0 0 .2rem hsla(208,6%,54%,.5)}.btn-secondary.disabled,.btn-secondary:disabled{background-color:#6c757d;border-color:#6c757d;color:#fff}.btn-secondary:not(:disabled):not(.disabled).active,.btn-secondary:not(:disabled):not(.disabled):active,.show>.btn-secondary.dropdown-toggle{background-color:#545b62;border-color:#4e555b;color:#fff}.btn-secondary:not(:disabled):not(.disabled).active:focus,.btn-secondary:not(:disabled):not(.disabled):active:focus,.show>.btn-secondary.dropdown-toggle:focus{box-shadow:0 0 0 .2rem hsla(208,6%,54%,.5)}.btn-success{background-color:#28a745;border-color:#28a745;color:#fff}.btn-success.focus,.btn-success:focus,.btn-success:hover{background-color:#218838;border-color:#1e7e34;color:#fff}.btn-success.focus,.btn-success:focus{box-shadow:0 0 0 .2rem rgba(72,180,97,.5)}.btn-success.disabled,.btn-success:disabled{background-color:#28a745;border-color:#28a745;color:#fff}.btn-success:not(:disabled):not(.disabled).active,.btn-success:not(:disabled):not(.disabled):active,.show>.btn-success.dropdown-toggle{background-color:#1e7e34;border-color:#1c7430;color:#fff}.btn-success:not(:disabled):not(.disabled).active:focus,.btn-success:not(:disabled):not(.disabled):active:focus,.show>.btn-success.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(72,180,97,.5)}.btn-info{background-color:#17a2b8;border-color:#17a2b8;color:#fff}.btn-info.focus,.btn-info:focus,.btn-info:hover{background-color:#138496;border-color:#117a8b;color:#fff}.btn-info.focus,.btn-info:focus{box-shadow:0 0 0 .2rem rgba(58,176,195,.5)}.btn-info.disabled,.btn-info:disabled{background-color:#17a2b8;border-color:#17a2b8;color:#fff}.btn-info:not(:disabled):not(.disabled).active,.btn-info:not(:disabled):not(.disabled):active,.show>.btn-info.dropdown-toggle{background-color:#117a8b;border-color:#10707f;color:#fff}.btn-info:not(:disabled):not(.disabled).active:focus,.btn-info:not(:disabled):not(.disabled):active:focus,.show>.btn-info.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(58,176,195,.5)}.btn-warning{background-color:#ffc107;border-color:#ffc107;color:#212529}.btn-warning.focus,.btn-warning:focus,.btn-warning:hover{background-color:#e0a800;border-color:#d39e00;color:#212529}.btn-warning.focus,.btn-warning:focus{box-shadow:0 0 0 .2rem rgba(222,170,12,.5)}.btn-warning.disabled,.btn-warning:disabled{background-color:#ffc107;border-color:#ffc107;color:#212529}.btn-warning:not(:disabled):not(.disabled).active,.btn-warning:not(:disabled):not(.disabled):active,.show>.btn-warning.dropdown-toggle{background-color:#d39e00;border-color:#c69500;color:#212529}.btn-warning:not(:disabled):not(.disabled).active:focus,.btn-warning:not(:disabled):not(.disabled):active:focus,.show>.btn-warning.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(222,170,12,.5)}.btn-danger{background-color:#dc3545;border-color:#dc3545;color:#fff}.btn-danger.focus,.btn-danger:focus,.btn-danger:hover{background-color:#c82333;border-color:#bd2130;color:#fff}.btn-danger.focus,.btn-danger:focus{box-shadow:0 0 0 .2rem rgba(225,83,97,.5)}.btn-danger.disabled,.btn-danger:disabled{background-color:#dc3545;border-color:#dc3545;color:#fff}.btn-danger:not(:disabled):not(.disabled).active,.btn-danger:not(:disabled):not(.disabled):active,.show>.btn-danger.dropdown-toggle{background-color:#bd2130;border-color:#b21f2d;color:#fff}.btn-danger:not(:disabled):not(.disabled).active:focus,.btn-danger:not(:disabled):not(.disabled):active:focus,.show>.btn-danger.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(225,83,97,.5)}.btn-light{background-color:#f8f9fa;border-color:#f8f9fa;color:#212529}.btn-light.focus,.btn-light:focus,.btn-light:hover{background-color:#e2e6ea;border-color:#dae0e5;color:#212529}.btn-light.focus,.btn-light:focus{box-shadow:0 0 0 .2rem hsla(220,4%,85%,.5)}.btn-light.disabled,.btn-light:disabled{background-color:#f8f9fa;border-color:#f8f9fa;color:#212529}.btn-light:not(:disabled):not(.disabled).active,.btn-light:not(:disabled):not(.disabled):active,.show>.btn-light.dropdown-toggle{background-color:#dae0e5;border-color:#d3d9df;color:#212529}.btn-light:not(:disabled):not(.disabled).active:focus,.btn-light:not(:disabled):not(.disabled):active:focus,.show>.btn-light.dropdown-toggle:focus{box-shadow:0 0 0 .2rem hsla(220,4%,85%,.5)}.btn-dark{background-color:#343a40;border-color:#343a40;color:#fff}.btn-dark.focus,.btn-dark:focus,.btn-dark:hover{background-color:#23272b;border-color:#1d2124;color:#fff}.btn-dark.focus,.btn-dark:focus{box-shadow:0 0 0 .2rem rgba(82,88,93,.5)}.btn-dark.disabled,.btn-dark:disabled{background-color:#343a40;border-color:#343a40;color:#fff}.btn-dark:not(:disabled):not(.disabled).active,.btn-dark:not(:disabled):not(.disabled):active,.show>.btn-dark.dropdown-toggle{background-color:#1d2124;border-color:#171a1d;color:#fff}.btn-dark:not(:disabled):not(.disabled).active:focus,.btn-dark:not(:disabled):not(.disabled):active:focus,.show>.btn-dark.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(82,88,93,.5)}.btn-outline-primary{border-color:#007bff;color:#007bff}.btn-outline-primary:hover{background-color:#007bff;border-color:#007bff;color:#fff}.btn-outline-primary.focus,.btn-outline-primary:focus{box-shadow:0 0 0 .2rem rgba(0,123,255,.5)}.btn-outline-primary.disabled,.btn-outline-primary:disabled{background-color:transparent;color:#007bff}.btn-outline-primary:not(:disabled):not(.disabled).active,.btn-outline-primary:not(:disabled):not(.disabled):active,.show>.btn-outline-primary.dropdown-toggle{background-color:#007bff;border-color:#007bff;color:#fff}.btn-outline-primary:not(:disabled):not(.disabled).active:focus,.btn-outline-primary:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-primary.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(0,123,255,.5)}.btn-outline-secondary{border-color:#6c757d;color:#6c757d}.btn-outline-secondary:hover{background-color:#6c757d;border-color:#6c757d;color:#fff}.btn-outline-secondary.focus,.btn-outline-secondary:focus{box-shadow:0 0 0 .2rem hsla(208,7%,46%,.5)}.btn-outline-secondary.disabled,.btn-outline-secondary:disabled{background-color:transparent;color:#6c757d}.btn-outline-secondary:not(:disabled):not(.disabled).active,.btn-outline-secondary:not(:disabled):not(.disabled):active,.show>.btn-outline-secondary.dropdown-toggle{background-color:#6c757d;border-color:#6c757d;color:#fff}.btn-outline-secondary:not(:disabled):not(.disabled).active:focus,.btn-outline-secondary:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-secondary.dropdown-toggle:focus{box-shadow:0 0 0 .2rem hsla(208,7%,46%,.5)}.btn-outline-success{border-color:#28a745;color:#28a745}.btn-outline-success:hover{background-color:#28a745;border-color:#28a745;color:#fff}.btn-outline-success.focus,.btn-outline-success:focus{box-shadow:0 0 0 .2rem rgba(40,167,69,.5)}.btn-outline-success.disabled,.btn-outline-success:disabled{background-color:transparent;color:#28a745}.btn-outline-success:not(:disabled):not(.disabled).active,.btn-outline-success:not(:disabled):not(.disabled):active,.show>.btn-outline-success.dropdown-toggle{background-color:#28a745;border-color:#28a745;color:#fff}.btn-outline-success:not(:disabled):not(.disabled).active:focus,.btn-outline-success:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-success.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(40,167,69,.5)}.btn-outline-info{border-color:#17a2b8;color:#17a2b8}.btn-outline-info:hover{background-color:#17a2b8;border-color:#17a2b8;color:#fff}.btn-outline-info.focus,.btn-outline-info:focus{box-shadow:0 0 0 .2rem rgba(23,162,184,.5)}.btn-outline-info.disabled,.btn-outline-info:disabled{background-color:transparent;color:#17a2b8}.btn-outline-info:not(:disabled):not(.disabled).active,.btn-outline-info:not(:disabled):not(.disabled):active,.show>.btn-outline-info.dropdown-toggle{background-color:#17a2b8;border-color:#17a2b8;color:#fff}.btn-outline-info:not(:disabled):not(.disabled).active:focus,.btn-outline-info:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-info.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(23,162,184,.5)}.btn-outline-warning{border-color:#ffc107;color:#ffc107}.btn-outline-warning:hover{background-color:#ffc107;border-color:#ffc107;color:#212529}.btn-outline-warning.focus,.btn-outline-warning:focus{box-shadow:0 0 0 .2rem rgba(255,193,7,.5)}.btn-outline-warning.disabled,.btn-outline-warning:disabled{background-color:transparent;color:#ffc107}.btn-outline-warning:not(:disabled):not(.disabled).active,.btn-outline-warning:not(:disabled):not(.disabled):active,.show>.btn-outline-warning.dropdown-toggle{background-color:#ffc107;border-color:#ffc107;color:#212529}.btn-outline-warning:not(:disabled):not(.disabled).active:focus,.btn-outline-warning:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-warning.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(255,193,7,.5)}.btn-outline-danger{border-color:#dc3545;color:#dc3545}.btn-outline-danger:hover{background-color:#dc3545;border-color:#dc3545;color:#fff}.btn-outline-danger.focus,.btn-outline-danger:focus{box-shadow:0 0 0 .2rem rgba(220,53,69,.5)}.btn-outline-danger.disabled,.btn-outline-danger:disabled{background-color:transparent;color:#dc3545}.btn-outline-danger:not(:disabled):not(.disabled).active,.btn-outline-danger:not(:disabled):not(.disabled):active,.show>.btn-outline-danger.dropdown-toggle{background-color:#dc3545;border-color:#dc3545;color:#fff}.btn-outline-danger:not(:disabled):not(.disabled).active:focus,.btn-outline-danger:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-danger.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(220,53,69,.5)}.btn-outline-light{border-color:#f8f9fa;color:#f8f9fa}.btn-outline-light:hover{background-color:#f8f9fa;border-color:#f8f9fa;color:#212529}.btn-outline-light.focus,.btn-outline-light:focus{box-shadow:0 0 0 .2rem rgba(248,249,250,.5)}.btn-outline-light.disabled,.btn-outline-light:disabled{background-color:transparent;color:#f8f9fa}.btn-outline-light:not(:disabled):not(.disabled).active,.btn-outline-light:not(:disabled):not(.disabled):active,.show>.btn-outline-light.dropdown-toggle{background-color:#f8f9fa;border-color:#f8f9fa;color:#212529}.btn-outline-light:not(:disabled):not(.disabled).active:focus,.btn-outline-light:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-light.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(248,249,250,.5)}.btn-outline-dark{border-color:#343a40;color:#343a40}.btn-outline-dark:hover{background-color:#343a40;border-color:#343a40;color:#fff}.btn-outline-dark.focus,.btn-outline-dark:focus{box-shadow:0 0 0 .2rem rgba(52,58,64,.5)}.btn-outline-dark.disabled,.btn-outline-dark:disabled{background-color:transparent;color:#343a40}.btn-outline-dark:not(:disabled):not(.disabled).active,.btn-outline-dark:not(:disabled):not(.disabled):active,.show>.btn-outline-dark.dropdown-toggle{background-color:#343a40;border-color:#343a40;color:#fff}.btn-outline-dark:not(:disabled):not(.disabled).active:focus,.btn-outline-dark:not(:disabled):not(.disabled):active:focus,.show>.btn-outline-dark.dropdown-toggle:focus{box-shadow:0 0 0 .2rem rgba(52,58,64,.5)}.btn-link{color:#007bff;font-weight:400;text-decoration:none}.btn-link:hover{color:#0056b3}.btn-link.focus,.btn-link:focus,.btn-link:hover{text-decoration:underline}.btn-link.disabled,.btn-link:disabled{color:#6c757d;pointer-events:none}.btn-group-lg>.btn,.btn-lg{border-radius:.3rem;font-size:1.25rem;line-height:1.5;padding:.5rem 1rem}.btn-group-sm>.btn,.btn-sm{border-radius:.2rem;font-size:.875rem;line-height:1.5;padding:.25rem .5rem}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:.5rem}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{transition:opacity .15s linear}@media (prefers-reduced-motion:reduce){.fade{transition:none}}.fade:not(.show){opacity:0}.collapse:not(.show){display:none}.collapsing{height:0;overflow:hidden;position:relative;transition:height .35s ease}@media (prefers-reduced-motion:reduce){.collapsing{transition:none}}.dropdown,.dropleft,.dropright,.dropup{position:relative}.dropdown-toggle{white-space:nowrap}.dropdown-toggle:after{border-bottom:0;border-left:.3em solid transparent;border-right:.3em solid transparent;border-top:.3em solid;margin-left:.255em;vertical-align:.255em}.dropdown-toggle:empty:after{margin-left:0}.dropdown-menu{background-clip:padding-box;background-color:#fff;border:1px solid rgba(0,0,0,.15);border-radius:.25rem;color:#212529;display:none;float:left;font-size:1rem;left:0;list-style:none;margin:.125rem 0 0;min-width:10rem;padding:.5rem 0;position:absolute;text-align:left;top:100%;z-index:1000}.dropdown-menu-left{left:0;right:auto}.dropdown-menu-right{left:auto;right:0}@media (min-width:576px){.dropdown-menu-sm-left{left:0;right:auto}.dropdown-menu-sm-right{left:auto;right:0}}@media (min-width:768px){.dropdown-menu-md-left{left:0;right:auto}.dropdown-menu-md-right{left:auto;right:0}}@media (min-width:992px){.dropdown-menu-lg-left{left:0;right:auto}.dropdown-menu-lg-right{left:auto;right:0}}@media (min-width:1200px){.dropdown-menu-xl-left{left:0;right:auto}.dropdown-menu-xl-right{left:auto;right:0}}.dropup .dropdown-menu{bottom:100%;margin-bottom:.125rem;margin-top:0;top:auto}.dropup .dropdown-toggle:after{border-bottom:.3em solid;border-left:.3em solid transparent;border-right:.3em solid transparent;border-top:0;content:"";display:inline-block;margin-left:.255em;vertical-align:.255em}.dropup .dropdown-toggle:empty:after{margin-left:0}.dropright .dropdown-menu{left:100%;margin-left:.125rem;margin-top:0;right:auto;top:0}.dropright .dropdown-toggle:after{border-bottom:.3em solid transparent;border-left:.3em solid;border-right:0;border-top:.3em solid transparent;content:"";display:inline-block;margin-left:.255em;vertical-align:.255em}.dropright .dropdown-toggle:empty:after{margin-left:0}.dropright .dropdown-toggle:after{vertical-align:0}.dropleft .dropdown-menu{left:auto;margin-right:.125rem;margin-top:0;right:100%;top:0}.dropleft .dropdown-toggle:after{content:"";display:inline-block;display:none;margin-left:.255em;vertical-align:.255em}.dropleft .dropdown-toggle:before{border-bottom:.3em solid transparent;border-right:.3em solid;border-top:.3em solid transparent;content:"";display:inline-block;margin-right:.255em;vertical-align:.255em}.dropleft .dropdown-toggle:empty:after{margin-left:0}.dropleft .dropdown-toggle:before{vertical-align:0}.dropdown-menu[x-placement^=bottom],.dropdown-menu[x-placement^=left],.dropdown-menu[x-placement^=right],.dropdown-menu[x-placement^=top]{bottom:auto;right:auto}.dropdown-divider{border-top:1px solid #e9ecef;height:0;margin:.5rem 0;overflow:hidden}.dropdown-item{background-color:transparent;border:0;clear:both;color:#212529;display:block;font-weight:400;padding:.25rem 1.5rem;text-align:inherit;white-space:nowrap;width:100%}.dropdown-item:focus,.dropdown-item:hover{background-color:#f8f9fa;color:#16181b}.dropdown-item.active,.dropdown-item:active{background-color:#007bff}.dropdown-item.disabled,.dropdown-item:disabled{background-color:transparent;color:#6c757d;pointer-events:none}.dropdown-menu.show{display:block}.dropdown-header{color:#6c757d;display:block;font-size:.875rem;margin-bottom:0;padding:.5rem 1.5rem;white-space:nowrap}.dropdown-item-text{color:#212529;display:block;padding:.25rem 1.5rem}.btn-group,.btn-group-vertical{display:inline-flex;position:relative;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{flex:1 1 auto;position:relative}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:1}.btn-toolbar{display:flex;flex-wrap:wrap;justify-content:flex-start}.btn-toolbar .input-group{width:auto}.btn-group>.btn-group:not(:first-child),.btn-group>.btn:not(:first-child){margin-left:-1px}.btn-group>.btn-group:not(:last-child)>.btn,.btn-group>.btn:not(:last-child):not(.dropdown-toggle){border-bottom-right-radius:0;border-top-right-radius:0}.btn-group>.btn-group:not(:first-child)>.btn,.btn-group>.btn:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.dropdown-toggle-split{padding-left:.5625rem;padding-right:.5625rem}.dropdown-toggle-split:after,.dropright .dropdown-toggle-split:after,.dropup .dropdown-toggle-split:after{margin-left:0}.dropleft .dropdown-toggle-split:before{margin-right:0}.btn-group-sm>.btn+.dropdown-toggle-split,.btn-sm+.dropdown-toggle-split{padding-left:.375rem;padding-right:.375rem}.btn-group-lg>.btn+.dropdown-toggle-split,.btn-lg+.dropdown-toggle-split{padding-left:.75rem;padding-right:.75rem}.btn-group-vertical{align-items:flex-start;flex-direction:column;justify-content:center}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group{width:100%}.btn-group-vertical>.btn-group:not(:first-child),.btn-group-vertical>.btn:not(:first-child){margin-top:-1px}.btn-group-vertical>.btn-group:not(:last-child)>.btn,.btn-group-vertical>.btn:not(:last-child):not(.dropdown-toggle){border-bottom-left-radius:0;border-bottom-right-radius:0}.btn-group-vertical>.btn-group:not(:first-child)>.btn,.btn-group-vertical>.btn:not(:first-child){border-top-left-radius:0;border-top-right-radius:0}.btn-group-toggle>.btn,.btn-group-toggle>.btn-group>.btn{margin-bottom:0}.btn-group-toggle>.btn input[type=checkbox],.btn-group-toggle>.btn input[type=radio],.btn-group-toggle>.btn-group>.btn input[type=checkbox],.btn-group-toggle>.btn-group>.btn input[type=radio]{clip:rect(0,0,0,0);pointer-events:none;position:absolute}.input-group{align-items:stretch;display:flex;flex-wrap:wrap;position:relative;width:100%}.input-group>.custom-file,.input-group>.custom-select,.input-group>.form-control,.input-group>.form-control-plaintext{flex:1 1 auto;margin-bottom:0;min-width:0;position:relative;width:1%}.input-group>.custom-file+.custom-file,.input-group>.custom-file+.custom-select,.input-group>.custom-file+.form-control,.input-group>.custom-select+.custom-file,.input-group>.custom-select+.custom-select,.input-group>.custom-select+.form-control,.input-group>.form-control+.custom-file,.input-group>.form-control+.custom-select,.input-group>.form-control+.form-control,.input-group>.form-control-plaintext+.custom-file,.input-group>.form-control-plaintext+.custom-select,.input-group>.form-control-plaintext+.form-control{margin-left:-1px}.input-group>.custom-file .custom-file-input:focus~.custom-file-label,.input-group>.custom-select:focus,.input-group>.form-control:focus{z-index:3}.input-group>.custom-file .custom-file-input:focus{z-index:4}.input-group>.custom-select:not(:last-child),.input-group>.form-control:not(:last-child){border-bottom-right-radius:0;border-top-right-radius:0}.input-group>.custom-select:not(:first-child),.input-group>.form-control:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.input-group>.custom-file{align-items:center;display:flex}.input-group>.custom-file:not(:last-child) .custom-file-label,.input-group>.custom-file:not(:last-child) .custom-file-label:after{border-bottom-right-radius:0;border-top-right-radius:0}.input-group>.custom-file:not(:first-child) .custom-file-label{border-bottom-left-radius:0;border-top-left-radius:0}.input-group-append,.input-group-prepend{display:flex}.input-group-append .btn,.input-group-prepend .btn{position:relative;z-index:2}.input-group-append .btn:focus,.input-group-prepend .btn:focus{z-index:3}.input-group-append .btn+.btn,.input-group-append .btn+.input-group-text,.input-group-append .input-group-text+.btn,.input-group-append .input-group-text+.input-group-text,.input-group-prepend .btn+.btn,.input-group-prepend .btn+.input-group-text,.input-group-prepend .input-group-text+.btn,.input-group-prepend .input-group-text+.input-group-text{margin-left:-1px}.input-group-prepend{margin-right:-1px}.input-group-append{margin-left:-1px}.input-group-text{align-items:center;background-color:#e9ecef;border:1px solid #ced4da;border-radius:.25rem;color:#495057;display:flex;font-size:1rem;font-weight:400;line-height:1.5;margin-bottom:0;padding:.375rem .75rem;text-align:center;white-space:nowrap}.input-group-text input[type=checkbox],.input-group-text input[type=radio]{margin-top:0}.input-group-lg>.custom-select,.input-group-lg>.form-control:not(textarea){height:calc(1.5em + 1rem + 2px)}.input-group-lg>.custom-select,.input-group-lg>.form-control,.input-group-lg>.input-group-append>.btn,.input-group-lg>.input-group-append>.input-group-text,.input-group-lg>.input-group-prepend>.btn,.input-group-lg>.input-group-prepend>.input-group-text{border-radius:.3rem;font-size:1.25rem;line-height:1.5;padding:.5rem 1rem}.input-group-sm>.custom-select,.input-group-sm>.form-control:not(textarea){height:calc(1.5em + .5rem + 2px)}.input-group-sm>.custom-select,.input-group-sm>.form-control,.input-group-sm>.input-group-append>.btn,.input-group-sm>.input-group-append>.input-group-text,.input-group-sm>.input-group-prepend>.btn,.input-group-sm>.input-group-prepend>.input-group-text{border-radius:.2rem;font-size:.875rem;line-height:1.5;padding:.25rem .5rem}.input-group-lg>.custom-select,.input-group-sm>.custom-select{padding-right:1.75rem}.input-group>.input-group-append:last-child>.btn:not(:last-child):not(.dropdown-toggle),.input-group>.input-group-append:last-child>.input-group-text:not(:last-child),.input-group>.input-group-append:not(:last-child)>.btn,.input-group>.input-group-append:not(:last-child)>.input-group-text,.input-group>.input-group-prepend>.btn,.input-group>.input-group-prepend>.input-group-text{border-bottom-right-radius:0;border-top-right-radius:0}.input-group>.input-group-append>.btn,.input-group>.input-group-append>.input-group-text,.input-group>.input-group-prepend:first-child>.btn:not(:first-child),.input-group>.input-group-prepend:first-child>.input-group-text:not(:first-child),.input-group>.input-group-prepend:not(:first-child)>.btn,.input-group>.input-group-prepend:not(:first-child)>.input-group-text{border-bottom-left-radius:0;border-top-left-radius:0}.custom-control{color-adjust:exact;display:block;min-height:1.5rem;padding-left:1.5rem;position:relative;-webkit-print-color-adjust:exact;z-index:1}.custom-control-inline{display:inline-flex;margin-right:1rem}.custom-control-input{height:1.25rem;left:0;opacity:0;position:absolute;width:1rem;z-index:-1}.custom-control-input:checked~.custom-control-label:before{background-color:#007bff;border-color:#007bff;color:#fff}.custom-control-input:focus~.custom-control-label:before{box-shadow:0 0 0 .2rem rgba(0,123,255,.25)}.custom-control-input:focus:not(:checked)~.custom-control-label:before{border-color:#80bdff}.custom-control-input:not(:disabled):active~.custom-control-label:before{background-color:#b3d7ff;border-color:#b3d7ff;color:#fff}.custom-control-input:disabled~.custom-control-label,.custom-control-input[disabled]~.custom-control-label{color:#6c757d}.custom-control-input:disabled~.custom-control-label:before,.custom-control-input[disabled]~.custom-control-label:before{background-color:#e9ecef}.custom-control-label{margin-bottom:0;position:relative;vertical-align:top}.custom-control-label:before{background-color:#fff;border:1px solid #adb5bd;pointer-events:none}.custom-control-label:after,.custom-control-label:before{content:"";display:block;height:1rem;left:-1.5rem;position:absolute;top:.25rem;width:1rem}.custom-control-label:after{background:no-repeat 50%/50% 50%}.custom-checkbox .custom-control-label:before{border-radius:.25rem}.custom-checkbox .custom-control-input:checked~.custom-control-label:after{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='8' height='8' viewBox='0 0 8 8'%3E%3Cpath fill='%23fff' d='m6.564.75-3.59 3.612-1.538-1.55L0 4.26l2.974 2.99L8 2.193z'/%3E%3C/svg%3E")}.custom-checkbox .custom-control-input:indeterminate~.custom-control-label:before{background-color:#007bff;border-color:#007bff}.custom-checkbox .custom-control-input:indeterminate~.custom-control-label:after{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='4' height='4' viewBox='0 0 4 4'%3E%3Cpath stroke='%23fff' d='M0 2h4'/%3E%3C/svg%3E")}.custom-checkbox .custom-control-input:disabled:checked~.custom-control-label:before{background-color:rgba(0,123,255,.5)}.custom-checkbox .custom-control-input:disabled:indeterminate~.custom-control-label:before{background-color:rgba(0,123,255,.5)}.custom-radio .custom-control-label:before{border-radius:50%}.custom-radio .custom-control-input:checked~.custom-control-label:after{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='12' height='12' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")}.custom-radio .custom-control-input:disabled:checked~.custom-control-label:before{background-color:rgba(0,123,255,.5)}.custom-switch{padding-left:2.25rem}.custom-switch .custom-control-label:before{border-radius:.5rem;left:-2.25rem;pointer-events:all;width:1.75rem}.custom-switch .custom-control-label:after{background-color:#adb5bd;border-radius:.5rem;height:calc(1rem - 4px);left:calc(-2.25rem + 2px);top:calc(.25rem + 2px);transition:transform .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:calc(1rem - 4px)}@media (prefers-reduced-motion:reduce){.custom-switch .custom-control-label:after{transition:none}}.custom-switch .custom-control-input:checked~.custom-control-label:after{background-color:#fff;transform:translateX(.75rem)}.custom-switch .custom-control-input:disabled:checked~.custom-control-label:before{background-color:rgba(0,123,255,.5)}.custom-select{-webkit-appearance:none;appearance:none;background:#fff url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='4' height='5' viewBox='0 0 4 5'%3E%3Cpath fill='%23343a40' d='M2 0 0 2h4zm0 5L0 3h4z'/%3E%3C/svg%3E") no-repeat right .75rem center/8px 10px;border:1px solid #ced4da;border-radius:.25rem;color:#495057;display:inline-block;font-size:1rem;font-weight:400;height:calc(1.5em + .75rem + 2px);line-height:1.5;padding:.375rem 1.75rem .375rem .75rem;vertical-align:middle;width:100%}.custom-select:focus{border-color:#80bdff;box-shadow:0 0 0 .2rem rgba(0,123,255,.25);outline:0}.custom-select:focus::-ms-value{background-color:#fff;color:#495057}.custom-select[multiple],.custom-select[size]:not([size="1"]){background-image:none;height:auto;padding-right:.75rem}.custom-select:disabled{background-color:#e9ecef;color:#6c757d}.custom-select::-ms-expand{display:none}.custom-select:-moz-focusring{color:transparent;text-shadow:0 0 0 #495057}.custom-select-sm{font-size:.875rem;height:calc(1.5em + .5rem + 2px);padding-bottom:.25rem;padding-left:.5rem;padding-top:.25rem}.custom-select-lg{font-size:1.25rem;height:calc(1.5em + 1rem + 2px);padding-bottom:.5rem;padding-left:1rem;padding-top:.5rem}.custom-file{display:inline-block;margin-bottom:0}.custom-file,.custom-file-input{height:calc(1.5em + .75rem + 2px);position:relative;width:100%}.custom-file-input{margin:0;opacity:0;z-index:2}.custom-file-input:focus~.custom-file-label{border-color:#80bdff;box-shadow:0 0 0 .2rem rgba(0,123,255,.25)}.custom-file-input:disabled~.custom-file-label,.custom-file-input[disabled]~.custom-file-label{background-color:#e9ecef}.custom-file-input:lang(en)~.custom-file-label:after{content:"Browse"}.custom-file-input~.custom-file-label[data-browse]:after{content:attr(data-browse)}.custom-file-label{background-color:#fff;border:1px solid #ced4da;border-radius:.25rem;font-weight:400;height:calc(1.5em + .75rem + 2px);left:0;z-index:1}.custom-file-label,.custom-file-label:after{color:#495057;line-height:1.5;padding:.375rem .75rem;position:absolute;right:0;top:0}.custom-file-label:after{background-color:#e9ecef;border-left:inherit;border-radius:0 .25rem .25rem 0;bottom:0;content:"Browse";display:block;height:calc(1.5em + .75rem);z-index:3}.custom-range{-webkit-appearance:none;appearance:none;background-color:transparent;height:1.4rem;padding:0;width:100%}.custom-range:focus{outline:0}.custom-range:focus::-webkit-slider-thumb{box-shadow:0 0 0 1px #fff,0 0 0 .2rem rgba(0,123,255,.25)}.custom-range:focus::-moz-range-thumb{box-shadow:0 0 0 1px #fff,0 0 0 .2rem rgba(0,123,255,.25)}.custom-range:focus::-ms-thumb{box-shadow:0 0 0 1px #fff,0 0 0 .2rem rgba(0,123,255,.25)}.custom-range::-moz-focus-outer{border:0}.custom-range::-webkit-slider-thumb{-webkit-appearance:none;appearance:none;background-color:#007bff;border:0;border-radius:1rem;height:1rem;margin-top:-.25rem;-webkit-transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:1rem}@media (prefers-reduced-motion:reduce){.custom-range::-webkit-slider-thumb{-webkit-transition:none;transition:none}}.custom-range::-webkit-slider-thumb:active{background-color:#b3d7ff}.custom-range::-webkit-slider-runnable-track{background-color:#dee2e6;border-color:transparent;border-radius:1rem;color:transparent;cursor:pointer;height:.5rem;width:100%}.custom-range::-moz-range-thumb{appearance:none;background-color:#007bff;border:0;border-radius:1rem;height:1rem;-moz-transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:1rem}@media (prefers-reduced-motion:reduce){.custom-range::-moz-range-thumb{-moz-transition:none;transition:none}}.custom-range::-moz-range-thumb:active{background-color:#b3d7ff}.custom-range::-moz-range-track{background-color:#dee2e6;border-color:transparent;border-radius:1rem;color:transparent;cursor:pointer;height:.5rem;width:100%}.custom-range::-ms-thumb{appearance:none;background-color:#007bff;border:0;border-radius:1rem;height:1rem;margin-left:.2rem;margin-right:.2rem;margin-top:0;-ms-transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:1rem}@media (prefers-reduced-motion:reduce){.custom-range::-ms-thumb{-ms-transition:none;transition:none}}.custom-range::-ms-thumb:active{background-color:#b3d7ff}.custom-range::-ms-track{background-color:transparent;border-color:transparent;border-width:.5rem;color:transparent;cursor:pointer;height:.5rem;width:100%}.custom-range::-ms-fill-lower,.custom-range::-ms-fill-upper{background-color:#dee2e6;border-radius:1rem}.custom-range::-ms-fill-upper{margin-right:15px}.custom-range:disabled::-webkit-slider-thumb{background-color:#adb5bd}.custom-range:disabled::-webkit-slider-runnable-track{cursor:default}.custom-range:disabled::-moz-range-thumb{background-color:#adb5bd}.custom-range:disabled::-moz-range-track{cursor:default}.custom-range:disabled::-ms-thumb{background-color:#adb5bd}.custom-control-label:before,.custom-file-label,.custom-select{transition:background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out}@media (prefers-reduced-motion:reduce){.custom-control-label:before,.custom-file-label,.custom-select{transition:none}}.nav{display:flex;flex-wrap:wrap;list-style:none;margin-bottom:0;padding-left:0}.nav-link{display:block;padding:.5rem 1rem}.nav-link:focus,.nav-link:hover{text-decoration:none}.nav-link.disabled{color:#6c757d;cursor:default;pointer-events:none}.nav-tabs{border-bottom:1px solid #dee2e6}.nav-tabs .nav-item{margin-bottom:-1px}.nav-tabs .nav-link{border:1px solid transparent;border-top-left-radius:.25rem;border-top-right-radius:.25rem}.nav-tabs .nav-link:focus,.nav-tabs .nav-link:hover{border-color:#e9ecef #e9ecef #dee2e6}.nav-tabs .nav-link.disabled{background-color:transparent;border-color:transparent;color:#6c757d}.nav-tabs .nav-item.show .nav-link,.nav-tabs .nav-link.active{background-color:#fff;border-color:#dee2e6 #dee2e6 #fff;color:#495057}.nav-tabs .dropdown-menu{border-top-left-radius:0;border-top-right-radius:0;margin-top:-1px}.nav-pills .nav-link{border-radius:.25rem}.nav-pills .nav-link.active,.nav-pills .show>.nav-link{background-color:#007bff;color:#fff}.nav-fill .nav-item,.nav-fill>.nav-link{flex:1 1 auto;text-align:center}.nav-justified .nav-item,.nav-justified>.nav-link{flex-basis:0;flex-grow:1;text-align:center}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.navbar{padding:.5rem 1rem;position:relative}.navbar,.navbar .container,.navbar .container-fluid,.navbar .container-lg,.navbar .container-md,.navbar .container-sm,.navbar .container-xl{align-items:center;display:flex;flex-wrap:wrap;justify-content:space-between}.navbar-brand{display:inline-block;font-size:1.25rem;line-height:inherit;margin-right:1rem;padding-bottom:.3125rem;padding-top:.3125rem;white-space:nowrap}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-nav{display:flex;flex-direction:column;list-style:none;margin-bottom:0;padding-left:0}.navbar-nav .nav-link{padding-left:0;padding-right:0}.navbar-nav .dropdown-menu{float:none;position:static}.navbar-text{display:inline-block;padding-bottom:.5rem;padding-top:.5rem}.navbar-collapse{align-items:center;flex-basis:100%;flex-grow:1}.navbar-toggler{background-color:transparent;border:1px solid transparent;border-radius:.25rem;font-size:1.25rem;line-height:1;padding:.25rem .75rem}.navbar-toggler:focus,.navbar-toggler:hover{text-decoration:none}.navbar-toggler-icon{background:no-repeat 50%;background-size:100% 100%;content:"";display:inline-block;height:1.5em;vertical-align:middle;width:1.5em}@media (max-width:575.98px){.navbar-expand-sm>.container,.navbar-expand-sm>.container-fluid,.navbar-expand-sm>.container-lg,.navbar-expand-sm>.container-md,.navbar-expand-sm>.container-sm,.navbar-expand-sm>.container-xl{padding-left:0;padding-right:0}}@media (min-width:576px){.navbar-expand-sm{flex-flow:row nowrap;justify-content:flex-start}.navbar-expand-sm .navbar-nav{flex-direction:row}.navbar-expand-sm .navbar-nav .dropdown-menu{position:absolute}.navbar-expand-sm .navbar-nav .nav-link{padding-left:.5rem;padding-right:.5rem}.navbar-expand-sm>.container,.navbar-expand-sm>.container-fluid,.navbar-expand-sm>.container-lg,.navbar-expand-sm>.container-md,.navbar-expand-sm>.container-sm,.navbar-expand-sm>.container-xl{flex-wrap:nowrap}.navbar-expand-sm .navbar-collapse{display:flex!important;flex-basis:auto}.navbar-expand-sm .navbar-toggler{display:none}}@media (max-width:767.98px){.navbar-expand-md>.container,.navbar-expand-md>.container-fluid,.navbar-expand-md>.container-lg,.navbar-expand-md>.container-md,.navbar-expand-md>.container-sm,.navbar-expand-md>.container-xl{padding-left:0;padding-right:0}}@media (min-width:768px){.navbar-expand-md{flex-flow:row nowrap;justify-content:flex-start}.navbar-expand-md .navbar-nav{flex-direction:row}.navbar-expand-md .navbar-nav .dropdown-menu{position:absolute}.navbar-expand-md .navbar-nav .nav-link{padding-left:.5rem;padding-right:.5rem}.navbar-expand-md>.container,.navbar-expand-md>.container-fluid,.navbar-expand-md>.container-lg,.navbar-expand-md>.container-md,.navbar-expand-md>.container-sm,.navbar-expand-md>.container-xl{flex-wrap:nowrap}.navbar-expand-md .navbar-collapse{display:flex!important;flex-basis:auto}.navbar-expand-md .navbar-toggler{display:none}}@media (max-width:991.98px){.navbar-expand-lg>.container,.navbar-expand-lg>.container-fluid,.navbar-expand-lg>.container-lg,.navbar-expand-lg>.container-md,.navbar-expand-lg>.container-sm,.navbar-expand-lg>.container-xl{padding-left:0;padding-right:0}}@media (min-width:992px){.navbar-expand-lg{flex-flow:row nowrap;justify-content:flex-start}.navbar-expand-lg .navbar-nav{flex-direction:row}.navbar-expand-lg .navbar-nav .dropdown-menu{position:absolute}.navbar-expand-lg .navbar-nav .nav-link{padding-left:.5rem;padding-right:.5rem}.navbar-expand-lg>.container,.navbar-expand-lg>.container-fluid,.navbar-expand-lg>.container-lg,.navbar-expand-lg>.container-md,.navbar-expand-lg>.container-sm,.navbar-expand-lg>.container-xl{flex-wrap:nowrap}.navbar-expand-lg .navbar-collapse{display:flex!important;flex-basis:auto}.navbar-expand-lg .navbar-toggler{display:none}}@media (max-width:1199.98px){.navbar-expand-xl>.container,.navbar-expand-xl>.container-fluid,.navbar-expand-xl>.container-lg,.navbar-expand-xl>.container-md,.navbar-expand-xl>.container-sm,.navbar-expand-xl>.container-xl{padding-left:0;padding-right:0}}@media (min-width:1200px){.navbar-expand-xl{flex-flow:row nowrap;justify-content:flex-start}.navbar-expand-xl .navbar-nav{flex-direction:row}.navbar-expand-xl .navbar-nav .dropdown-menu{position:absolute}.navbar-expand-xl .navbar-nav .nav-link{padding-left:.5rem;padding-right:.5rem}.navbar-expand-xl>.container,.navbar-expand-xl>.container-fluid,.navbar-expand-xl>.container-lg,.navbar-expand-xl>.container-md,.navbar-expand-xl>.container-sm,.navbar-expand-xl>.container-xl{flex-wrap:nowrap}.navbar-expand-xl .navbar-collapse{display:flex!important;flex-basis:auto}.navbar-expand-xl .navbar-toggler{display:none}}.navbar-expand{flex-flow:row nowrap;justify-content:flex-start}.navbar-expand>.container,.navbar-expand>.container-fluid,.navbar-expand>.container-lg,.navbar-expand>.container-md,.navbar-expand>.container-sm,.navbar-expand>.container-xl{padding-left:0;padding-right:0}.navbar-expand .navbar-nav{flex-direction:row}.navbar-expand .navbar-nav .dropdown-menu{position:absolute}.navbar-expand .navbar-nav .nav-link{padding-left:.5rem;padding-right:.5rem}.navbar-expand>.container,.navbar-expand>.container-fluid,.navbar-expand>.container-lg,.navbar-expand>.container-md,.navbar-expand>.container-sm,.navbar-expand>.container-xl{flex-wrap:nowrap}.navbar-expand .navbar-collapse{display:flex!important;flex-basis:auto}.navbar-expand .navbar-toggler{display:none}.navbar-light .navbar-brand,.navbar-light .navbar-brand:focus,.navbar-light .navbar-brand:hover{color:rgba(0,0,0,.9)}.navbar-light .navbar-nav .nav-link{color:rgba(0,0,0,.5)}.navbar-light .navbar-nav .nav-link:focus,.navbar-light .navbar-nav .nav-link:hover{color:rgba(0,0,0,.7)}.navbar-light .navbar-nav .nav-link.disabled{color:rgba(0,0,0,.3)}.navbar-light .navbar-nav .active>.nav-link,.navbar-light .navbar-nav .nav-link.active,.navbar-light .navbar-nav .nav-link.show,.navbar-light .navbar-nav .show>.nav-link{color:rgba(0,0,0,.9)}.navbar-light .navbar-toggler{border-color:rgba(0,0,0,.1);color:rgba(0,0,0,.5)}.navbar-light .navbar-toggler-icon{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='30' height='30' viewBox='0 0 30 30'%3E%3Cpath stroke='rgba(0, 0, 0, 0.5)' stroke-linecap='round' stroke-miterlimit='10' stroke-width='2' d='M4 7h22M4 15h22M4 23h22'/%3E%3C/svg%3E")}.navbar-light .navbar-text{color:rgba(0,0,0,.5)}.navbar-light .navbar-text a,.navbar-light .navbar-text a:focus,.navbar-light .navbar-text a:hover{color:rgba(0,0,0,.9)}.navbar-dark .navbar-brand,.navbar-dark .navbar-brand:focus,.navbar-dark .navbar-brand:hover{color:#fff}.navbar-dark .navbar-nav .nav-link{color:hsla(0,0%,100%,.5)}.navbar-dark .navbar-nav .nav-link:focus,.navbar-dark .navbar-nav .nav-link:hover{color:hsla(0,0%,100%,.75)}.navbar-dark .navbar-nav .nav-link.disabled{color:hsla(0,0%,100%,.25)}.navbar-dark .navbar-nav .active>.nav-link,.navbar-dark .navbar-nav .nav-link.active,.navbar-dark .navbar-nav .nav-link.show,.navbar-dark .navbar-nav .show>.nav-link{color:#fff}.navbar-dark .navbar-toggler{border-color:hsla(0,0%,100%,.1);color:hsla(0,0%,100%,.5)}.navbar-dark .navbar-toggler-icon{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='30' height='30' viewBox='0 0 30 30'%3E%3Cpath stroke='rgba(255, 255, 255, 0.5)' stroke-linecap='round' stroke-miterlimit='10' stroke-width='2' d='M4 7h22M4 15h22M4 23h22'/%3E%3C/svg%3E")}.navbar-dark .navbar-text{color:hsla(0,0%,100%,.5)}.navbar-dark .navbar-text a,.navbar-dark .navbar-text a:focus,.navbar-dark .navbar-text a:hover{color:#fff}.card{word-wrap:break-word;background-clip:border-box;background-color:#fff;border:1px solid rgba(0,0,0,.125);border-radius:.25rem;display:flex;flex-direction:column;min-width:0;position:relative}.card>hr{margin-left:0;margin-right:0}.card>.list-group{border-bottom:inherit;border-top:inherit}.card>.list-group:first-child{border-top-left-radius:calc(.25rem - 1px);border-top-right-radius:calc(.25rem - 1px);border-top-width:0}.card>.list-group:last-child{border-bottom-left-radius:calc(.25rem - 1px);border-bottom-right-radius:calc(.25rem - 1px);border-bottom-width:0}.card>.card-header+.list-group,.card>.list-group+.card-footer{border-top:0}.card-body{flex:1 1 auto;min-height:1px;padding:1.25rem}.card-title{margin-bottom:.75rem}.card-subtitle{margin-top:-.375rem}.card-subtitle,.card-text:last-child{margin-bottom:0}.card-link:hover{text-decoration:none}.card-link+.card-link{margin-left:1.25rem}.card-header{background-color:rgba(0,0,0,.03);border-bottom:1px solid rgba(0,0,0,.125);margin-bottom:0;padding:.75rem 1.25rem}.card-header:first-child{border-radius:calc(.25rem - 1px) calc(.25rem - 1px) 0 0}.card-footer{background-color:rgba(0,0,0,.03);border-top:1px solid rgba(0,0,0,.125);padding:.75rem 1.25rem}.card-footer:last-child{border-radius:0 0 calc(.25rem - 1px) calc(.25rem - 1px)}.card-header-tabs{border-bottom:0;margin-bottom:-.75rem}.card-header-pills,.card-header-tabs{margin-left:-.625rem;margin-right:-.625rem}.card-img-overlay{border-radius:calc(.25rem - 1px);bottom:0;left:0;padding:1.25rem;position:absolute;right:0;top:0}.card-img,.card-img-bottom,.card-img-top{flex-shrink:0;width:100%}.card-img,.card-img-top{border-top-left-radius:calc(.25rem - 1px);border-top-right-radius:calc(.25rem - 1px)}.card-img,.card-img-bottom{border-bottom-left-radius:calc(.25rem - 1px);border-bottom-right-radius:calc(.25rem - 1px)}.card-deck .card{margin-bottom:15px}@media (min-width:576px){.card-deck{display:flex;flex-flow:row wrap;margin-left:-15px;margin-right:-15px}.card-deck .card{flex:1 0;margin-bottom:0;margin-left:15px;margin-right:15px}}.card-group>.card{margin-bottom:15px}@media (min-width:576px){.card-group{display:flex;flex-flow:row wrap}.card-group>.card{flex:1 0;margin-bottom:0}.card-group>.card+.card{border-left:0;margin-left:0}.card-group>.card:not(:last-child){border-bottom-right-radius:0;border-top-right-radius:0}.card-group>.card:not(:last-child) .card-header,.card-group>.card:not(:last-child) .card-img-top{border-top-right-radius:0}.card-group>.card:not(:last-child) .card-footer,.card-group>.card:not(:last-child) .card-img-bottom{border-bottom-right-radius:0}.card-group>.card:not(:first-child){border-bottom-left-radius:0;border-top-left-radius:0}.card-group>.card:not(:first-child) .card-header,.card-group>.card:not(:first-child) .card-img-top{border-top-left-radius:0}.card-group>.card:not(:first-child) .card-footer,.card-group>.card:not(:first-child) .card-img-bottom{border-bottom-left-radius:0}}.card-columns .card{margin-bottom:.75rem}@media (min-width:576px){.card-columns{column-count:3;column-gap:1.25rem;orphans:1;widows:1}.card-columns .card{display:inline-block;width:100%}}.accordion{overflow-anchor:none}.accordion>.card{overflow:hidden}.accordion>.card:not(:last-of-type){border-bottom:0;border-bottom-left-radius:0;border-bottom-right-radius:0}.accordion>.card:not(:first-of-type){border-top-left-radius:0;border-top-right-radius:0}.accordion>.card>.card-header{border-radius:0;margin-bottom:-1px}.breadcrumb{background-color:#e9ecef;border-radius:.25rem;flex-wrap:wrap;list-style:none;margin-bottom:1rem;padding:.75rem 1rem}.breadcrumb,.breadcrumb-item{display:flex}.breadcrumb-item+.breadcrumb-item{padding-left:.5rem}.breadcrumb-item+.breadcrumb-item:before{color:#6c757d;content:"/";display:inline-block;padding-right:.5rem}.breadcrumb-item+.breadcrumb-item:hover:before{text-decoration:underline;text-decoration:none}.breadcrumb-item.active{color:#6c757d}.pagination{border-radius:.25rem;display:flex;list-style:none;padding-left:0}.page-link{background-color:#fff;border:1px solid #dee2e6;color:#007bff;display:block;line-height:1.25;margin-left:-1px;padding:.5rem .75rem;position:relative}.page-link:hover{background-color:#e9ecef;border-color:#dee2e6;color:#0056b3;text-decoration:none;z-index:2}.page-link:focus{box-shadow:0 0 0 .2rem rgba(0,123,255,.25);outline:0;z-index:3}.page-item:first-child .page-link{border-bottom-left-radius:.25rem;border-top-left-radius:.25rem;margin-left:0}.page-item:last-child .page-link{border-bottom-right-radius:.25rem;border-top-right-radius:.25rem}.page-item.active .page-link{background-color:#007bff;border-color:#007bff;color:#fff;z-index:3}.page-item.disabled .page-link{background-color:#fff;border-color:#dee2e6;color:#6c757d;cursor:auto;pointer-events:none}.pagination-lg .page-link{font-size:1.25rem;line-height:1.5;padding:.75rem 1.5rem}.pagination-lg .page-item:first-child .page-link{border-bottom-left-radius:.3rem;border-top-left-radius:.3rem}.pagination-lg .page-item:last-child .page-link{border-bottom-right-radius:.3rem;border-top-right-radius:.3rem}.pagination-sm .page-link{font-size:.875rem;line-height:1.5;padding:.25rem .5rem}.pagination-sm .page-item:first-child .page-link{border-bottom-left-radius:.2rem;border-top-left-radius:.2rem}.pagination-sm .page-item:last-child .page-link{border-bottom-right-radius:.2rem;border-top-right-radius:.2rem}.badge{border-radius:.25rem;display:inline-block;font-size:75%;font-weight:700;line-height:1;padding:.25em .4em;text-align:center;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;vertical-align:baseline;white-space:nowrap}@media (prefers-reduced-motion:reduce){.badge{transition:none}}a.badge:focus,a.badge:hover{text-decoration:none}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.badge-pill{border-radius:10rem;padding-left:.6em;padding-right:.6em}.badge-primary{background-color:#007bff;color:#fff}a.badge-primary:focus,a.badge-primary:hover{background-color:#0062cc;color:#fff}a.badge-primary.focus,a.badge-primary:focus{box-shadow:0 0 0 .2rem rgba(0,123,255,.5);outline:0}.badge-secondary{background-color:#6c757d;color:#fff}a.badge-secondary:focus,a.badge-secondary:hover{background-color:#545b62;color:#fff}a.badge-secondary.focus,a.badge-secondary:focus{box-shadow:0 0 0 .2rem hsla(208,7%,46%,.5);outline:0}.badge-success{background-color:#28a745;color:#fff}a.badge-success:focus,a.badge-success:hover{background-color:#1e7e34;color:#fff}a.badge-success.focus,a.badge-success:focus{box-shadow:0 0 0 .2rem rgba(40,167,69,.5);outline:0}.badge-info{background-color:#17a2b8;color:#fff}a.badge-info:focus,a.badge-info:hover{background-color:#117a8b;color:#fff}a.badge-info.focus,a.badge-info:focus{box-shadow:0 0 0 .2rem rgba(23,162,184,.5);outline:0}.badge-warning{background-color:#ffc107;color:#212529}a.badge-warning:focus,a.badge-warning:hover{background-color:#d39e00;color:#212529}a.badge-warning.focus,a.badge-warning:focus{box-shadow:0 0 0 .2rem rgba(255,193,7,.5);outline:0}.badge-danger{background-color:#dc3545;color:#fff}a.badge-danger:focus,a.badge-danger:hover{background-color:#bd2130;color:#fff}a.badge-danger.focus,a.badge-danger:focus{box-shadow:0 0 0 .2rem rgba(220,53,69,.5);outline:0}.badge-light{background-color:#f8f9fa;color:#212529}a.badge-light:focus,a.badge-light:hover{background-color:#dae0e5;color:#212529}a.badge-light.focus,a.badge-light:focus{box-shadow:0 0 0 .2rem rgba(248,249,250,.5);outline:0}.badge-dark{background-color:#343a40;color:#fff}a.badge-dark:focus,a.badge-dark:hover{background-color:#1d2124;color:#fff}a.badge-dark.focus,a.badge-dark:focus{box-shadow:0 0 0 .2rem rgba(52,58,64,.5);outline:0}.jumbotron{background-color:#e9ecef;border-radius:.3rem;margin-bottom:2rem;padding:2rem 1rem}@media (min-width:576px){.jumbotron{padding:4rem 2rem}}.jumbotron-fluid{border-radius:0;padding-left:0;padding-right:0}.alert{border:1px solid transparent;border-radius:.25rem;margin-bottom:1rem;padding:.75rem 1.25rem;position:relative}.alert-heading{color:inherit}.alert-link{font-weight:700}.alert-dismissible{padding-right:4rem}.alert-dismissible .close{color:inherit;padding:.75rem 1.25rem;position:absolute;right:0;top:0;z-index:2}.alert-primary{background-color:#cce5ff;border-color:#b8daff;color:#004085}.alert-primary hr{border-top-color:#9fcdff}.alert-primary .alert-link{color:#002752}.alert-secondary{background-color:#e2e3e5;border-color:#d6d8db;color:#383d41}.alert-secondary hr{border-top-color:#c8cbcf}.alert-secondary .alert-link{color:#202326}.alert-success{background-color:#d4edda;border-color:#c3e6cb;color:#155724}.alert-success hr{border-top-color:#b1dfbb}.alert-success .alert-link{color:#0b2e13}.alert-info{background-color:#d1ecf1;border-color:#bee5eb;color:#0c5460}.alert-info hr{border-top-color:#abdde5}.alert-info .alert-link{color:#062c33}.alert-warning{background-color:#fff3cd;border-color:#ffeeba;color:#856404}.alert-warning hr{border-top-color:#ffe8a1}.alert-warning .alert-link{color:#533f03}.alert-danger{background-color:#f8d7da;border-color:#f5c6cb;color:#721c24}.alert-danger hr{border-top-color:#f1b0b7}.alert-danger .alert-link{color:#491217}.alert-light{background-color:#fefefe;border-color:#fdfdfe;color:#818182}.alert-light hr{border-top-color:#ececf6}.alert-light .alert-link{color:#686868}.alert-dark{background-color:#d6d8d9;border-color:#c6c8ca;color:#1b1e21}.alert-dark hr{border-top-color:#b9bbbe}.alert-dark .alert-link{color:#040505}@keyframes progress-bar-stripes{0%{background-position:1rem 0}to{background-position:0 0}}.progress{background-color:#e9ecef;border-radius:.25rem;font-size:.75rem;height:1rem;line-height:0}.progress,.progress-bar{display:flex;overflow:hidden}.progress-bar{background-color:#007bff;color:#fff;flex-direction:column;justify-content:center;text-align:center;transition:width .6s ease;white-space:nowrap}@media (prefers-reduced-motion:reduce){.progress-bar{transition:none}}.progress-bar-striped{background-image:linear-gradient(45deg,hsla(0,0%,100%,.15) 25%,transparent 0,transparent 50%,hsla(0,0%,100%,.15) 0,hsla(0,0%,100%,.15) 75%,transparent 0,transparent);background-size:1rem 1rem}.progress-bar-animated{animation:progress-bar-stripes 1s linear infinite}@media (prefers-reduced-motion:reduce){.progress-bar-animated{animation:none}}.media{align-items:flex-start;display:flex}.media-body{flex:1 1}.list-group{border-radius:.25rem;display:flex;flex-direction:column;margin-bottom:0;padding-left:0}.list-group-item-action{color:#495057;text-align:inherit;width:100%}.list-group-item-action:focus,.list-group-item-action:hover{background-color:#f8f9fa;color:#495057;text-decoration:none;z-index:1}.list-group-item-action:active{background-color:#e9ecef;color:#212529}.list-group-item{background-color:#fff;border:1px solid rgba(0,0,0,.125);display:block;padding:.75rem 1.25rem;position:relative}.list-group-item:first-child{border-top-left-radius:inherit;border-top-right-radius:inherit}.list-group-item:last-child{border-bottom-left-radius:inherit;border-bottom-right-radius:inherit}.list-group-item.disabled,.list-group-item:disabled{background-color:#fff;color:#6c757d;pointer-events:none}.list-group-item.active{background-color:#007bff;border-color:#007bff;color:#fff;z-index:2}.list-group-item+.list-group-item{border-top-width:0}.list-group-item+.list-group-item.active{border-top-width:1px;margin-top:-1px}.list-group-horizontal{flex-direction:row}.list-group-horizontal>.list-group-item:first-child{border-bottom-left-radius:.25rem;border-top-right-radius:0}.list-group-horizontal>.list-group-item:last-child{border-bottom-left-radius:0;border-top-right-radius:.25rem}.list-group-horizontal>.list-group-item.active{margin-top:0}.list-group-horizontal>.list-group-item+.list-group-item{border-left-width:0;border-top-width:1px}.list-group-horizontal>.list-group-item+.list-group-item.active{border-left-width:1px;margin-left:-1px}@media (min-width:576px){.list-group-horizontal-sm{flex-direction:row}.list-group-horizontal-sm>.list-group-item:first-child{border-bottom-left-radius:.25rem;border-top-right-radius:0}.list-group-horizontal-sm>.list-group-item:last-child{border-bottom-left-radius:0;border-top-right-radius:.25rem}.list-group-horizontal-sm>.list-group-item.active{margin-top:0}.list-group-horizontal-sm>.list-group-item+.list-group-item{border-left-width:0;border-top-width:1px}.list-group-horizontal-sm>.list-group-item+.list-group-item.active{border-left-width:1px;margin-left:-1px}}@media (min-width:768px){.list-group-horizontal-md{flex-direction:row}.list-group-horizontal-md>.list-group-item:first-child{border-bottom-left-radius:.25rem;border-top-right-radius:0}.list-group-horizontal-md>.list-group-item:last-child{border-bottom-left-radius:0;border-top-right-radius:.25rem}.list-group-horizontal-md>.list-group-item.active{margin-top:0}.list-group-horizontal-md>.list-group-item+.list-group-item{border-left-width:0;border-top-width:1px}.list-group-horizontal-md>.list-group-item+.list-group-item.active{border-left-width:1px;margin-left:-1px}}@media (min-width:992px){.list-group-horizontal-lg{flex-direction:row}.list-group-horizontal-lg>.list-group-item:first-child{border-bottom-left-radius:.25rem;border-top-right-radius:0}.list-group-horizontal-lg>.list-group-item:last-child{border-bottom-left-radius:0;border-top-right-radius:.25rem}.list-group-horizontal-lg>.list-group-item.active{margin-top:0}.list-group-horizontal-lg>.list-group-item+.list-group-item{border-left-width:0;border-top-width:1px}.list-group-horizontal-lg>.list-group-item+.list-group-item.active{border-left-width:1px;margin-left:-1px}}@media (min-width:1200px){.list-group-horizontal-xl{flex-direction:row}.list-group-horizontal-xl>.list-group-item:first-child{border-bottom-left-radius:.25rem;border-top-right-radius:0}.list-group-horizontal-xl>.list-group-item:last-child{border-bottom-left-radius:0;border-top-right-radius:.25rem}.list-group-horizontal-xl>.list-group-item.active{margin-top:0}.list-group-horizontal-xl>.list-group-item+.list-group-item{border-left-width:0;border-top-width:1px}.list-group-horizontal-xl>.list-group-item+.list-group-item.active{border-left-width:1px;margin-left:-1px}}.list-group-flush{border-radius:0}.list-group-flush>.list-group-item{border-width:0 0 1px}.list-group-flush>.list-group-item:last-child{border-bottom-width:0}.list-group-item-primary{background-color:#b8daff;color:#004085}.list-group-item-primary.list-group-item-action:focus,.list-group-item-primary.list-group-item-action:hover{background-color:#9fcdff;color:#004085}.list-group-item-primary.list-group-item-action.active{background-color:#004085;border-color:#004085;color:#fff}.list-group-item-secondary{background-color:#d6d8db;color:#383d41}.list-group-item-secondary.list-group-item-action:focus,.list-group-item-secondary.list-group-item-action:hover{background-color:#c8cbcf;color:#383d41}.list-group-item-secondary.list-group-item-action.active{background-color:#383d41;border-color:#383d41;color:#fff}.list-group-item-success{background-color:#c3e6cb;color:#155724}.list-group-item-success.list-group-item-action:focus,.list-group-item-success.list-group-item-action:hover{background-color:#b1dfbb;color:#155724}.list-group-item-success.list-group-item-action.active{background-color:#155724;border-color:#155724;color:#fff}.list-group-item-info{background-color:#bee5eb;color:#0c5460}.list-group-item-info.list-group-item-action:focus,.list-group-item-info.list-group-item-action:hover{background-color:#abdde5;color:#0c5460}.list-group-item-info.list-group-item-action.active{background-color:#0c5460;border-color:#0c5460;color:#fff}.list-group-item-warning{background-color:#ffeeba;color:#856404}.list-group-item-warning.list-group-item-action:focus,.list-group-item-warning.list-group-item-action:hover{background-color:#ffe8a1;color:#856404}.list-group-item-warning.list-group-item-action.active{background-color:#856404;border-color:#856404;color:#fff}.list-group-item-danger{background-color:#f5c6cb;color:#721c24}.list-group-item-danger.list-group-item-action:focus,.list-group-item-danger.list-group-item-action:hover{background-color:#f1b0b7;color:#721c24}.list-group-item-danger.list-group-item-action.active{background-color:#721c24;border-color:#721c24;color:#fff}.list-group-item-light{background-color:#fdfdfe;color:#818182}.list-group-item-light.list-group-item-action:focus,.list-group-item-light.list-group-item-action:hover{background-color:#ececf6;color:#818182}.list-group-item-light.list-group-item-action.active{background-color:#818182;border-color:#818182;color:#fff}.list-group-item-dark{background-color:#c6c8ca;color:#1b1e21}.list-group-item-dark.list-group-item-action:focus,.list-group-item-dark.list-group-item-action:hover{background-color:#b9bbbe;color:#1b1e21}.list-group-item-dark.list-group-item-action.active{background-color:#1b1e21;border-color:#1b1e21;color:#fff}.close{color:#000;float:right;font-size:1.5rem;font-weight:700;line-height:1;opacity:.5;text-shadow:0 1px 0 #fff}.close:hover{color:#000;text-decoration:none}.close:not(:disabled):not(.disabled):focus,.close:not(:disabled):not(.disabled):hover{opacity:.75}button.close{background-color:transparent;border:0;padding:0}a.close.disabled{pointer-events:none}.toast{background-clip:padding-box;background-color:hsla(0,0%,100%,.85);border:1px solid rgba(0,0,0,.1);border-radius:.25rem;box-shadow:0 .25rem .75rem rgba(0,0,0,.1);flex-basis:350px;font-size:.875rem;max-width:350px;opacity:0}.toast:not(:last-child){margin-bottom:.75rem}.toast.showing{opacity:1}.toast.show{display:block;opacity:1}.toast.hide{display:none}.toast-header{align-items:center;background-clip:padding-box;background-color:hsla(0,0%,100%,.85);border-bottom:1px solid rgba(0,0,0,.05);border-top-left-radius:calc(.25rem - 1px);border-top-right-radius:calc(.25rem - 1px);color:#6c757d;display:flex;padding:.25rem .75rem}.toast-body{padding:.75rem}.modal-open{overflow:hidden}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal{display:none;height:100%;left:0;outline:0;overflow:hidden;position:fixed;top:0;width:100%;z-index:1050}.modal-dialog{margin:.5rem;pointer-events:none;position:relative;width:auto}.modal.fade .modal-dialog{transform:translateY(-50px);transition:transform .3s ease-out}@media (prefers-reduced-motion:reduce){.modal.fade .modal-dialog{transition:none}}.modal.show .modal-dialog{transform:none}.modal.modal-static .modal-dialog{transform:scale(1.02)}.modal-dialog-scrollable{display:flex;max-height:calc(100% - 1rem)}.modal-dialog-scrollable .modal-content{max-height:calc(100vh - 1rem);overflow:hidden}.modal-dialog-scrollable .modal-footer,.modal-dialog-scrollable .modal-header{flex-shrink:0}.modal-dialog-scrollable .modal-body{overflow-y:auto}.modal-dialog-centered{align-items:center;display:flex;min-height:calc(100% - 1rem)}.modal-dialog-centered:before{content:"";display:block;height:calc(100vh - 1rem);height:-webkit-min-content;height:min-content}.modal-dialog-centered.modal-dialog-scrollable{flex-direction:column;height:100%;justify-content:center}.modal-dialog-centered.modal-dialog-scrollable .modal-content{max-height:none}.modal-dialog-centered.modal-dialog-scrollable:before{content:none}.modal-content{background-clip:padding-box;background-color:#fff;border:1px solid rgba(0,0,0,.2);border-radius:.3rem;display:flex;flex-direction:column;outline:0;pointer-events:auto;position:relative;width:100%}.modal-backdrop{background-color:#000;height:100vh;left:0;position:fixed;top:0;width:100vw;z-index:1040}.modal-backdrop.fade{opacity:0}.modal-backdrop.show{opacity:.5}.modal-header{align-items:flex-start;border-bottom:1px solid #dee2e6;border-top-left-radius:calc(.3rem - 1px);border-top-right-radius:calc(.3rem - 1px);display:flex;justify-content:space-between;padding:1rem}.modal-header .close{margin:-1rem -1rem -1rem auto;padding:1rem}.modal-title{line-height:1.5;margin-bottom:0}.modal-body{flex:1 1 auto;padding:1rem;position:relative}.modal-footer{align-items:center;border-bottom-left-radius:calc(.3rem - 1px);border-bottom-right-radius:calc(.3rem - 1px);border-top:1px solid #dee2e6;display:flex;flex-wrap:wrap;justify-content:flex-end;padding:.75rem}.modal-footer>*{margin:.25rem}.modal-scrollbar-measure{height:50px;overflow:scroll;position:absolute;top:-9999px;width:50px}@media (min-width:576px){.modal-dialog{margin:1.75rem auto;max-width:500px}.modal-dialog-scrollable{max-height:calc(100% - 3.5rem)}.modal-dialog-scrollable .modal-content{max-height:calc(100vh - 3.5rem)}.modal-dialog-centered{min-height:calc(100% - 3.5rem)}.modal-dialog-centered:before{height:calc(100vh - 3.5rem);height:-webkit-min-content;height:min-content}.modal-sm{max-width:300px}}@media (min-width:992px){.modal-lg,.modal-xl{max-width:800px}}@media (min-width:1200px){.modal-xl{max-width:1140px}}.tooltip{word-wrap:break-word;display:block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji;font-size:.875rem;font-style:normal;font-weight:400;letter-spacing:normal;line-break:auto;line-height:1.5;margin:0;opacity:0;position:absolute;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;white-space:normal;word-break:normal;word-spacing:normal;z-index:1070}.tooltip.show{opacity:.9}.tooltip .arrow{display:block;height:.4rem;position:absolute;width:.8rem}.tooltip .arrow:before{border-color:transparent;border-style:solid;content:"";position:absolute}.bs-tooltip-auto[x-placement^=top],.bs-tooltip-top{padding:.4rem 0}.bs-tooltip-auto[x-placement^=top] .arrow,.bs-tooltip-top .arrow{bottom:0}.bs-tooltip-auto[x-placement^=top] .arrow:before,.bs-tooltip-top .arrow:before{border-top-color:#000;border-width:.4rem .4rem 0;top:0}.bs-tooltip-auto[x-placement^=right],.bs-tooltip-right{padding:0 .4rem}.bs-tooltip-auto[x-placement^=right] .arrow,.bs-tooltip-right .arrow{height:.8rem;left:0;width:.4rem}.bs-tooltip-auto[x-placement^=right] .arrow:before,.bs-tooltip-right .arrow:before{border-right-color:#000;border-width:.4rem .4rem .4rem 0;right:0}.bs-tooltip-auto[x-placement^=bottom],.bs-tooltip-bottom{padding:.4rem 0}.bs-tooltip-auto[x-placement^=bottom] .arrow,.bs-tooltip-bottom .arrow{top:0}.bs-tooltip-auto[x-placement^=bottom] .arrow:before,.bs-tooltip-bottom .arrow:before{border-bottom-color:#000;border-width:0 .4rem .4rem;bottom:0}.bs-tooltip-auto[x-placement^=left],.bs-tooltip-left{padding:0 .4rem}.bs-tooltip-auto[x-placement^=left] .arrow,.bs-tooltip-left .arrow{height:.8rem;right:0;width:.4rem}.bs-tooltip-auto[x-placement^=left] .arrow:before,.bs-tooltip-left .arrow:before{border-left-color:#000;border-width:.4rem 0 .4rem .4rem;left:0}.tooltip-inner{background-color:#000;border-radius:.25rem;color:#fff;max-width:200px;padding:.25rem .5rem;text-align:center}.popover{word-wrap:break-word;background-clip:padding-box;background-color:#fff;border:1px solid rgba(0,0,0,.2);border-radius:.3rem;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji;font-size:.875rem;font-style:normal;font-weight:400;left:0;letter-spacing:normal;line-break:auto;line-height:1.5;max-width:276px;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;top:0;white-space:normal;word-break:normal;word-spacing:normal;z-index:1060}.popover,.popover .arrow{display:block;position:absolute}.popover .arrow{height:.5rem;margin:0 .3rem;width:1rem}.popover .arrow:after,.popover .arrow:before{border-color:transparent;border-style:solid;content:"";display:block;position:absolute}.bs-popover-auto[x-placement^=top],.bs-popover-top{margin-bottom:.5rem}.bs-popover-auto[x-placement^=top]>.arrow,.bs-popover-top>.arrow{bottom:calc(-.5rem - 1px)}.bs-popover-auto[x-placement^=top]>.arrow:before,.bs-popover-top>.arrow:before{border-top-color:rgba(0,0,0,.25);border-width:.5rem .5rem 0;bottom:0}.bs-popover-auto[x-placement^=top]>.arrow:after,.bs-popover-top>.arrow:after{border-top-color:#fff;border-width:.5rem .5rem 0;bottom:1px}.bs-popover-auto[x-placement^=right],.bs-popover-right{margin-left:.5rem}.bs-popover-auto[x-placement^=right]>.arrow,.bs-popover-right>.arrow{height:1rem;left:calc(-.5rem - 1px);margin:.3rem 0;width:.5rem}.bs-popover-auto[x-placement^=right]>.arrow:before,.bs-popover-right>.arrow:before{border-right-color:rgba(0,0,0,.25);border-width:.5rem .5rem .5rem 0;left:0}.bs-popover-auto[x-placement^=right]>.arrow:after,.bs-popover-right>.arrow:after{border-right-color:#fff;border-width:.5rem .5rem .5rem 0;left:1px}.bs-popover-auto[x-placement^=bottom],.bs-popover-bottom{margin-top:.5rem}.bs-popover-auto[x-placement^=bottom]>.arrow,.bs-popover-bottom>.arrow{top:calc(-.5rem - 1px)}.bs-popover-auto[x-placement^=bottom]>.arrow:before,.bs-popover-bottom>.arrow:before{border-bottom-color:rgba(0,0,0,.25);border-width:0 .5rem .5rem;top:0}.bs-popover-auto[x-placement^=bottom]>.arrow:after,.bs-popover-bottom>.arrow:after{border-bottom-color:#fff;border-width:0 .5rem .5rem;top:1px}.bs-popover-auto[x-placement^=bottom] .popover-header:before,.bs-popover-bottom .popover-header:before{border-bottom:1px solid #f7f7f7;content:"";display:block;left:50%;margin-left:-.5rem;position:absolute;top:0;width:1rem}.bs-popover-auto[x-placement^=left],.bs-popover-left{margin-right:.5rem}.bs-popover-auto[x-placement^=left]>.arrow,.bs-popover-left>.arrow{height:1rem;margin:.3rem 0;right:calc(-.5rem - 1px);width:.5rem}.bs-popover-auto[x-placement^=left]>.arrow:before,.bs-popover-left>.arrow:before{border-left-color:rgba(0,0,0,.25);border-width:.5rem 0 .5rem .5rem;right:0}.bs-popover-auto[x-placement^=left]>.arrow:after,.bs-popover-left>.arrow:after{border-left-color:#fff;border-width:.5rem 0 .5rem .5rem;right:1px}.popover-header{background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-top-left-radius:calc(.3rem - 1px);border-top-right-radius:calc(.3rem - 1px);font-size:1rem;margin-bottom:0;padding:.5rem .75rem}.popover-header:empty{display:none}.popover-body{color:#212529;padding:.5rem .75rem}.carousel{position:relative}.carousel.pointer-event{touch-action:pan-y}.carousel-inner{overflow:hidden;position:relative;width:100%}.carousel-inner:after{clear:both;content:"";display:block}.carousel-item{-webkit-backface-visibility:hidden;backface-visibility:hidden;display:none;float:left;margin-right:-100%;position:relative;transition:transform .6s ease-in-out;width:100%}@media (prefers-reduced-motion:reduce){.carousel-item{transition:none}}.carousel-item-next,.carousel-item-prev,.carousel-item.active{display:block}.active.carousel-item-right,.carousel-item-next:not(.carousel-item-left){transform:translateX(100%)}.active.carousel-item-left,.carousel-item-prev:not(.carousel-item-right){transform:translateX(-100%)}.carousel-fade .carousel-item{opacity:0;transform:none;transition-property:opacity}.carousel-fade .carousel-item-next.carousel-item-left,.carousel-fade .carousel-item-prev.carousel-item-right,.carousel-fade .carousel-item.active{opacity:1;z-index:1}.carousel-fade .active.carousel-item-left,.carousel-fade .active.carousel-item-right{opacity:0;transition:opacity 0s .6s;z-index:0}@media (prefers-reduced-motion:reduce){.carousel-fade .active.carousel-item-left,.carousel-fade .active.carousel-item-right{transition:none}}.carousel-control-next,.carousel-control-prev{align-items:center;bottom:0;color:#fff;display:flex;justify-content:center;opacity:.5;position:absolute;text-align:center;top:0;transition:opacity .15s ease;width:15%;z-index:1}@media (prefers-reduced-motion:reduce){.carousel-control-next,.carousel-control-prev{transition:none}}.carousel-control-next:focus,.carousel-control-next:hover,.carousel-control-prev:focus,.carousel-control-prev:hover{color:#fff;opacity:.9;outline:0;text-decoration:none}.carousel-control-prev{left:0}.carousel-control-next{right:0}.carousel-control-next-icon,.carousel-control-prev-icon{background:no-repeat 50%/100% 100%;display:inline-block;height:20px;width:20px}.carousel-control-prev-icon{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='8' height='8' fill='%23fff' viewBox='0 0 8 8'%3E%3Cpath d='m5.25 0-4 4 4 4 1.5-1.5L4.25 4l2.5-2.5L5.25 0z'/%3E%3C/svg%3E")}.carousel-control-next-icon{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='8' height='8' fill='%23fff' viewBox='0 0 8 8'%3E%3Cpath d='m2.75 0-1.5 1.5L3.75 4l-2.5 2.5L2.75 8l4-4-4-4z'/%3E%3C/svg%3E")}.carousel-indicators{bottom:0;display:flex;justify-content:center;left:0;list-style:none;margin-left:15%;margin-right:15%;padding-left:0;position:absolute;right:0;z-index:15}.carousel-indicators li{background-clip:padding-box;background-color:#fff;border-bottom:10px solid transparent;border-top:10px solid transparent;box-sizing:content-box;cursor:pointer;flex:0 1 auto;height:3px;margin-left:3px;margin-right:3px;opacity:.5;text-indent:-999px;transition:opacity .6s ease;width:30px}@media (prefers-reduced-motion:reduce){.carousel-indicators li{transition:none}}.carousel-indicators .active{opacity:1}.carousel-caption{bottom:20px;color:#fff;left:15%;padding-bottom:20px;padding-top:20px;position:absolute;right:15%;text-align:center;z-index:10}@keyframes spinner-border{to{transform:rotate(1turn)}}.spinner-border{animation:spinner-border .75s linear infinite;border:.25em solid;border-radius:50%;border-right:.25em solid transparent;display:inline-block;height:2rem;vertical-align:text-bottom;width:2rem}.spinner-border-sm{border-width:.2em;height:1rem;width:1rem}@keyframes spinner-grow{0%{transform:scale(0)}50%{opacity:1;transform:none}}.spinner-grow{animation:spinner-grow .75s linear infinite;background-color:currentColor;border-radius:50%;display:inline-block;height:2rem;opacity:0;vertical-align:text-bottom;width:2rem}.spinner-grow-sm{height:1rem;width:1rem}.align-baseline{vertical-align:baseline!important}.align-top{vertical-align:top!important}.align-middle{vertical-align:middle!important}.align-bottom{vertical-align:bottom!important}.align-text-bottom{vertical-align:text-bottom!important}.align-text-top{vertical-align:text-top!important}.bg-primary{background-color:#007bff!important}a.bg-primary:focus,a.bg-primary:hover,button.bg-primary:focus,button.bg-primary:hover{background-color:#0062cc!important}.bg-secondary{background-color:#6c757d!important}a.bg-secondary:focus,a.bg-secondary:hover,button.bg-secondary:focus,button.bg-secondary:hover{background-color:#545b62!important}.bg-success{background-color:#28a745!important}a.bg-success:focus,a.bg-success:hover,button.bg-success:focus,button.bg-success:hover{background-color:#1e7e34!important}.bg-info{background-color:#17a2b8!important}a.bg-info:focus,a.bg-info:hover,button.bg-info:focus,button.bg-info:hover{background-color:#117a8b!important}.bg-warning{background-color:#ffc107!important}a.bg-warning:focus,a.bg-warning:hover,button.bg-warning:focus,button.bg-warning:hover{background-color:#d39e00!important}.bg-danger{background-color:#dc3545!important}a.bg-danger:focus,a.bg-danger:hover,button.bg-danger:focus,button.bg-danger:hover{background-color:#bd2130!important}.bg-light{background-color:#f8f9fa!important}a.bg-light:focus,a.bg-light:hover,button.bg-light:focus,button.bg-light:hover{background-color:#dae0e5!important}.bg-dark{background-color:#343a40!important}a.bg-dark:focus,a.bg-dark:hover,button.bg-dark:focus,button.bg-dark:hover{background-color:#1d2124!important}.bg-white{background-color:#fff!important}.bg-transparent{background-color:transparent!important}.border{border:1px solid #dee2e6!important}.border-top{border-top:1px solid #dee2e6!important}.border-right{border-right:1px solid #dee2e6!important}.border-bottom{border-bottom:1px solid #dee2e6!important}.border-left{border-left:1px solid #dee2e6!important}.border-0{border:0!important}.border-top-0{border-top:0!important}.border-right-0{border-right:0!important}.border-bottom-0{border-bottom:0!important}.border-left-0{border-left:0!important}.border-primary{border-color:#007bff!important}.border-secondary{border-color:#6c757d!important}.border-success{border-color:#28a745!important}.border-info{border-color:#17a2b8!important}.border-warning{border-color:#ffc107!important}.border-danger{border-color:#dc3545!important}.border-light{border-color:#f8f9fa!important}.border-dark{border-color:#343a40!important}.border-white{border-color:#fff!important}.rounded-sm{border-radius:.2rem!important}.rounded{border-radius:.25rem!important}.rounded-top{border-top-left-radius:.25rem!important}.rounded-right,.rounded-top{border-top-right-radius:.25rem!important}.rounded-bottom,.rounded-right{border-bottom-right-radius:.25rem!important}.rounded-bottom,.rounded-left{border-bottom-left-radius:.25rem!important}.rounded-left{border-top-left-radius:.25rem!important}.rounded-lg{border-radius:.3rem!important}.rounded-circle{border-radius:50%!important}.rounded-pill{border-radius:50rem!important}.rounded-0{border-radius:0!important}.clearfix:after{clear:both;content:"";display:block}.d-none{display:none!important}.d-inline{display:inline!important}.d-inline-block{display:inline-block!important}.d-block{display:block!important}.d-table{display:table!important}.d-table-row{display:table-row!important}.d-table-cell{display:table-cell!important}.d-flex{display:flex!important}.d-inline-flex{display:inline-flex!important}@media (min-width:576px){.d-sm-none{display:none!important}.d-sm-inline{display:inline!important}.d-sm-inline-block{display:inline-block!important}.d-sm-block{display:block!important}.d-sm-table{display:table!important}.d-sm-table-row{display:table-row!important}.d-sm-table-cell{display:table-cell!important}.d-sm-flex{display:flex!important}.d-sm-inline-flex{display:inline-flex!important}}@media (min-width:768px){.d-md-none{display:none!important}.d-md-inline{display:inline!important}.d-md-inline-block{display:inline-block!important}.d-md-block{display:block!important}.d-md-table{display:table!important}.d-md-table-row{display:table-row!important}.d-md-table-cell{display:table-cell!important}.d-md-flex{display:flex!important}.d-md-inline-flex{display:inline-flex!important}}@media (min-width:992px){.d-lg-none{display:none!important}.d-lg-inline{display:inline!important}.d-lg-inline-block{display:inline-block!important}.d-lg-block{display:block!important}.d-lg-table{display:table!important}.d-lg-table-row{display:table-row!important}.d-lg-table-cell{display:table-cell!important}.d-lg-flex{display:flex!important}.d-lg-inline-flex{display:inline-flex!important}}@media (min-width:1200px){.d-xl-none{display:none!important}.d-xl-inline{display:inline!important}.d-xl-inline-block{display:inline-block!important}.d-xl-block{display:block!important}.d-xl-table{display:table!important}.d-xl-table-row{display:table-row!important}.d-xl-table-cell{display:table-cell!important}.d-xl-flex{display:flex!important}.d-xl-inline-flex{display:inline-flex!important}}@media print{.d-print-none{display:none!important}.d-print-inline{display:inline!important}.d-print-inline-block{display:inline-block!important}.d-print-block{display:block!important}.d-print-table{display:table!important}.d-print-table-row{display:table-row!important}.d-print-table-cell{display:table-cell!important}.d-print-flex{display:flex!important}.d-print-inline-flex{display:inline-flex!important}}.embed-responsive{display:block;overflow:hidden;padding:0;position:relative;width:100%}.embed-responsive:before{content:"";display:block}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{border:0;bottom:0;height:100%;left:0;position:absolute;top:0;width:100%}.embed-responsive-21by9:before{padding-top:42.857143%}.embed-responsive-16by9:before{padding-top:56.25%}.embed-responsive-4by3:before{padding-top:75%}.embed-responsive-1by1:before{padding-top:100%}.flex-row{flex-direction:row!important}.flex-column{flex-direction:column!important}.flex-row-reverse{flex-direction:row-reverse!important}.flex-column-reverse{flex-direction:column-reverse!important}.flex-wrap{flex-wrap:wrap!important}.flex-nowrap{flex-wrap:nowrap!important}.flex-wrap-reverse{flex-wrap:wrap-reverse!important}.flex-fill{flex:1 1 auto!important}.flex-grow-0{flex-grow:0!important}.flex-grow-1{flex-grow:1!important}.flex-shrink-0{flex-shrink:0!important}.flex-shrink-1{flex-shrink:1!important}.justify-content-start{justify-content:flex-start!important}.justify-content-end{justify-content:flex-end!important}.justify-content-center{justify-content:center!important}.justify-content-between{justify-content:space-between!important}.justify-content-around{justify-content:space-around!important}.align-items-start{align-items:flex-start!important}.align-items-end{align-items:flex-end!important}.align-items-center{align-items:center!important}.align-items-baseline{align-items:baseline!important}.align-items-stretch{align-items:stretch!important}.align-content-start{align-content:flex-start!important}.align-content-end{align-content:flex-end!important}.align-content-center{align-content:center!important}.align-content-between{align-content:space-between!important}.align-content-around{align-content:space-around!important}.align-content-stretch{align-content:stretch!important}.align-self-auto{align-self:auto!important}.align-self-start{align-self:flex-start!important}.align-self-end{align-self:flex-end!important}.align-self-center{align-self:center!important}.align-self-baseline{align-self:baseline!important}.align-self-stretch{align-self:stretch!important}@media (min-width:576px){.flex-sm-row{flex-direction:row!important}.flex-sm-column{flex-direction:column!important}.flex-sm-row-reverse{flex-direction:row-reverse!important}.flex-sm-column-reverse{flex-direction:column-reverse!important}.flex-sm-wrap{flex-wrap:wrap!important}.flex-sm-nowrap{flex-wrap:nowrap!important}.flex-sm-wrap-reverse{flex-wrap:wrap-reverse!important}.flex-sm-fill{flex:1 1 auto!important}.flex-sm-grow-0{flex-grow:0!important}.flex-sm-grow-1{flex-grow:1!important}.flex-sm-shrink-0{flex-shrink:0!important}.flex-sm-shrink-1{flex-shrink:1!important}.justify-content-sm-start{justify-content:flex-start!important}.justify-content-sm-end{justify-content:flex-end!important}.justify-content-sm-center{justify-content:center!important}.justify-content-sm-between{justify-content:space-between!important}.justify-content-sm-around{justify-content:space-around!important}.align-items-sm-start{align-items:flex-start!important}.align-items-sm-end{align-items:flex-end!important}.align-items-sm-center{align-items:center!important}.align-items-sm-baseline{align-items:baseline!important}.align-items-sm-stretch{align-items:stretch!important}.align-content-sm-start{align-content:flex-start!important}.align-content-sm-end{align-content:flex-end!important}.align-content-sm-center{align-content:center!important}.align-content-sm-between{align-content:space-between!important}.align-content-sm-around{align-content:space-around!important}.align-content-sm-stretch{align-content:stretch!important}.align-self-sm-auto{align-self:auto!important}.align-self-sm-start{align-self:flex-start!important}.align-self-sm-end{align-self:flex-end!important}.align-self-sm-center{align-self:center!important}.align-self-sm-baseline{align-self:baseline!important}.align-self-sm-stretch{align-self:stretch!important}}@media (min-width:768px){.flex-md-row{flex-direction:row!important}.flex-md-column{flex-direction:column!important}.flex-md-row-reverse{flex-direction:row-reverse!important}.flex-md-column-reverse{flex-direction:column-reverse!important}.flex-md-wrap{flex-wrap:wrap!important}.flex-md-nowrap{flex-wrap:nowrap!important}.flex-md-wrap-reverse{flex-wrap:wrap-reverse!important}.flex-md-fill{flex:1 1 auto!important}.flex-md-grow-0{flex-grow:0!important}.flex-md-grow-1{flex-grow:1!important}.flex-md-shrink-0{flex-shrink:0!important}.flex-md-shrink-1{flex-shrink:1!important}.justify-content-md-start{justify-content:flex-start!important}.justify-content-md-end{justify-content:flex-end!important}.justify-content-md-center{justify-content:center!important}.justify-content-md-between{justify-content:space-between!important}.justify-content-md-around{justify-content:space-around!important}.align-items-md-start{align-items:flex-start!important}.align-items-md-end{align-items:flex-end!important}.align-items-md-center{align-items:center!important}.align-items-md-baseline{align-items:baseline!important}.align-items-md-stretch{align-items:stretch!important}.align-content-md-start{align-content:flex-start!important}.align-content-md-end{align-content:flex-end!important}.align-content-md-center{align-content:center!important}.align-content-md-between{align-content:space-between!important}.align-content-md-around{align-content:space-around!important}.align-content-md-stretch{align-content:stretch!important}.align-self-md-auto{align-self:auto!important}.align-self-md-start{align-self:flex-start!important}.align-self-md-end{align-self:flex-end!important}.align-self-md-center{align-self:center!important}.align-self-md-baseline{align-self:baseline!important}.align-self-md-stretch{align-self:stretch!important}}@media (min-width:992px){.flex-lg-row{flex-direction:row!important}.flex-lg-column{flex-direction:column!important}.flex-lg-row-reverse{flex-direction:row-reverse!important}.flex-lg-column-reverse{flex-direction:column-reverse!important}.flex-lg-wrap{flex-wrap:wrap!important}.flex-lg-nowrap{flex-wrap:nowrap!important}.flex-lg-wrap-reverse{flex-wrap:wrap-reverse!important}.flex-lg-fill{flex:1 1 auto!important}.flex-lg-grow-0{flex-grow:0!important}.flex-lg-grow-1{flex-grow:1!important}.flex-lg-shrink-0{flex-shrink:0!important}.flex-lg-shrink-1{flex-shrink:1!important}.justify-content-lg-start{justify-content:flex-start!important}.justify-content-lg-end{justify-content:flex-end!important}.justify-content-lg-center{justify-content:center!important}.justify-content-lg-between{justify-content:space-between!important}.justify-content-lg-around{justify-content:space-around!important}.align-items-lg-start{align-items:flex-start!important}.align-items-lg-end{align-items:flex-end!important}.align-items-lg-center{align-items:center!important}.align-items-lg-baseline{align-items:baseline!important}.align-items-lg-stretch{align-items:stretch!important}.align-content-lg-start{align-content:flex-start!important}.align-content-lg-end{align-content:flex-end!important}.align-content-lg-center{align-content:center!important}.align-content-lg-between{align-content:space-between!important}.align-content-lg-around{align-content:space-around!important}.align-content-lg-stretch{align-content:stretch!important}.align-self-lg-auto{align-self:auto!important}.align-self-lg-start{align-self:flex-start!important}.align-self-lg-end{align-self:flex-end!important}.align-self-lg-center{align-self:center!important}.align-self-lg-baseline{align-self:baseline!important}.align-self-lg-stretch{align-self:stretch!important}}@media (min-width:1200px){.flex-xl-row{flex-direction:row!important}.flex-xl-column{flex-direction:column!important}.flex-xl-row-reverse{flex-direction:row-reverse!important}.flex-xl-column-reverse{flex-direction:column-reverse!important}.flex-xl-wrap{flex-wrap:wrap!important}.flex-xl-nowrap{flex-wrap:nowrap!important}.flex-xl-wrap-reverse{flex-wrap:wrap-reverse!important}.flex-xl-fill{flex:1 1 auto!important}.flex-xl-grow-0{flex-grow:0!important}.flex-xl-grow-1{flex-grow:1!important}.flex-xl-shrink-0{flex-shrink:0!important}.flex-xl-shrink-1{flex-shrink:1!important}.justify-content-xl-start{justify-content:flex-start!important}.justify-content-xl-end{justify-content:flex-end!important}.justify-content-xl-center{justify-content:center!important}.justify-content-xl-between{justify-content:space-between!important}.justify-content-xl-around{justify-content:space-around!important}.align-items-xl-start{align-items:flex-start!important}.align-items-xl-end{align-items:flex-end!important}.align-items-xl-center{align-items:center!important}.align-items-xl-baseline{align-items:baseline!important}.align-items-xl-stretch{align-items:stretch!important}.align-content-xl-start{align-content:flex-start!important}.align-content-xl-end{align-content:flex-end!important}.align-content-xl-center{align-content:center!important}.align-content-xl-between{align-content:space-between!important}.align-content-xl-around{align-content:space-around!important}.align-content-xl-stretch{align-content:stretch!important}.align-self-xl-auto{align-self:auto!important}.align-self-xl-start{align-self:flex-start!important}.align-self-xl-end{align-self:flex-end!important}.align-self-xl-center{align-self:center!important}.align-self-xl-baseline{align-self:baseline!important}.align-self-xl-stretch{align-self:stretch!important}}.float-left{float:left!important}.float-right{float:right!important}.float-none{float:none!important}@media (min-width:576px){.float-sm-left{float:left!important}.float-sm-right{float:right!important}.float-sm-none{float:none!important}}@media (min-width:768px){.float-md-left{float:left!important}.float-md-right{float:right!important}.float-md-none{float:none!important}}@media (min-width:992px){.float-lg-left{float:left!important}.float-lg-right{float:right!important}.float-lg-none{float:none!important}}@media (min-width:1200px){.float-xl-left{float:left!important}.float-xl-right{float:right!important}.float-xl-none{float:none!important}}.user-select-all{-webkit-user-select:all!important;user-select:all!important}.user-select-auto{-webkit-user-select:auto!important;user-select:auto!important}.user-select-none{-webkit-user-select:none!important;user-select:none!important}.overflow-auto{overflow:auto!important}.overflow-hidden{overflow:hidden!important}.position-static{position:static!important}.position-relative{position:relative!important}.position-absolute{position:absolute!important}.position-fixed{position:fixed!important}.position-sticky{position:-webkit-sticky!important;position:sticky!important}.fixed-top{top:0}.fixed-bottom,.fixed-top{left:0;position:fixed;right:0;z-index:1030}.fixed-bottom{bottom:0}@supports ((position:-webkit-sticky) or (position:sticky)){.sticky-top{position:-webkit-sticky;position:sticky;top:0;z-index:1020}}.sr-only{clip:rect(0,0,0,0);border:0;height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:1px}.sr-only-focusable:active,.sr-only-focusable:focus{clip:auto;height:auto;overflow:visible;position:static;white-space:normal;width:auto}.shadow-sm{box-shadow:0 .125rem .25rem rgba(0,0,0,.075)!important}.shadow{box-shadow:0 .5rem 1rem rgba(0,0,0,.15)!important}.shadow-lg{box-shadow:0 1rem 3rem rgba(0,0,0,.175)!important}.shadow-none{box-shadow:none!important}.w-25{width:25%!important}.w-50{width:50%!important}.w-75{width:75%!important}.w-100{width:100%!important}.w-auto{width:auto!important}.h-25{height:25%!important}.h-50{height:50%!important}.h-75{height:75%!important}.h-100{height:100%!important}.h-auto{height:auto!important}.mw-100{max-width:100%!important}.mh-100{max-height:100%!important}.min-vw-100{min-width:100vw!important}.min-vh-100{min-height:100vh!important}.vw-100{width:100vw!important}.vh-100{height:100vh!important}.m-0{margin:0!important}.mt-0,.my-0{margin-top:0!important}.mr-0,.mx-0{margin-right:0!important}.mb-0,.my-0{margin-bottom:0!important}.ml-0,.mx-0{margin-left:0!important}.m-1{margin:.25rem!important}.mt-1,.my-1{margin-top:.25rem!important}.mr-1,.mx-1{margin-right:.25rem!important}.mb-1,.my-1{margin-bottom:.25rem!important}.ml-1,.mx-1{margin-left:.25rem!important}.m-2{margin:.5rem!important}.mt-2,.my-2{margin-top:.5rem!important}.mr-2,.mx-2{margin-right:.5rem!important}.mb-2,.my-2{margin-bottom:.5rem!important}.ml-2,.mx-2{margin-left:.5rem!important}.m-3{margin:1rem!important}.mt-3,.my-3{margin-top:1rem!important}.mr-3,.mx-3{margin-right:1rem!important}.mb-3,.my-3{margin-bottom:1rem!important}.ml-3,.mx-3{margin-left:1rem!important}.m-4{margin:1.5rem!important}.mt-4,.my-4{margin-top:1.5rem!important}.mr-4,.mx-4{margin-right:1.5rem!important}.mb-4,.my-4{margin-bottom:1.5rem!important}.ml-4,.mx-4{margin-left:1.5rem!important}.m-5{margin:3rem!important}.mt-5,.my-5{margin-top:3rem!important}.mr-5,.mx-5{margin-right:3rem!important}.mb-5,.my-5{margin-bottom:3rem!important}.ml-5,.mx-5{margin-left:3rem!important}.p-0{padding:0!important}.pt-0,.py-0{padding-top:0!important}.pr-0,.px-0{padding-right:0!important}.pb-0,.py-0{padding-bottom:0!important}.pl-0,.px-0{padding-left:0!important}.p-1{padding:.25rem!important}.pt-1,.py-1{padding-top:.25rem!important}.pr-1,.px-1{padding-right:.25rem!important}.pb-1,.py-1{padding-bottom:.25rem!important}.pl-1,.px-1{padding-left:.25rem!important}.p-2{padding:.5rem!important}.pt-2,.py-2{padding-top:.5rem!important}.pr-2,.px-2{padding-right:.5rem!important}.pb-2,.py-2{padding-bottom:.5rem!important}.pl-2,.px-2{padding-left:.5rem!important}.p-3{padding:1rem!important}.pt-3,.py-3{padding-top:1rem!important}.pr-3,.px-3{padding-right:1rem!important}.pb-3,.py-3{padding-bottom:1rem!important}.pl-3,.px-3{padding-left:1rem!important}.p-4{padding:1.5rem!important}.pt-4,.py-4{padding-top:1.5rem!important}.pr-4,.px-4{padding-right:1.5rem!important}.pb-4,.py-4{padding-bottom:1.5rem!important}.pl-4,.px-4{padding-left:1.5rem!important}.p-5{padding:3rem!important}.pt-5,.py-5{padding-top:3rem!important}.pr-5,.px-5{padding-right:3rem!important}.pb-5,.py-5{padding-bottom:3rem!important}.pl-5,.px-5{padding-left:3rem!important}.m-n1{margin:-.25rem!important}.mt-n1,.my-n1{margin-top:-.25rem!important}.mr-n1,.mx-n1{margin-right:-.25rem!important}.mb-n1,.my-n1{margin-bottom:-.25rem!important}.ml-n1,.mx-n1{margin-left:-.25rem!important}.m-n2{margin:-.5rem!important}.mt-n2,.my-n2{margin-top:-.5rem!important}.mr-n2,.mx-n2{margin-right:-.5rem!important}.mb-n2,.my-n2{margin-bottom:-.5rem!important}.ml-n2,.mx-n2{margin-left:-.5rem!important}.m-n3{margin:-1rem!important}.mt-n3,.my-n3{margin-top:-1rem!important}.mr-n3,.mx-n3{margin-right:-1rem!important}.mb-n3,.my-n3{margin-bottom:-1rem!important}.ml-n3,.mx-n3{margin-left:-1rem!important}.m-n4{margin:-1.5rem!important}.mt-n4,.my-n4{margin-top:-1.5rem!important}.mr-n4,.mx-n4{margin-right:-1.5rem!important}.mb-n4,.my-n4{margin-bottom:-1.5rem!important}.ml-n4,.mx-n4{margin-left:-1.5rem!important}.m-n5{margin:-3rem!important}.mt-n5,.my-n5{margin-top:-3rem!important}.mr-n5,.mx-n5{margin-right:-3rem!important}.mb-n5,.my-n5{margin-bottom:-3rem!important}.ml-n5,.mx-n5{margin-left:-3rem!important}.m-auto{margin:auto!important}.mt-auto,.my-auto{margin-top:auto!important}.mr-auto,.mx-auto{margin-right:auto!important}.mb-auto,.my-auto{margin-bottom:auto!important}.ml-auto,.mx-auto{margin-left:auto!important}@media (min-width:576px){.m-sm-0{margin:0!important}.mt-sm-0,.my-sm-0{margin-top:0!important}.mr-sm-0,.mx-sm-0{margin-right:0!important}.mb-sm-0,.my-sm-0{margin-bottom:0!important}.ml-sm-0,.mx-sm-0{margin-left:0!important}.m-sm-1{margin:.25rem!important}.mt-sm-1,.my-sm-1{margin-top:.25rem!important}.mr-sm-1,.mx-sm-1{margin-right:.25rem!important}.mb-sm-1,.my-sm-1{margin-bottom:.25rem!important}.ml-sm-1,.mx-sm-1{margin-left:.25rem!important}.m-sm-2{margin:.5rem!important}.mt-sm-2,.my-sm-2{margin-top:.5rem!important}.mr-sm-2,.mx-sm-2{margin-right:.5rem!important}.mb-sm-2,.my-sm-2{margin-bottom:.5rem!important}.ml-sm-2,.mx-sm-2{margin-left:.5rem!important}.m-sm-3{margin:1rem!important}.mt-sm-3,.my-sm-3{margin-top:1rem!important}.mr-sm-3,.mx-sm-3{margin-right:1rem!important}.mb-sm-3,.my-sm-3{margin-bottom:1rem!important}.ml-sm-3,.mx-sm-3{margin-left:1rem!important}.m-sm-4{margin:1.5rem!important}.mt-sm-4,.my-sm-4{margin-top:1.5rem!important}.mr-sm-4,.mx-sm-4{margin-right:1.5rem!important}.mb-sm-4,.my-sm-4{margin-bottom:1.5rem!important}.ml-sm-4,.mx-sm-4{margin-left:1.5rem!important}.m-sm-5{margin:3rem!important}.mt-sm-5,.my-sm-5{margin-top:3rem!important}.mr-sm-5,.mx-sm-5{margin-right:3rem!important}.mb-sm-5,.my-sm-5{margin-bottom:3rem!important}.ml-sm-5,.mx-sm-5{margin-left:3rem!important}.p-sm-0{padding:0!important}.pt-sm-0,.py-sm-0{padding-top:0!important}.pr-sm-0,.px-sm-0{padding-right:0!important}.pb-sm-0,.py-sm-0{padding-bottom:0!important}.pl-sm-0,.px-sm-0{padding-left:0!important}.p-sm-1{padding:.25rem!important}.pt-sm-1,.py-sm-1{padding-top:.25rem!important}.pr-sm-1,.px-sm-1{padding-right:.25rem!important}.pb-sm-1,.py-sm-1{padding-bottom:.25rem!important}.pl-sm-1,.px-sm-1{padding-left:.25rem!important}.p-sm-2{padding:.5rem!important}.pt-sm-2,.py-sm-2{padding-top:.5rem!important}.pr-sm-2,.px-sm-2{padding-right:.5rem!important}.pb-sm-2,.py-sm-2{padding-bottom:.5rem!important}.pl-sm-2,.px-sm-2{padding-left:.5rem!important}.p-sm-3{padding:1rem!important}.pt-sm-3,.py-sm-3{padding-top:1rem!important}.pr-sm-3,.px-sm-3{padding-right:1rem!important}.pb-sm-3,.py-sm-3{padding-bottom:1rem!important}.pl-sm-3,.px-sm-3{padding-left:1rem!important}.p-sm-4{padding:1.5rem!important}.pt-sm-4,.py-sm-4{padding-top:1.5rem!important}.pr-sm-4,.px-sm-4{padding-right:1.5rem!important}.pb-sm-4,.py-sm-4{padding-bottom:1.5rem!important}.pl-sm-4,.px-sm-4{padding-left:1.5rem!important}.p-sm-5{padding:3rem!important}.pt-sm-5,.py-sm-5{padding-top:3rem!important}.pr-sm-5,.px-sm-5{padding-right:3rem!important}.pb-sm-5,.py-sm-5{padding-bottom:3rem!important}.pl-sm-5,.px-sm-5{padding-left:3rem!important}.m-sm-n1{margin:-.25rem!important}.mt-sm-n1,.my-sm-n1{margin-top:-.25rem!important}.mr-sm-n1,.mx-sm-n1{margin-right:-.25rem!important}.mb-sm-n1,.my-sm-n1{margin-bottom:-.25rem!important}.ml-sm-n1,.mx-sm-n1{margin-left:-.25rem!important}.m-sm-n2{margin:-.5rem!important}.mt-sm-n2,.my-sm-n2{margin-top:-.5rem!important}.mr-sm-n2,.mx-sm-n2{margin-right:-.5rem!important}.mb-sm-n2,.my-sm-n2{margin-bottom:-.5rem!important}.ml-sm-n2,.mx-sm-n2{margin-left:-.5rem!important}.m-sm-n3{margin:-1rem!important}.mt-sm-n3,.my-sm-n3{margin-top:-1rem!important}.mr-sm-n3,.mx-sm-n3{margin-right:-1rem!important}.mb-sm-n3,.my-sm-n3{margin-bottom:-1rem!important}.ml-sm-n3,.mx-sm-n3{margin-left:-1rem!important}.m-sm-n4{margin:-1.5rem!important}.mt-sm-n4,.my-sm-n4{margin-top:-1.5rem!important}.mr-sm-n4,.mx-sm-n4{margin-right:-1.5rem!important}.mb-sm-n4,.my-sm-n4{margin-bottom:-1.5rem!important}.ml-sm-n4,.mx-sm-n4{margin-left:-1.5rem!important}.m-sm-n5{margin:-3rem!important}.mt-sm-n5,.my-sm-n5{margin-top:-3rem!important}.mr-sm-n5,.mx-sm-n5{margin-right:-3rem!important}.mb-sm-n5,.my-sm-n5{margin-bottom:-3rem!important}.ml-sm-n5,.mx-sm-n5{margin-left:-3rem!important}.m-sm-auto{margin:auto!important}.mt-sm-auto,.my-sm-auto{margin-top:auto!important}.mr-sm-auto,.mx-sm-auto{margin-right:auto!important}.mb-sm-auto,.my-sm-auto{margin-bottom:auto!important}.ml-sm-auto,.mx-sm-auto{margin-left:auto!important}}@media (min-width:768px){.m-md-0{margin:0!important}.mt-md-0,.my-md-0{margin-top:0!important}.mr-md-0,.mx-md-0{margin-right:0!important}.mb-md-0,.my-md-0{margin-bottom:0!important}.ml-md-0,.mx-md-0{margin-left:0!important}.m-md-1{margin:.25rem!important}.mt-md-1,.my-md-1{margin-top:.25rem!important}.mr-md-1,.mx-md-1{margin-right:.25rem!important}.mb-md-1,.my-md-1{margin-bottom:.25rem!important}.ml-md-1,.mx-md-1{margin-left:.25rem!important}.m-md-2{margin:.5rem!important}.mt-md-2,.my-md-2{margin-top:.5rem!important}.mr-md-2,.mx-md-2{margin-right:.5rem!important}.mb-md-2,.my-md-2{margin-bottom:.5rem!important}.ml-md-2,.mx-md-2{margin-left:.5rem!important}.m-md-3{margin:1rem!important}.mt-md-3,.my-md-3{margin-top:1rem!important}.mr-md-3,.mx-md-3{margin-right:1rem!important}.mb-md-3,.my-md-3{margin-bottom:1rem!important}.ml-md-3,.mx-md-3{margin-left:1rem!important}.m-md-4{margin:1.5rem!important}.mt-md-4,.my-md-4{margin-top:1.5rem!important}.mr-md-4,.mx-md-4{margin-right:1.5rem!important}.mb-md-4,.my-md-4{margin-bottom:1.5rem!important}.ml-md-4,.mx-md-4{margin-left:1.5rem!important}.m-md-5{margin:3rem!important}.mt-md-5,.my-md-5{margin-top:3rem!important}.mr-md-5,.mx-md-5{margin-right:3rem!important}.mb-md-5,.my-md-5{margin-bottom:3rem!important}.ml-md-5,.mx-md-5{margin-left:3rem!important}.p-md-0{padding:0!important}.pt-md-0,.py-md-0{padding-top:0!important}.pr-md-0,.px-md-0{padding-right:0!important}.pb-md-0,.py-md-0{padding-bottom:0!important}.pl-md-0,.px-md-0{padding-left:0!important}.p-md-1{padding:.25rem!important}.pt-md-1,.py-md-1{padding-top:.25rem!important}.pr-md-1,.px-md-1{padding-right:.25rem!important}.pb-md-1,.py-md-1{padding-bottom:.25rem!important}.pl-md-1,.px-md-1{padding-left:.25rem!important}.p-md-2{padding:.5rem!important}.pt-md-2,.py-md-2{padding-top:.5rem!important}.pr-md-2,.px-md-2{padding-right:.5rem!important}.pb-md-2,.py-md-2{padding-bottom:.5rem!important}.pl-md-2,.px-md-2{padding-left:.5rem!important}.p-md-3{padding:1rem!important}.pt-md-3,.py-md-3{padding-top:1rem!important}.pr-md-3,.px-md-3{padding-right:1rem!important}.pb-md-3,.py-md-3{padding-bottom:1rem!important}.pl-md-3,.px-md-3{padding-left:1rem!important}.p-md-4{padding:1.5rem!important}.pt-md-4,.py-md-4{padding-top:1.5rem!important}.pr-md-4,.px-md-4{padding-right:1.5rem!important}.pb-md-4,.py-md-4{padding-bottom:1.5rem!important}.pl-md-4,.px-md-4{padding-left:1.5rem!important}.p-md-5{padding:3rem!important}.pt-md-5,.py-md-5{padding-top:3rem!important}.pr-md-5,.px-md-5{padding-right:3rem!important}.pb-md-5,.py-md-5{padding-bottom:3rem!important}.pl-md-5,.px-md-5{padding-left:3rem!important}.m-md-n1{margin:-.25rem!important}.mt-md-n1,.my-md-n1{margin-top:-.25rem!important}.mr-md-n1,.mx-md-n1{margin-right:-.25rem!important}.mb-md-n1,.my-md-n1{margin-bottom:-.25rem!important}.ml-md-n1,.mx-md-n1{margin-left:-.25rem!important}.m-md-n2{margin:-.5rem!important}.mt-md-n2,.my-md-n2{margin-top:-.5rem!important}.mr-md-n2,.mx-md-n2{margin-right:-.5rem!important}.mb-md-n2,.my-md-n2{margin-bottom:-.5rem!important}.ml-md-n2,.mx-md-n2{margin-left:-.5rem!important}.m-md-n3{margin:-1rem!important}.mt-md-n3,.my-md-n3{margin-top:-1rem!important}.mr-md-n3,.mx-md-n3{margin-right:-1rem!important}.mb-md-n3,.my-md-n3{margin-bottom:-1rem!important}.ml-md-n3,.mx-md-n3{margin-left:-1rem!important}.m-md-n4{margin:-1.5rem!important}.mt-md-n4,.my-md-n4{margin-top:-1.5rem!important}.mr-md-n4,.mx-md-n4{margin-right:-1.5rem!important}.mb-md-n4,.my-md-n4{margin-bottom:-1.5rem!important}.ml-md-n4,.mx-md-n4{margin-left:-1.5rem!important}.m-md-n5{margin:-3rem!important}.mt-md-n5,.my-md-n5{margin-top:-3rem!important}.mr-md-n5,.mx-md-n5{margin-right:-3rem!important}.mb-md-n5,.my-md-n5{margin-bottom:-3rem!important}.ml-md-n5,.mx-md-n5{margin-left:-3rem!important}.m-md-auto{margin:auto!important}.mt-md-auto,.my-md-auto{margin-top:auto!important}.mr-md-auto,.mx-md-auto{margin-right:auto!important}.mb-md-auto,.my-md-auto{margin-bottom:auto!important}.ml-md-auto,.mx-md-auto{margin-left:auto!important}}@media (min-width:992px){.m-lg-0{margin:0!important}.mt-lg-0,.my-lg-0{margin-top:0!important}.mr-lg-0,.mx-lg-0{margin-right:0!important}.mb-lg-0,.my-lg-0{margin-bottom:0!important}.ml-lg-0,.mx-lg-0{margin-left:0!important}.m-lg-1{margin:.25rem!important}.mt-lg-1,.my-lg-1{margin-top:.25rem!important}.mr-lg-1,.mx-lg-1{margin-right:.25rem!important}.mb-lg-1,.my-lg-1{margin-bottom:.25rem!important}.ml-lg-1,.mx-lg-1{margin-left:.25rem!important}.m-lg-2{margin:.5rem!important}.mt-lg-2,.my-lg-2{margin-top:.5rem!important}.mr-lg-2,.mx-lg-2{margin-right:.5rem!important}.mb-lg-2,.my-lg-2{margin-bottom:.5rem!important}.ml-lg-2,.mx-lg-2{margin-left:.5rem!important}.m-lg-3{margin:1rem!important}.mt-lg-3,.my-lg-3{margin-top:1rem!important}.mr-lg-3,.mx-lg-3{margin-right:1rem!important}.mb-lg-3,.my-lg-3{margin-bottom:1rem!important}.ml-lg-3,.mx-lg-3{margin-left:1rem!important}.m-lg-4{margin:1.5rem!important}.mt-lg-4,.my-lg-4{margin-top:1.5rem!important}.mr-lg-4,.mx-lg-4{margin-right:1.5rem!important}.mb-lg-4,.my-lg-4{margin-bottom:1.5rem!important}.ml-lg-4,.mx-lg-4{margin-left:1.5rem!important}.m-lg-5{margin:3rem!important}.mt-lg-5,.my-lg-5{margin-top:3rem!important}.mr-lg-5,.mx-lg-5{margin-right:3rem!important}.mb-lg-5,.my-lg-5{margin-bottom:3rem!important}.ml-lg-5,.mx-lg-5{margin-left:3rem!important}.p-lg-0{padding:0!important}.pt-lg-0,.py-lg-0{padding-top:0!important}.pr-lg-0,.px-lg-0{padding-right:0!important}.pb-lg-0,.py-lg-0{padding-bottom:0!important}.pl-lg-0,.px-lg-0{padding-left:0!important}.p-lg-1{padding:.25rem!important}.pt-lg-1,.py-lg-1{padding-top:.25rem!important}.pr-lg-1,.px-lg-1{padding-right:.25rem!important}.pb-lg-1,.py-lg-1{padding-bottom:.25rem!important}.pl-lg-1,.px-lg-1{padding-left:.25rem!important}.p-lg-2{padding:.5rem!important}.pt-lg-2,.py-lg-2{padding-top:.5rem!important}.pr-lg-2,.px-lg-2{padding-right:.5rem!important}.pb-lg-2,.py-lg-2{padding-bottom:.5rem!important}.pl-lg-2,.px-lg-2{padding-left:.5rem!important}.p-lg-3{padding:1rem!important}.pt-lg-3,.py-lg-3{padding-top:1rem!important}.pr-lg-3,.px-lg-3{padding-right:1rem!important}.pb-lg-3,.py-lg-3{padding-bottom:1rem!important}.pl-lg-3,.px-lg-3{padding-left:1rem!important}.p-lg-4{padding:1.5rem!important}.pt-lg-4,.py-lg-4{padding-top:1.5rem!important}.pr-lg-4,.px-lg-4{padding-right:1.5rem!important}.pb-lg-4,.py-lg-4{padding-bottom:1.5rem!important}.pl-lg-4,.px-lg-4{padding-left:1.5rem!important}.p-lg-5{padding:3rem!important}.pt-lg-5,.py-lg-5{padding-top:3rem!important}.pr-lg-5,.px-lg-5{padding-right:3rem!important}.pb-lg-5,.py-lg-5{padding-bottom:3rem!important}.pl-lg-5,.px-lg-5{padding-left:3rem!important}.m-lg-n1{margin:-.25rem!important}.mt-lg-n1,.my-lg-n1{margin-top:-.25rem!important}.mr-lg-n1,.mx-lg-n1{margin-right:-.25rem!important}.mb-lg-n1,.my-lg-n1{margin-bottom:-.25rem!important}.ml-lg-n1,.mx-lg-n1{margin-left:-.25rem!important}.m-lg-n2{margin:-.5rem!important}.mt-lg-n2,.my-lg-n2{margin-top:-.5rem!important}.mr-lg-n2,.mx-lg-n2{margin-right:-.5rem!important}.mb-lg-n2,.my-lg-n2{margin-bottom:-.5rem!important}.ml-lg-n2,.mx-lg-n2{margin-left:-.5rem!important}.m-lg-n3{margin:-1rem!important}.mt-lg-n3,.my-lg-n3{margin-top:-1rem!important}.mr-lg-n3,.mx-lg-n3{margin-right:-1rem!important}.mb-lg-n3,.my-lg-n3{margin-bottom:-1rem!important}.ml-lg-n3,.mx-lg-n3{margin-left:-1rem!important}.m-lg-n4{margin:-1.5rem!important}.mt-lg-n4,.my-lg-n4{margin-top:-1.5rem!important}.mr-lg-n4,.mx-lg-n4{margin-right:-1.5rem!important}.mb-lg-n4,.my-lg-n4{margin-bottom:-1.5rem!important}.ml-lg-n4,.mx-lg-n4{margin-left:-1.5rem!important}.m-lg-n5{margin:-3rem!important}.mt-lg-n5,.my-lg-n5{margin-top:-3rem!important}.mr-lg-n5,.mx-lg-n5{margin-right:-3rem!important}.mb-lg-n5,.my-lg-n5{margin-bottom:-3rem!important}.ml-lg-n5,.mx-lg-n5{margin-left:-3rem!important}.m-lg-auto{margin:auto!important}.mt-lg-auto,.my-lg-auto{margin-top:auto!important}.mr-lg-auto,.mx-lg-auto{margin-right:auto!important}.mb-lg-auto,.my-lg-auto{margin-bottom:auto!important}.ml-lg-auto,.mx-lg-auto{margin-left:auto!important}}@media (min-width:1200px){.m-xl-0{margin:0!important}.mt-xl-0,.my-xl-0{margin-top:0!important}.mr-xl-0,.mx-xl-0{margin-right:0!important}.mb-xl-0,.my-xl-0{margin-bottom:0!important}.ml-xl-0,.mx-xl-0{margin-left:0!important}.m-xl-1{margin:.25rem!important}.mt-xl-1,.my-xl-1{margin-top:.25rem!important}.mr-xl-1,.mx-xl-1{margin-right:.25rem!important}.mb-xl-1,.my-xl-1{margin-bottom:.25rem!important}.ml-xl-1,.mx-xl-1{margin-left:.25rem!important}.m-xl-2{margin:.5rem!important}.mt-xl-2,.my-xl-2{margin-top:.5rem!important}.mr-xl-2,.mx-xl-2{margin-right:.5rem!important}.mb-xl-2,.my-xl-2{margin-bottom:.5rem!important}.ml-xl-2,.mx-xl-2{margin-left:.5rem!important}.m-xl-3{margin:1rem!important}.mt-xl-3,.my-xl-3{margin-top:1rem!important}.mr-xl-3,.mx-xl-3{margin-right:1rem!important}.mb-xl-3,.my-xl-3{margin-bottom:1rem!important}.ml-xl-3,.mx-xl-3{margin-left:1rem!important}.m-xl-4{margin:1.5rem!important}.mt-xl-4,.my-xl-4{margin-top:1.5rem!important}.mr-xl-4,.mx-xl-4{margin-right:1.5rem!important}.mb-xl-4,.my-xl-4{margin-bottom:1.5rem!important}.ml-xl-4,.mx-xl-4{margin-left:1.5rem!important}.m-xl-5{margin:3rem!important}.mt-xl-5,.my-xl-5{margin-top:3rem!important}.mr-xl-5,.mx-xl-5{margin-right:3rem!important}.mb-xl-5,.my-xl-5{margin-bottom:3rem!important}.ml-xl-5,.mx-xl-5{margin-left:3rem!important}.p-xl-0{padding:0!important}.pt-xl-0,.py-xl-0{padding-top:0!important}.pr-xl-0,.px-xl-0{padding-right:0!important}.pb-xl-0,.py-xl-0{padding-bottom:0!important}.pl-xl-0,.px-xl-0{padding-left:0!important}.p-xl-1{padding:.25rem!important}.pt-xl-1,.py-xl-1{padding-top:.25rem!important}.pr-xl-1,.px-xl-1{padding-right:.25rem!important}.pb-xl-1,.py-xl-1{padding-bottom:.25rem!important}.pl-xl-1,.px-xl-1{padding-left:.25rem!important}.p-xl-2{padding:.5rem!important}.pt-xl-2,.py-xl-2{padding-top:.5rem!important}.pr-xl-2,.px-xl-2{padding-right:.5rem!important}.pb-xl-2,.py-xl-2{padding-bottom:.5rem!important}.pl-xl-2,.px-xl-2{padding-left:.5rem!important}.p-xl-3{padding:1rem!important}.pt-xl-3,.py-xl-3{padding-top:1rem!important}.pr-xl-3,.px-xl-3{padding-right:1rem!important}.pb-xl-3,.py-xl-3{padding-bottom:1rem!important}.pl-xl-3,.px-xl-3{padding-left:1rem!important}.p-xl-4{padding:1.5rem!important}.pt-xl-4,.py-xl-4{padding-top:1.5rem!important}.pr-xl-4,.px-xl-4{padding-right:1.5rem!important}.pb-xl-4,.py-xl-4{padding-bottom:1.5rem!important}.pl-xl-4,.px-xl-4{padding-left:1.5rem!important}.p-xl-5{padding:3rem!important}.pt-xl-5,.py-xl-5{padding-top:3rem!important}.pr-xl-5,.px-xl-5{padding-right:3rem!important}.pb-xl-5,.py-xl-5{padding-bottom:3rem!important}.pl-xl-5,.px-xl-5{padding-left:3rem!important}.m-xl-n1{margin:-.25rem!important}.mt-xl-n1,.my-xl-n1{margin-top:-.25rem!important}.mr-xl-n1,.mx-xl-n1{margin-right:-.25rem!important}.mb-xl-n1,.my-xl-n1{margin-bottom:-.25rem!important}.ml-xl-n1,.mx-xl-n1{margin-left:-.25rem!important}.m-xl-n2{margin:-.5rem!important}.mt-xl-n2,.my-xl-n2{margin-top:-.5rem!important}.mr-xl-n2,.mx-xl-n2{margin-right:-.5rem!important}.mb-xl-n2,.my-xl-n2{margin-bottom:-.5rem!important}.ml-xl-n2,.mx-xl-n2{margin-left:-.5rem!important}.m-xl-n3{margin:-1rem!important}.mt-xl-n3,.my-xl-n3{margin-top:-1rem!important}.mr-xl-n3,.mx-xl-n3{margin-right:-1rem!important}.mb-xl-n3,.my-xl-n3{margin-bottom:-1rem!important}.ml-xl-n3,.mx-xl-n3{margin-left:-1rem!important}.m-xl-n4{margin:-1.5rem!important}.mt-xl-n4,.my-xl-n4{margin-top:-1.5rem!important}.mr-xl-n4,.mx-xl-n4{margin-right:-1.5rem!important}.mb-xl-n4,.my-xl-n4{margin-bottom:-1.5rem!important}.ml-xl-n4,.mx-xl-n4{margin-left:-1.5rem!important}.m-xl-n5{margin:-3rem!important}.mt-xl-n5,.my-xl-n5{margin-top:-3rem!important}.mr-xl-n5,.mx-xl-n5{margin-right:-3rem!important}.mb-xl-n5,.my-xl-n5{margin-bottom:-3rem!important}.ml-xl-n5,.mx-xl-n5{margin-left:-3rem!important}.m-xl-auto{margin:auto!important}.mt-xl-auto,.my-xl-auto{margin-top:auto!important}.mr-xl-auto,.mx-xl-auto{margin-right:auto!important}.mb-xl-auto,.my-xl-auto{margin-bottom:auto!important}.ml-xl-auto,.mx-xl-auto{margin-left:auto!important}}.stretched-link:after{background-color:transparent;bottom:0;content:"";left:0;pointer-events:auto;position:absolute;right:0;top:0;z-index:1}.text-monospace{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace!important}.text-justify{text-align:justify!important}.text-wrap{white-space:normal!important}.text-nowrap{white-space:nowrap!important}.text-truncate{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.text-left{text-align:left!important}.text-right{text-align:right!important}.text-center{text-align:center!important}@media (min-width:576px){.text-sm-left{text-align:left!important}.text-sm-right{text-align:right!important}.text-sm-center{text-align:center!important}}@media (min-width:768px){.text-md-left{text-align:left!important}.text-md-right{text-align:right!important}.text-md-center{text-align:center!important}}@media (min-width:992px){.text-lg-left{text-align:left!important}.text-lg-right{text-align:right!important}.text-lg-center{text-align:center!important}}@media (min-width:1200px){.text-xl-left{text-align:left!important}.text-xl-right{text-align:right!important}.text-xl-center{text-align:center!important}}.text-lowercase{text-transform:lowercase!important}.text-uppercase{text-transform:uppercase!important}.text-capitalize{text-transform:capitalize!important}.font-weight-light{font-weight:300!important}.font-weight-lighter{font-weight:lighter!important}.font-weight-normal{font-weight:400!important}.font-weight-bold{font-weight:700!important}.font-weight-bolder{font-weight:bolder!important}.font-italic{font-style:italic!important}.text-white{color:#fff!important}.text-primary{color:#007bff!important}a.text-primary:focus,a.text-primary:hover{color:#0056b3!important}.text-secondary{color:#6c757d!important}a.text-secondary:focus,a.text-secondary:hover{color:#494f54!important}.text-success{color:#28a745!important}a.text-success:focus,a.text-success:hover{color:#19692c!important}.text-info{color:#17a2b8!important}a.text-info:focus,a.text-info:hover{color:#0f6674!important}.text-warning{color:#ffc107!important}a.text-warning:focus,a.text-warning:hover{color:#ba8b00!important}.text-danger{color:#dc3545!important}a.text-danger:focus,a.text-danger:hover{color:#a71d2a!important}.text-light{color:#f8f9fa!important}a.text-light:focus,a.text-light:hover{color:#cbd3da!important}.text-dark{color:#343a40!important}a.text-dark:focus,a.text-dark:hover{color:#121416!important}.text-body{color:#212529!important}.text-muted{color:#6c757d!important}.text-black-50{color:rgba(0,0,0,.5)!important}.text-white-50{color:hsla(0,0%,100%,.5)!important}.text-hide{background-color:transparent;border:0;color:transparent;font:0/0 a;text-shadow:none}.text-decoration-none{text-decoration:none!important}.text-break{word-wrap:break-word!important;word-break:break-word!important}.text-reset{color:inherit!important}.visible{visibility:visible!important}.invisible{visibility:hidden!important}@media print{*,:after,:before{box-shadow:none!important;text-shadow:none!important}a:not(.btn){text-decoration:underline}abbr[title]:after{content:" (" attr(title) ")"}pre{white-space:pre-wrap!important}blockquote,pre{border:1px solid #adb5bd;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}@page{size:a3}.container,body{min-width:992px!important}.navbar{display:none}.badge{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #dee2e6!important}.table-dark{color:inherit}.table-dark tbody+tbody,.table-dark td,.table-dark th,.table-dark thead th{border-color:#dee2e6}.table .thead-dark th{border-color:#dee2e6;color:inherit}}body{color:#171717;font-family:Public Sans,sans-serif;font-size:16px;line-height:26px}.white-bg{background-color:#fff}.top-logo{background-color:#ebebeb}.top-header-logo{background-color:#065fa9;height:101px}.modal-empty .modal-content{border:none}.second-header-search{background-color:#044276;padding:16px;position:absolute;transition:all .4s;transition-timing-function:ease-in-out;z-index:1000}.div-modal{background-color:#000;height:100%;opacity:.5;position:fixed;z-index:900}.hhs-logo{border:0}.top-title-box{height:70px}.second-title-box{height:44px!important;width:calc(100% - 88px)}.top-logo-box{border-right:2px solid #a6bed2;margin:20px 10px 15px 0;padding-right:0;text-align:right}.title-h1,.title-h1 a,.title-h1 a:visited{color:#fff;font-family:Public Sans,sans-serif;font-size:24px;font-weight:700;letter-spacing:0;line-height:28px;text-decoration:none}.inner ul li a:hover,.navbar-light li a:hover{text-decoration:underline}.title-hide-br{display:none}.title-h3-white,.title-h3-white a,.title-h3-white a:visited{color:#fff;font-family:Public Sans,sans-serif;font-size:14px;letter-spacing:0;line-height:28px;margin-bottom:0;padding-top:5px;text-decoration:none}.top-breadcrumb{padding:16px 0 20px 2px}.top-breadcrumb a{color:#005ea2;font-size:16px;line-height:24px;text-decoration:underline}.top-breadcrumb a:hover{text-decoration:none}.bread-crumb-slash{color:#dcdee0}.nih-logo-footer{height:auto;width:60px}.img-btm-logo{text-align:right}.bottom-coloumn-logo{padding-right:0}.footer-site-url{font-size:13px}.footer-official{font-size:18px;font-weight:500}.footer-official-link{font-size:18px!important;font-weight:500!important;line-height:26px!important}.bottom-col-texturl{padding-left:0}.footer-date-list li{display:inline}.footer-date-list li+li+li:before{border-right:1px solid #171717;content:"";display:inline-block;height:.8em;margin:0 5px;transform:rotate(0deg)}.footer-bottom{color:#171717;font-size:16px;padding-left:0;padding-top:25px}.footer-bottom a,.footer-bottom-home a,.footer-top a{color:#171717;font-size:16px;line-height:35px;text-decoration:underline}.footer-bottom a:hover,.footer-bottom-home a:hover,.footer-top a:hover{text-decoration:none}.footer-block{background-color:#e6e6e6}.footer-block-top{background-color:#f0f0f0}.footer-top{padding:20px 0}#sidebar ul li{border-bottom:.5px solid #dcdee0}#sidebar ul li ul li ul li:first-of-type,#sidebar ul li ul li:first-of-type,#sidebar ul li:first-of-type{border-top:.5px solid #dcdee0}#sidebar ul li ul li ul li:last-of-type,#sidebar ul li ul li:last-of-type{border-bottom:0}#sidebar ul li a{color:#171717;display:inline-block;padding:.5rem 1rem;text-decoration:none;width:100%}#sidebar ul li a:hover{background-color:#f0f0f0;color:#005ea2;text-decoration:none}.archive-list{list-style:none;padding:0}.archive-list li{padding:6px 0}.archive-list li a{word-break:break-word!important}.sidebar-card-mobile .archive-list{padding-left:10px}.archive-date-header{margin-top:10px!important}.nav-item-active{color:#005ea2!important;font-weight:700;position:relative}.nav-head{background-color:#f0f0f0;margin-bottom:0;padding:6px 0 6px 10px}.skip-nav-color{color:#000}.nav-item-active:before{background-color:#005ea2;border-radius:99rem;bottom:.25rem;content:"";display:block;left:0;position:absolute;top:.25rem;width:.25rem}.nav-head-link,.nav-head-link:hover{color:#171717;font-weight:500}.nav-head-link:after{content:url(data:image/svg+xml;base64,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);float:right;padding-right:15px}.nav-head>.collapsed:after{content:url(data:image/svg+xml;base64,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);float:right;padding-right:15px}.txt-chunk-wrapper{line-height:30px;padding-bottom:35px;padding-left:5px}.single-box-content a,.txt-chunk-wrapper a{color:#005ea2;font-weight:500;text-decoration:underline;word-break:break-word}.single-box-content a:hover,.txt-chunk-wrapper a:hover{text-decoration:none}.highlight-box{border-bottom:5px solid #dcdee0;border-top:5px solid #dcdee0;margin:15px 0;padding-bottom:16px;padding-top:16px}.accord-box{border:1px solid #ebebeb;margin-bottom:30px}.accord-heading{padding:15px}@media (max-width:640px){.acc-h4-title{background-color:#f0f0f0;cursor:pointer;font-style:normal!important;font-weight:500!important;margin-bottom:0;margin-top:0!important;padding:5px 5px 5px 10px;text-align:center}}.acc-h4-title-opened:after{content:url(data:image/svg+xml;base64,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);display:inline-flex}.acc-h4-title-closed:after{content:url(data:image/svg+xml;base64,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);display:inline-flex}ol.super{counter-reset:start var(--start);list-style:none;padding:0}.super li:before{content:counter(start,lower-alpha);counter-increment:start;font-size:10px;line-height:2em;margin-left:-9px;position:absolute;text-align:center;top:-2px;vertical-align:super!important}.super li{display:block;line-height:25px;padding:0;position:relative}ol li{margin-bottom:10 px}.accord-table{--accord-border-color:#dcdee0}.accord-test-table td,.accord-test-table th{border-right:1px solid var(--accord-border-color)}.accord-test-table thead th{background-color:#e6e6e6;color:#212529;text-align:center}.accord-test-table thead tr th{border-left:0 solid var(--accord-border-color);border-top:0 solid var(--accord-border-color)}.accord-test-table tbody tr td{border-bottom:1px solid var(--accord-border-color)}.table-test-bordered th{border-bottom:1.5px solid var(--accord-border-color)}@media (max-width:760px){.table-bordered table,.table-bordered tbody,.table-bordered td,.table-bordered th,.table-bordered thead,.table-bordered tr{display:block;margin:0 auto;width:100%!important}.table-bordered tr{border-bottom:1pt solid var(--accord-border-color)}.accord-table-footnote{font-size:12px;margin:0 0 0 15px}.accord-box-table{border:1px solid #ebebeb;margin-bottom:30px}.accord-footnote{border-top:1px solid var(--accord-border-color);font-size:12px;padding-left:17px}.table-bordered thead{display:none}.table-bordered td{border:none}.table-bordered td:first-child{background-color:#dee8f3;color:#000;font-size:16px;font-weight:300;padding:5px 15px}.table-bordered td:first-child:before{font-size:18px;font-weight:100;text-transform:uppercase}.table-bordered td:not(:first-child){padding:5px 25px}.table-bordered td:not(:first-child):before{color:#384e95;text-transform:uppercase}.table-bordered td:before{color:#212529;content:attr(label);float:left;width:100%}}.table-bordered td,.table-bordered th{border:unset}@media (min-width:760px){.acc-h4-title{background-color:#f0f0f0;border-right:1px solid var(--accord-border-color);cursor:pointer;font-style:normal!important;font-weight:500!important;margin-bottom:0;margin-top:0!important;padding:5px 5px 5px 10px}.accord-table{margin-bottom:unset!important}.accord-table-footnote{border-right:1px solid var(--accord-border-color);font-size:12px;margin:-5px 0 -5px 15px;padding-top:15px}.accord-table-footnote ol:not(:first-child){margin-top:-5px!important}.accord-footnote{border-top:1px solid var(--accord-border-color);font-size:12px;padding-left:17px}.accord-table td,.accord-table th{border-right:1px solid var(--accord-border-color)}.accord-table{border-collapse:collapse}.accord-table tr{border-bottom:1px solid var(--accord-border-color)}.accord-box-table{border:1px solid #ebebeb;border-right:0!important;margin-bottom:30px}.accord-table thead tr{border-bottom:1px solid var(--accord-border-color)!important}}.accord-table thead th{background-color:#e6e6e6;color:#212529;text-align:center}.table-responsive{border:none!important}table{border-collapse:collapse;margin-bottom:15px;width:99%}table.noinnerborders td{border-left:none;border-right:none}caption{color:#171717}table th{background-color:#065fa9;border:1px solid #065fa9;border-bottom:1px solid #1870eb;border-right:1px solid #1870eb;color:#fff;height:45px;padding:5px 15px}table td{border:1px solid #cbd5df;padding:5px;vertical-align:top}.box-table{color:#cbd5df}.large-table-ico{background-color:#f0f0f0;cursor:pointer;margin:10px 0 15px}.large-image-ico{background-color:inherit;margin-bottom:0;position:relative}.large-table-ico td{height:40px;width:50%}table caption{display:none}.table-footer-col{border:0}table th a{color:#fff!important;text-decoration:underline!important}table th h2,table th h3{color:#fff!important;text-align:center!important}.td-name-col{width:40%}.td-equal-col{width:50%}table td p{margin-bottom:3px}table td ul{margin-left:-20px!important}.th-center-align,.th-heading-h2{text-align:center}.th-heading-h2{font-size:22px;font-weight:500;line-height:26.4px;margin-top:8px}.th-heading-h3,.th-heading-normal-txt{font-weight:400}.txt-chunk-wrapper h1{color:#000;font-size:32px;font-weight:500;line-height:38.4px}.txt-chunk-wrapper h2{color:#000;font-size:22px;font-weight:500;line-height:26.4px;margin-top:30px}.txt-chunk-wrapper h3{color:#000;font-size:18px;font-weight:500;padding-top:5px}.txt-chunk-wrapper h4{color:#000;font-size:16px;font-style:italic;font-weight:400;padding-top:5px}.txt-chunk-wrapper h5{color:#000;font-size:14px;font-weight:300;padding-top:5px}.txt-chunk-wrapper h6{color:#000;font-size:12px;font-weight:300;padding-top:5px}.txt-chunk-wrapper ul{margin:5px 0 15px -10px}.txt-chunk-wrapper ol{margin:5px 10px 5px 0}.hide-link{display:none}.box-red{border:1px solid red}.box-green{border:1px solid green}.box-gray{border:1px solid gray}.txt-chunk-wrapper{padding-top:30px}.hr-2x{border:0;border-top:2px solid rgba(0,0,0,.1)}.hr-2x,.hr-3x{margin-bottom:1rem;margin-top:1rem}.hr-3x{border:0;border-top:3px solid rgba(0,0,0,.1)}.externalIcon{padding-left:4px}.emailIcon:after,.externalIcon:after,span.ext{content:"";height:10px;padding-right:16px;text-decoration:none;width:10px}@media screen{.emailIcon:after,.externalIcon:after,span.ext{background:url(data:image/svg+xml;base64,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) 2px no-repeat}.submit-button .externalIcon:after{background:url(data:image/svg+xml;base64,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) 2px no-repeat}.txt-chunk-wrapper a .externalIcon:after{background:url(data:image/svg+xml;base64,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) 2px no-repeat}}@media print{.emailIcon:after,.externalIcon:after,span.ext{content:url(data:image/svg+xml;base64,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)}.submit-button .externalIcon:after{content:url(data:image/svg+xml;base64,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)}.txt-chunk-wrapper a .externalIcon:after{content:url(data:image/svg+xml;base64,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)}}.archived-Status{padding-left:5px;padding-right:5px}.archive-banner-box,.archive-banner-box a{color:#171717}.archive-banner-box a{text-decoration:underline}.archive-banner-box a:hover{text-decoration:none}.archive-text-banner{overflow:hidden;padding:25px 0 5px}.top-banner-title{font-weight:500}.top-banner-p,.top-banner-title{font-size:16px;line-height:20px}.red-banner{background-color:#f5e6af}.banner-list{font-size:16px;line-height:1.1;margin-bottom:0;padding-left:20px}.banner-list li{display:inline}.banner-list li:before{content:"";margin:20px 5px}.banner-mobile-list{font-size:16px;margin-bottom:0;margin-left:-15px}.wrapper-div-over-table{align-items:center;position:relative}.wrapper-div-over-image,.wrapper-div-over-table{display:flex;justify-content:center;text-align:center}.wrapper-div-over-image{align-items:flex-end;background:linear-gradient(180deg,transparent,#fff 70%,#fff);bottom:0;height:77px;position:absolute;width:100%}.div-over-table{align-items:center;background-color:#fff;color:#065fa9;cursor:pointer;font:700 18px;position:relative;text-align:center;top:-100px;width:60%;z-index:99}nav.bread-crumb ol{list-style:none;margin:0;padding-left:0}nav.bread-crumb li{display:inline}nav.bread-crumb li+li:before{border-right:.1em solid #dcdee0;content:"";display:inline-block;height:.8em;margin:0 .25em;transform:rotate(20deg)}nav.bread-crumb [aria-current=page]{color:#171717;text-decoration:none}footer.footer-links ol{list-style:none;margin:0;padding-left:0}.txt-chunk-single-box{border-top:5px solid #dcdee0;margin:20px 0;padding:25px 0 0}.fullscreen .modal-dialog{background-color:#162e51;color:#fff;height:100%;margin:0;max-width:100%;min-height:100%;padding:0;width:100%}.fullscreen .modal-content{background:#162e51;border-radius:0;color:#fff;height:100%;min-height:100%;overflow:auto}.fullscreen .modal-body a{color:#fff;font-size:100%}.second-lvl{display:none}#navbar-responsive ul.navbar-nav{background-color:#162e51;margin:0;width:auto!important}.nav-btn{width:50%}.nav-back{background-color:#71767a;padding-left:38px!important;position:relative}.nav-back:before{background-image:url(data:image/png;base64,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);background-repeat:no-repeat;background-size:16px 16px;content:"";height:16px;left:14px;position:absolute;top:19px;width:16px}.nav-close{background-color:#162e51;background:#162e51;border:0;box-shadow:none;color:#fff;float:right;font-weight:400;padding:15px 45px 18px;position:relative;text-align:right;width:100%}.nav-close:after{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACAAAAAgCAYAAABzenr0AAABGklEQVR42uyXKw7CQBCGW7BYEkwtTbCcCIFHIBBgkT0CggNwFjgAEiQ4gmKYDTRpNtvdeSVFMMmv9vF92cxu0xwAsi6rl3VcPytQYFaGnBKzCI64HvBSYM7wqSowzk2JuXz3W/vjMTgYSDThEJLwF2whXJUR3NUNM2oT6GN2BhIx+DR2AhYSZHibgEZizIHHBCQSbHhKgCMhglMEKBJiOFUgJfGQwjkCKQkRnCtAkWDBJQIuE8yzRWDP3c/qeRU/29ZwtoQWfsccNBJauGu4nubbQYFfI/B6nljCAq6SsIKLJSzhIgl/8SDRcNRbE5NYpk5gjnkp4LFn+4QZUnqglpDCQxJHH566BTMlvCmxCcFd8v/PadcCbwEGACWAXr2Qapk5AAAAAElFTkSuQmCC);background-repeat:no-repeat;background-size:16px 16px;content:"";height:16px;position:absolute;right:18px;top:20px;width:16px}.srch-Btn{background:url(data:image/png;base64,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);background-color:#065fa9;background-position:50%;background-repeat:no-repeat;background-size:20px 20px;border:none;border-radius:0;box-shadow:none;cursor:pointer;float:right;outline:0;transition:all .3s;width:50px}.srch-Btn:hover{background-color:#0076d6}.srch-txt{border-radius:0;height:45px}.srch-box{padding:10px 0}.modal-body_menu_mobile{padding:0}.modal-header_menu_mobile{padding:2px}.landingpage-menu{padding:0}ul.navbar-nav li.slide-menu ul li{background-color:#162e51;border-bottom:.5px solid #a9aeb1;font-weight:300;letter-spacing:0;margin-bottom:0;width:100%}ul.navbar-nav li.slide-menu ul li:first-child{border-top:.5px solid #a9aeb1}ul.navbar-nav li.slide-menu ul li.active{background-color:#2660a4}ul.navbar-nav li.slide-menu ul li .sub1,ul.navbar-nav li.slide-menu ul li .sub2{background-color:#162e51;background-image:url(data:image/png;base64,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);background-position:50%;background-repeat:no-repeat;background-size:10px 15px;border:none;border-left:1px solid #dfe1e2;box-shadow:none;display:block;float:right;height:54px;padding:0;width:55px}ul.navbar-nav li.slide-menu ul li .sub1:hover,ul.navbar-nav li.slide-menu ul li .sub2:hover{background-color:#1a4480}ul.navbar-nav li.slide-menu ul li a{display:inline-block;padding:15px 16px;width:100%}ul.navbar-nav li.slide-menu ul li a:hover{text-decoration:none}.nav-a-with-btn{width:calc(100% - 55px)!important}.sub-menu{padding:0}.sub-menu li:nth-child(n+3){padding-left:13px}ul.sub-menu li:first-child{border-top:1px solid #dfe1e2}.srch-Btn-mobile{background:url(data:image/png;base64,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) 0 no-repeat;background-color:transparent;background-position-y:27px;background-size:31px;border:none;border-radius:0;box-shadow:none;float:right;height:89px;outline:0;position:relative;transition:all .3s;width:40px}.div-close-btn{height:44px;padding-right:2px;padding-top:2px}.btn-mobile-menu{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIzMiIgaGVpZ2h0PSIzMiIgZmlsbD0iI2ZmZiIgY2xhc3M9InByZWZpeF9fYmkgcHJlZml4X19iaS1saXN0IiB2aWV3Qm94PSIwIDAgMTYgMTYiPjxwYXRoIGZpbGwtcnVsZT0iZXZlbm9kZCIgZD0iTTIuNSAxMmEuNS41IDAgMCAxIC41LS41aDEwYS41LjUgMCAwIDEgMCAxSDNhLjUuNSAwIDAgMS0uNS0uNXptMC00YS41LjUgMCAwIDEgLjUtLjVoMTBhLjUuNSAwIDAgMSAwIDFIM2EuNS41IDAgMCAxLS41LS41em0wLTRhLjUuNSAwIDAgMSAuNS0uNWgxMGEuNS41IDAgMCAxIDAgMUgzYS41LjUgMCAwIDEtLjUtLjV6Ii8+PC9zdmc+);background-position:bottom 34px right -1px;background-repeat:no-repeat;background-size:42px;border:none;box-shadow:none;color:#fff;font-size:10px;height:89px;padding:24px 0 0;position:absolute;right:0;transition:all .3s;width:40px}.btn-mobile-search-close{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+);background-position:bottom 24px right 4px;background-repeat:no-repeat;background-size:26px;font-size:9px;height:auto;padding-left:6px;padding-right:0;position:relative}.covid-search-input{padding-bottom:1rem}.covid-search-input-text{height:3rem}.covid-search-header-input-text{border:none;height:2.25rem}.covid-search-input-btn{background-color:#fbbb3d;border-radius:0;justify-content:center;opacity:1;padding:.375rem;width:4rem}.covid-search-input-btn:hover{opacity:.8}.covid-search-header-input-btn{width:3rem}.covid-search-input-span{background:url(data:image/png;base64,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) no-repeat top;background-size:contain;display:inline-block;width:2.25rem}.input-error::placeholder{color:#b50909;opacity:1}.input-error::-webkit-input-placeholder{color:#b50909}.input-error:-moz-placeholder,.input-error::-moz-placeholder{color:#b50909}.input-error:-ms-input-placeholder{color:#b50909}.input-error::-ms-input-placeholder{color:#b50909}.covid_search-result{margin-bottom:1.5rem}.covid_search-result:first-child{margin-top:1.5rem}.covid_search-result p{margin-bottom:.5rem}.covid_search-result a:first-child{text-decoration:none}.covid_search-result a:first-child:hover,a:first-child:active{text-decoration:underline}.no-underline{text-decoration:none!important}.no-padding{padding:0!important}.covid-search_bottomrow{margin-bottom:1rem}.covid_search-pagination{margin-left:0!important}.covid_search-pagination .page-link{border:none;border-radius:0!important;cursor:pointer;font-size:.875rem;text-decoration:none}.covid_search-pagination .page-item.active .page-link{background-color:#005ea2;border-color:#005ea2}.covid-search-returntotop-btn{float:right;margin-top:5px}.nav-col-right .sidebar-card{margin-left:0;width:100%}.covid-search_moreresults{display:none}.srch-box-dtop{padding:25px 0 10px}.srch-box-mobile{padding:0}.srch-txt-dtop{border:0;border-radius:0;height:38px}.srch-Btn-dtop{background:url(data:image/png;base64,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);background-color:#fbbb3d;background-position:50%;background-repeat:no-repeat;background-size:20px 20px;border:none;border-radius:0;box-shadow:none;cursor:pointer;float:right;outline:0;transition:all .3s;width:50px}.srch-Btn-dtop:focus,.srch-Btn:focus{z-index:0}.returntotop-button{border:.125rem solid #005ea2;border-radius:0;color:#005ea2}.returntotop-button:visited{border-color:#162e51;color:#162e51}.returntotop-button:hover{border-color:#1a4480;color:#1a4480}.returntotop-button:active{border-color:#162e51;color:#162e51}.search-label-color{color:#cce4ff}.search-label-result-page{color:#404040}.twitter-color{color:#d6d6d6}.print-logo{display:none}.twitter-button{background:url(data:image/svg+xml;base64,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) no-repeat 50%;background-color:#005ea2;background-size:auto;border-radius:.25rem;display:inline-block;height:2.5rem;margin-top:.6em;text-align:center;width:2.5rem!important}.search-content{max-width:80ex}.srch-txt-body{border-radius:0;height:3rem}.srch-box-body{padding-bottom:12px}.srch-Btn-body{background:url(data:image/png;base64,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);background-color:#fbbb3d;background-position:50%;background-repeat:no-repeat;background-size:28px 28px;border:none;border-radius:0;box-shadow:none;cursor:pointer;float:right;outline:0;transition:all .3s;width:64px}.srch-Btn-body:hover{background-color:#fa9441}.srch-Btn-body:focus{z-index:0}.sidebar-card-right{background-color:#f0f0f0;margin-bottom:1em;padding:1.3em 1em 1em;width:100%}.right-side-box{padding-top:45px!important}.recaptcha-copy{color:#595959;font-size:.7rem;line-height:18px;margin-top:5px;padding-left:1px!important;text-align:left}.grecaptcha-badge,.grecaptcha-badge textarea{opacity:0;visibility:hidden!important}#scroll_Top{background-color:rgba(251,187,61,.8);border:none;border-radius:50px;bottom:130px;color:#000;cursor:pointer;display:none;font-size:15px;height:80px;line-height:13.5px;outline:none;padding:5px;position:fixed;right:30px;text-align:right;text-align:center;width:80px;z-index:101}#div_arrow{background-image:url(data:image/svg+xml;base64,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);background-position:50%;background-repeat:no-repeat;display:block;height:15px}#div_bk,#div_totop{display:block;height:15px;padding-top:3px}#div_spacer{display:block;height:8px}.grid-col-auto,.grid-col-fill{flex:0 1 auto!important}.grid-col,.grid-col-auto,.grid-col-fill{max-width:100%!important;width:auto!important}.usa-banner{background-color:#f0f0f0;font-family:Source Sans Pro Web,Helvetica Neue,Helvetica,Roboto,Arial,sans-serif;font-size:1.06rem;line-height:1.5}.usa-banner-container{padding-left:5px}.usa-banner__inner{align-items:flex-start;display:flex!important;max-width:64rem;padding-right:0}.usa-banner__header{font-size:.8rem;font-weight:400;min-height:3rem;padding-bottom:.5rem;padding-top:.5rem;position:relative}.usa-accordion{color:#1b1b1b;font-size:1.06rem;line-height:1.5;list-style-type:none;margin:0;padding:0;width:100%}.usa-banner .usa-accordion{font-family:Source Sans Pro Web,Helvetica Neue,Helvetica,Roboto,Arial,sans-serif;font-size:1.06rem;line-height:1.5}.usa-accordion__button{background-color:#f0f0f0;background-position:right 1.25rem center;background-repeat:no-repeat;background-size:1rem;color:#1b1b1b;cursor:pointer;display:inline-block;line-height:1}.usa-accordion__button,.usa-banner__button{-moz-osx-font-smoothing:auto;-webkit-font-smoothing:subpixel-antialiased;border:0;border-radius:0;box-shadow:none;margin:0;padding:0;text-align:left;text-decoration:none}.usa-banner__button{background-color:transparent;bottom:0;color:#005ea2;display:block;font-size:.8rem;font-weight:400;height:auto;left:0;line-height:1.1;position:absolute;top:0;vertical-align:baseline;width:auto}.usa-banner__button[aria-expanded=false],.usa-banner__button[aria-expanded=true]{background-image:none}.usa-banner__button[aria-expanded=false]:after{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat}.usa-banner__button[aria-expanded=true]:after{background:0 0;background-color:#005ea2;-webkit-mask:url(data:image/svg+xml;base64,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) no-repeat center/1.3128205128ex .8ex;mask:url(data:image/svg+xml;base64,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) no-repeat center/1.3128205128ex .8ex;transform:rotate(180deg)}.usa-banner__button-text{left:-999em;position:absolute;text-decoration:underline}.grid-col-fill{flex:1 1!important;min-width:1px}[class*=grid-col]{box-sizing:border-box;position:relative;width:100%}.usa-banner__header-action{color:#005ea2;line-height:1.1;margin-bottom:0;margin-top:2px;text-decoration:underline}.usa-banner__header-text{font-size:.8rem;line-height:1.1;margin-bottom:0;margin-top:0}.usa-banner__header-flag{float:left;margin-right:.5rem;width:1rem}.usa-banner__content{background-color:transparent;font-size:1rem;margin-right:auto;max-width:64rem;overflow:hidden;padding:.25rem 1rem 1rem .5rem;width:100%}.usa-banner__guidance{align-items:flex-start;display:flex;max-width:64ex;padding-left:0}.usa-accordion__content{margin-top:0;overflow:auto;padding:1rem 1.25rem .75rem}.usa-media-block__img{flex-shrink:0;margin-right:.5rem}.usa-banner__icon{width:2.5rem}.usa-media-block__body{flex:1 1}.usa-banner__lock-image{height:1.5ex;width:1.21875ex}.yellow-banner-text{font-size:18px;font-weight:600}.alert-ico-img{margin-right:10px;width:1.1em}.yellow-banner-button{-moz-osx-font-smoothing:auto;-webkit-font-smoothing:subpixel-antialiased;background-color:transparent;border:0;border-radius:0;bottom:0;box-shadow:none;color:#005ea2;display:none;font-size:.8rem;font-weight:400;height:auto;left:0;line-height:1.1;margin:0;padding:0;position:absolute;text-align:left;text-decoration:none;top:0;vertical-align:baseline;width:100%}.usa-banner__button[aria-expanded=true],.yellow-banner-button[aria-expanded=false]{background-image:none}.yellow-banner-show{display:block}.banner-list-mobile-box{padding:15px 0 12px}.ref-accord-box{border:1px solid #ebebeb;margin-top:30px}.ref-h2-title{background-color:#ebebeb;cursor:pointer;margin-bottom:0;margin-top:0!important;padding:10px 10px 10px 15px}.ref-h2-title_longtable{background-color:transparent}.ref-h2-title-opened:after{content:url(data:image/svg+xml;base64,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);float:right;width:12px}.ref-h2-title-closed:after{content:url(data:image/svg+xml;base64,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);float:right;width:12px}.ref-accord-list{padding-bottom:15px;padding-top:10px;word-break:break-word}.covid-alert{background-color:#f0f0f0;background-position:1.5rem 1rem;background-repeat:no-repeat;background-size:2.4rem;margin-bottom:1.5rem;margin-top:1rem;padding:1.25rem 1.25rem 1.25rem 1.75rem;position:relative}.covid-alert-border{border-left:.5rem solid #00bde3!important}.covid-alert-info{background-color:#e7f6f8;background-image:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdmlld0JveD0iMCAwIDI0IDI0Ij48cGF0aCBmaWxsPSJub25lIiBkPSJNMCAwaDI0djI0SDB6Ii8+PHBhdGggZD0iTTEyIDJDNi40OCAyIDIgNi40OCAyIDEyczQuNDggMTAgMTAgMTAgMTAtNC40OCAxMC0xMFMxNy41MiAyIDEyIDJ6bTEgMTVoLTJ2LTZoMnY2em0wLThoLTJWN2gydjJ6Ii8+PC9zdmc+),linear-gradient(transparent,transparent)}.covid-alert-body{display:table-cell;vertical-align:top}.covid-alert-error_border{border-left:.5rem solid #b50909!important}.covid-alert-error{background-color:#f3e3db;background-image:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdHJhbnNmb3JtPSJyb3RhdGUoMTgwKSIgdmlld0JveD0iMCAwIDI0IDI0Ij48cGF0aCBmaWxsPSJub25lIiBkPSJNMCAwaDI0djI0SDB6Ii8+PHBhdGggZD0iTTEyIDJDNi40OCAyIDIgNi40OCAyIDEyczQuNDggMTAgMTAgMTAgMTAtNC40OCAxMC0xMFMxNy41MiAyIDEyIDJ6bTEgMTVoLTJ2LTZoMnY2em0wLThoLTJWN2gydjJ6Ii8+PC9zdmc+),linear-gradient(transparent,transparent)}.covid-alert-warning_border{border-left:.5rem solid #ffbe2e!important}.covid-alert-warning{background-color:#faf3d1;background-image:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdmlld0JveD0iMCAwIDI0IDI0Ij48cGF0aCBkPSJNMSAyMWgyMkwxMiAyIDEgMjF6bTEyLTNoLTJ2LTJoMnYyem0wLTRoLTJ2LTRoMnY0eiIvPjwvc3ZnPg==),linear-gradient(transparent,transparent)}.covid-alert-error .covid-alert-body,.covid-alert-info .covid-alert-body,.covid-alert-warning .covid-alert-body{padding-left:3.25rem}.detdr-down{background:#f0f0f0!important;border:3px solid #005ea2!important;color:#005ea2!important}.dr-dimension{padding:8px 0 15px}.det-page-tab ul{margin-left:0}.det-page-tab ul li a{background-color:#dcdee0!important;color:#424242;line-height:28px;min-width:145px;text-align:center;text-decoration:none!important}.det-page-tab ul li :active{color:#005ea2!important}.detail-page_content table{border:1px solid #cbd5df}.accord-box .ref-h2-title{background-color:transparent;color:#0f1010;line-height:26.4px;padding-top:10px}.accordion-block_content{padding-left:10px;padding-right:10px}.accordion-block_content>ul{margin:0;padding-left:16px}.drdown-list{padding-left:5px}.gldet-dropdown-hide .nav-link{padding:12px 25px 2px 30px}.nav-tabs.nav-link.active{color:#005ea2!important}.gl-dropdown{display:grid}.gldet-dropdown a{text-decoration:none}#content p{max-width:80ex}.st-width p{max-width:none!important}.gldet-margin{margin-left:0}.nav-tabs .nav-item.show .nav-link,.nav-tabs .nav-link.active{background-color:#fff!important;color:#005ea2!important;padding-top:8px!important}.dropdown-menu a{text-align:center;width:685px}.covid-alert-heading{margin-bottom:.5rem;margin-top:0}.covid-alert-text,.covid-alert-text p{margin-bottom:0;margin-top:0}.covid-alert-slim{background-position:1.75rem .55rem;background-size:1.5rem;padding-bottom:.5rem;padding-top:.5rem}.alert-modal{max-width:55rem;padding:1.5rem;width:100%}.alert-modal .modal-content{border-radius:.5rem}.alert-modal-body{margin:0 auto;max-width:40rem}.alert-modal-body h1,h2{font-weight:700}.alert_close-btn{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiM3NTc1NzUiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+);background-position:right 0;background-repeat:no-repeat;background-size:18px;border:none;font-size:9px;height:36px;position:relative;width:36px}.alert_close-btn:active,.alert_close-btn:focus,.alert_close-btn:hover{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+);background-color:transparent!important;background-position:right 0;background-repeat:no-repeat;background-size:18px;box-shadow:none!important}.alert_ok-btn{max-width:120px}.rating-popup{max-width:90%}.rating-popup_btn{color:#005ea2;font-size:inherit;-webkit-text-decoration:underline dotted!important;text-decoration:underline dotted!important;vertical-align:inherit}.rating-popup_btn:focus{box-shadow:none}@media print{.rating-popup_btn{color:inherit;text-decoration:none!important}}.sr-heading{background-color:#065fa9;border-bottom:1px solid #1870eb;border-right:1px solid #1870eb;color:#fff;display:flex;height:45px;justify-content:center;padding:5px 15px}.sr-heading-h2{color:#fff!important;font-weight:500!important;margin-top:4px!important}.sr-table-body{margin-bottom:15px}.sr-td{border:1px solid #cbd5df;border-top:0;padding:5px 5px 5px 15px;vertical-align:top}.sr-td ul{margin-left:-20px!important}@media (min-width:280px){.btn-mobile-menu,.btn-mobile-menu-home,.title-nxt-line{display:block}.srch-box-dtop{display:none}.srch-box-mobile{display:flex}#scrollTop{bottom:20px}.bottom-col-texturl{margin-left:15px}.footer-twitter-btn{float:left;margin-top:10px}.footer-date-list{padding-top:20px}.footer-date-list li:first-child{display:list-item}.footer-date-list li:nth-child(2),.footer-date-list li:nth-child(3){display:inline}.usa-banner__header-action:after{background:0 0;background-color:#005ea2;-webkit-mask:url(data:image/svg+xml;base64,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) no-repeat center/1.3128205128ex .8ex;mask:url(data:image/svg+xml;base64,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) no-repeat center/1.3128205128ex .8ex}.usa-banner__header-action-clicked{display:none}.usa-banner__header-action:after{content:"";display:inline-block;height:.8ex;margin-left:2px;vertical-align:middle;width:1.3128205128ex}}@media (min-width:320px){.top-banner-title{font-size:16px;line-height:15px}.top-banner-p{font-size:12px;line-height:15px}.archive-text-banner{padding:15px 0 5px}.gry-txt-box{background:linear-gradient(90deg,rgba(0,0,0,.7) 0,rgba(0,0,0,.7) 95%,transparent 0,transparent);bottom:65px;margin-left:15px}}@media (min-width:480px){.title-nxt-line{display:none}.dropdown-menu a{text-align:center}}@media (max-width:420px){.usa-banner__header-top{padding-right:48px!important}.rating-modal-body{padding-left:.5rem;padding-right:.5rem}}@media (max-width:499px){.yellow-banner-button[aria-expanded=false]:after{top:18px}.gry-txt-box{background:linear-gradient(90deg,rgba(0,0,0,.7) 0,rgba(0,0,0,.7) 95%,transparent 0,transparent);bottom:65px;margin-left:15px}.usa-banner__header-second{padding-right:24px!important}}@media (max-width:639px){.usa-banner__button{width:100%}.dropdown-menu a{text-align:center;width:318px}.usa-banner__button[aria-expanded=true]:before{background-color:#e6e6e6;bottom:0;content:"";display:block;height:3rem;position:absolute;right:0;top:0;width:3rem}.usa-banner__button[aria-expanded=true]:after{background:0 0;background-color:#005ea2;background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat 50%/1rem 1rem;bottom:0;content:"";display:inline-block;height:3rem;margin-left:0;-webkit-mask:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat center/1rem 1rem;mask:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat center/1rem 1rem;position:absolute;right:0;top:0;vertical-align:middle;width:3rem}.usa-banner-container{margin-left:0;margin-right:-15px;padding-left:5px;padding-right:0}}@media (min-width:640px){.usa-banner__button{bottom:auto;color:#005ea2;display:inline;left:auto;margin-left:.5rem;position:relative;right:auto;top:auto}.usa-banner__button-text{display:inline;position:static}.usa-banner__button:after{background:url(data:image/svg+xml;base64,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) no-repeat 50%/1.3128205128ex .8ex;content:"";display:inline-block;height:.8ex;margin-left:2px;vertical-align:middle;width:1.3128205128ex}.usa-banner{font-size:.87rem;padding-bottom:0}.usa-banner__header{min-height:0;padding-bottom:.25rem;padding-top:.25rem}.usa-banner__inner{align-items:center}.tablet\:grid-col-auto{flex:0 1 auto!important;max-width:100%!important;width:auto!important}.usa-banner__header-action{display:none}.usa-banner__header-flag{margin-right:.5rem;padding-top:0}.usa-banner__content{padding-bottom:1.5rem;padding-top:1.5rem}.usa-banner__header-action-clicked{display:none}.alert-ico-img{margin-right:10px;width:1.1em}}@media (min-width:768px){.top-banner-p,.top-banner-title{font-size:16px;line-height:20px}.archive-text-banner{padding:25px 0 5px}#scrollTop{bottom:60px}}@media (max-width:991px){.banner-list{padding-left:0}.banner-list li{display:block}.yellow-banner-button[aria-expanded=false]:after{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI2NCIgaGVpZ2h0PSIzOSIgdmlld0JveD0iMCAwIDY0IDM5Ij48cGF0aCBkPSJNNjMuMzYgNC4wMDQgNjAuMTU1Ljc0MWMtLjQyNy0uNDM2LS45MTktLjY1NC0xLjQ3NS0uNjU0LS41NTUgMC0xLjA0Ny4yMTgtMS40NzUuNjU0TDMyIDI2LjQgNi43OTguNzRDNi4zNy4zMDYgNS44NzguMDg4IDUuMzIzLjA4OGMtLjU1NiAwLTEuMDQ4LjIxOC0xLjQ3Ni42NTRMLjY0MiA0LjAwNUMuMjEzIDQuNDQgMCA0Ljk0MSAwIDUuNTA3YzAgLjU2NS4yMTQgMS4wNjYuNjQyIDEuNTAxbDI5Ljg4MyAzMC40MjdjLjQyNy40MzUuOTIuNjUyIDEuNDc1LjY1Mi41NTYgMCAxLjA0Ny0uMjE3IDEuNDc0LS42NTJMNjMuMzYxIDcuMDA4Yy40MjctLjQzNS42MzktLjkzNi42MzktMS41MDEgMC0uNTY2LS4yMTItMS4wNjctLjY0LTEuNTAzeiIvPjwvc3ZnPg==) no-repeat 50%/1rem 1rem!important;background-color:#171717;bottom:0;content:"";display:inline-block;height:16px;margin-left:10px;-webkit-mask:url(data:image/svg+xml;base64,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) no-repeat center/16px 16px;mask:url(data:image/svg+xml;base64,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) no-repeat center/16px 16px;position:absolute;right:16px;top:14px;vertical-align:middle;width:16px}.banner-list-box{display:none;padding:15px 0 12px}.yellow-banner-button{display:block}.yellow-banner-button[aria-expanded=false]:before,.yellow-banner-button[aria-expanded=true]:before{background-color:#f5e6af;bottom:0;content:"";display:block;height:2rem;position:absolute;right:1px;top:1px;width:2rem}.yellow-banner-button[aria-expanded=true]:after{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat 50%/1rem 1rem;bottom:0;content:"";display:inline-block;height:3rem;margin-left:0;-webkit-mask:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat center/1rem 1rem;mask:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+) no-repeat center/1rem 1rem;position:absolute;right:0;top:0;vertical-align:middle;width:3rem}.dropdown-menu a{text-align:center;width:100%}#scroll_Top{bottom:36px}.rating-popup{max-width:100%}}@media (min-width:992px){.btn-mobile-menu,.btn-mobile-menu-home{display:none}.srch-box-dtop{display:flex;width:240px}.fullscreen .modal-content,.fullscreen .modal-dialog{height:0;width:0}#scrollTop{bottom:130px}#scroll_Top:hover{background-color:#e59f17}.bottom-col-texturl{margin-left:0}.footer-twitter-btn{float:right;margin-top:0}.footer-date-list{padding-top:0}.footer-date-list li:first-child{display:inline}.usa-banner__header{min-height:0;padding-bottom:.25rem;padding-top:.25rem}.banner-list-box{display:block;padding:0}.banner-list-mobile-box{display:none}.gldet-dropdown{display:none!important}.line-height-lg-22{line-height:22px!important}.col-twitter_icon{max-width:40px}}@media (min-width:992px) and (max-width:1300px){.trim-padding-for-small-width-desktops .gldet-dropdown-hide .nav-link{min-width:auto;padding:.5rem 1rem}}@media (min-width:1200px){.srch-box-dtop{width:280px}.bottom-col-texturl{margin-left:-10px}}@media (min-width:768px){.container-md-ex{max-width:760px}}@media (min-width:838px){.container-md-ex{max-width:810px}}@media (min-width:992px){.container-md-ex{max-width:960px}}@media (min-width:1080px){.container-md-ex{max-width:1020px}}@media (min-width:1200px){.container-md-ex{max-width:1150px}}@media (min-width:1300px){.container-md-ex{max-width:1240px}}@media (min-width:1400px){.container-md-ex{max-width:1320px}}.full-width-content p{max-width:none!important}body{background-color:#f0f0f0}@media (min-width:320px){#sidebar ul li:first-of-type{border-top:0}.outer-box-menu{display:none}.title-h1{font-size:12px;line-height:9px;padding-top:4px}.title-h3-white{font-size:8px;line-height:20px}.title-hide-br{display:block}.top-title-box{padding-left:10px}.list-unstyled{padding-left:15px}.nav-head{border-bottom:#f0f0f0;display:block;margin-right:-40px}.footer-top{padding:15px 0}.footer-bottom{padding-bottom:40px;padding-top:40px}.txt-chunk-wrapper{padding-left:0;padding-right:0}.div-over-table{top:-125px}}@media (min-width:346px){#sidebar ul li:first-of-type{border-top:0}.title-h1{font-size:14px;line-height:13px;padding-top:0}.title-h3-white{font-size:9.5px;line-height:26px}.list-unstyled{padding-left:15px}.nav-head{border-bottom:#f0f0f0;display:block;margin-right:-40px}.div-over-table{top:-110px}}@media (min-width:480px){.title-h1{font-size:20px;line-height:14px;padding-top:0}.title-h3-white{font-size:14px;line-height:26px}}@media (min-width:580px){.title-h1{font-size:24px;line-height:28px}.title-h3-white{font-size:14px;line-height:28px}.list-unstyled{padding-left:20px}.nav-head{border-bottom:#f0f0f0;display:block;margin-right:-40px}}@media (min-width:768px){.nav-head{border-bottom:#f0f0f0;display:block;margin-right:-40px}#sidebar ul li:first-of-type{border-top:0}.list-unstyled{padding-left:25px}.title-hide-br{display:none}.top-title-box{padding-left:20px}}@media (min-width:992px){.nav-head{display:none}.outer-box-menu{display:block}#sidebar ul li:first-of-type{border-top:.5px solid #dcdee0}.outer-box-menu{border:0;margin-top:30px;padding-right:40px}.list-unstyled{padding-left:10px}#mainfullmenu{display:block}.txt-chunk-wrapper{padding-left:5px}.top-title-box{padding-left:25px}.footer-bottom{padding-bottom:25px;padding-top:25px}.footer-top{padding:20px 0}}.logo-lockup{margin:20px 10px 15px 0}.logo-lockup,.logo-lockup:hover,.logo-lockup:visited{text-decoration:none}.top-title-box{display:flex;flex-direction:column;height:auto;justify-content:center;padding-left:25px;padding-top:0}.title-h3-white{font-size:16px;line-height:24px;padding-top:0}.hhs-logo{height:70px;width:70px}.top-header-logo{height:auto}@media screen and (max-width:767px){.title-h3-black,.title-h3-white{font-size:11px;line-height:18px}.title-h1{font-size:16px;line-height:24px}.top-logo-box{padding-right:0}.top-title-box{padding-left:5px}.hhs-logo{height:60px;width:60px}}@media screen and (max-width:375px){.hhs-logo{height:35px;width:35px}.top-title-box{padding-left:5px}.title-h3-black,.title-h3-white{font-size:11px;line-height:18px}.title-h1{font-size:14px;line-height:18px;padding-top:0}}@media screen and (min-width:341px) and (max-width:374px){.title-h1{font-size:13px;line-height:18px;padding-top:0}}@media screen and (max-width:340px){.title-h1{font-size:12px;line-height:18px;padding-top:0}}.archive-text-banner{height:auto;padding-bottom:10px;padding-top:10px}.top-banner-p{margin-bottom:5px}@media screen and (max-width:767px){.top-banner-title{font-size:18px;line-height:24px;margin-bottom:10px}}.update-date{font-style:italic}.sidebar-title{font-size:18px;font-weight:500;line-height:1.2;margin-bottom:.5rem;margin-top:0}.sidebar-card{background-color:#f0f0f0;display:inline-block;margin-bottom:1em;margin-left:10px;max-width:332px;padding:1.3em 1em 1em;width:93.9%}.sidebar-card li a{display:inline-block;font-size:15px;line-height:18px;vertical-align:top}.sidebar-card a{color:#005ea2;display:-ms-inline-flexbox;font-weight:500;text-decoration:underline;word-break:break-word;word-break:break-all}.sidebar-card a:hover{text-decoration:none}.sidebar-card-mobile{display:none}.sidebar-card-contact{background-color:#f0f0f0;margin-bottom:1em;margin-top:1em;padding:1.3em 1em 1em;width:100%}.sidebar-card h3{font-size:18px}.guideline-pdf{border-top:5px solid #fbbb3d}@media screen and (max-width:991px){.sidebar-card{display:none}.sidebar-card-mobile{background-color:#f0f0f0;display:block;margin-bottom:1em;margin-top:1em;padding:1.3em 1em 1em;width:100%}.returntotop-button{width:100%}.twitter-button-panel{text-align:center}.covid-search_pagination{display:none}.covid-search_moreresults{display:block;margin-bottom:1rem}}.guideline-pdf-list{margin-bottom:0!important;padding-left:10px}.guideline-pdf-list li{align-items:flex-start;display:flex;flex:1 1;list-style-type:none;padding-bottom:1em}.guideline-pdf-list li a{display:inline-block;font-size:15px;line-height:18px;max-width:90%}.guideline-pdf-list li a:hover{text-decoration:none}.guideline-pdf-list li:before{background-image:url(data:image/svg+xml;base64,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);background-size:20px 20px;content:"";display:inline-block;height:20px;margin-right:10px;width:20px}.sidebar-card-para{font-size:14px;line-height:18px}.submit-button{-moz-osx-font-smoothing:grayscale;-webkit-font-smoothing:antialiased;-webkit-appearance:none;appearance:none;background-color:#005ea2;border:0;border-radius:.25rem;color:#fff;cursor:pointer;display:inline-block;font-size:1.06rem;font-weight:700;line-height:.9;margin-right:.5rem;padding:.75rem 1.25rem;text-align:center;text-decoration:none;width:100%}@media screen and (min-width:580px){.sidebar-card-contact .submit-button,.sidebar-card-mobile .submit-button,.sidebar-card-right .submit-button{width:auto!important}}@media screen and (min-width:992px){.sidebar-card-right .submit-button{width:100%!important}.sidebar-card-right{width:auto!important}}.submit-button:visited{color:#fff}.submit-button:hover{background-color:#1a4480!important;border-bottom:0;color:#fff;text-decoration:none}.submit-button:active,.submit-button:focus{background-color:#162e51!important;box-shadow:none!important;color:#fff}.submit-button:not([disabled]).usa-focus,.submit-button:not([disabled]):focus{outline-offset:.25rem}.submit-button:disabled{-moz-osx-font-smoothing:grayscale;-webkit-font-smoothing:antialiased;background-color:#c9c9c9;color:#fff;pointer-events:none}.sidebar-submit-button{margin-top:1em}.sidebar-input{-webkit-appearance:none;appearance:none;border:1px solid #565c65;border-radius:0;color:#1b1b1b;display:block;height:2.5rem;margin-top:.5rem;max-width:30rem;padding:.5rem;width:100%}.sidebar-label{margin-bottom:0}.nih-logo{height:auto;width:70px}.top-title-box-home{padding-left:5px}.top-logo-box-home{padding-right:0}.top-title-box{padding-left:0}@media screen and (max-width:374px){.top-header-logo,.top-header-logo-home{padding-left:8px;padding-right:8px}}@media print{body{background-color:#fff;color:#000;margin:0}.print-logo{display:block}.container-fluid{width:100%}.logo-lockup{text-decoration:none!important}#backtoTop,.bread-crumb,.btn-mobile-menu,.footer-banner,.footer-block,.grid-col-fill,.outer-box-menu,.red-banner,.usa-banner__button,.usa-banner__header-flag{display:none}.title-h1-white,.title-h3-white{color:#000}.container-fluid,.container-lg,.container-md,.container-sm,.container-xl{margin-bottom:20px;margin-left:30px;margin-right:30px;padding-left:2px;padding-right:2px}table th{background-color:#fff;border:1px solid #cbd5df!important;color:#000}table th h2,table th h3{color:#000!important}.nav-col-left{display:none}.covid-alert-border{border-left:.5rem solid #00bde3!important}}.sub-img-dsk{position:relative}.desk-top-img{align-items:center;display:flex;height:300px;justify-content:center}.desk-top-img,.sub-img-mob{background-position:50%;background-size:cover;margin-left:0;margin-right:0;width:100%}.sub-img-mob{height:auto}.sub-hero-img{display:block;margin-bottom:15px}.sub-img-sec1{background-image:url(/static/about-hero-image-a16f0f1fed099d6858e9971484d15c24.jpg)}.sub-img-sec2{background-image:url(/static/overview-hero-image-2f6ca86a6067548de12ec50b01327595.jpg)}.sub-img-sec3{background-image:url(/static/management-hero-image-42dbb47e27746624b64030a4e383a50a.jpg)}.sub-img-sec4{background-image:url(/static/therapies-hero-image-039f2006f6ca784771df72faa3b5d9a3.jpg)}.sub-img-sec5{background-image:url(/static/critical-care-hero-image-2e2d333bfc0b3f60b06f4b4850ab12e2.jpg)}.sub-img-sec6{background-image:url(/static/special-consideration-hero-image-c794376cb47db9319d1bd6c2a444d167.png)}.subpage-text-over-lay{bottom:48px;padding:10px 0;position:absolute}.gry-txt-box,.subpage-text-over-lay{color:#fff;left:0;margin:0 auto;right:0;width:100%;z-index:2}.gry-txt-box{background:linear-gradient(90deg,rgba(0,0,0,.7) 0,rgba(0,0,0,.7) 57%,transparent 0,transparent);bottom:65px;content:""}.ontop{position:relative;top:1.7em;z-index:2}.gray-box-col{padding:25px 40px 25px 0}.overlay-text,.overlay-title{color:#fff}.txt-box-gray{background-color:#f0f0f0;padding:30px 10px 30px 35px;width:57%}.sub-pge-row{padding-top:10px}.sub-pge-box{display:flex}.sub-pge-inner-box{background-color:#f0f0f0;border-radius:3px;cursor:pointer;margin-top:40px;overflow:hidden;transition-timing-function:ease-out;transition:.4s;width:100%}.sub-pge-inner-box:hover{background:#f9f9f9;box-shadow:0 4px 12px 0 rgba(0,0,0,.16);transform:translateY(-15px);transition-timing-function:ease-in;transition:.4s}.sub-box-top-pad{border-top:4px solid #fbbb3d}.even-inner-box,.even-top-pad{border-color:#065fa9}.left-pad-15{padding-left:15px}.sub-pge-inner-box p{font-size:14px;padding:0 15px 20px}.box-title{font-size:18px;font-weight:700;padding:25px 15px 15px}.sub-pge-inner-box:hover>.box-title{text-decoration:underline}.sub-pge-top-row{padding-top:45px}.navbar-nav li:hover>.dropdown-menu{display:block;min-width:100%;min-width:-webkit-fill-available;min-width:-moz-available}.navbar,.navbar>.container{padding-left:0}.navbar{padding-bottom:0;padding-top:0}.navbar-light .navbar-brand,.navbar-light .navbar-brand:focus,.navbar-light .navbar-brand:hover,.navbar-light .navbar-nav .active>.nav-link,.navbar-light .navbar-nav .nav-link,.navbar-light .navbar-nav .nav-link.active,.navbar-light .navbar-nav .nav-link.show,.navbar-light .navbar-nav .nav-link:focus,.navbar-light .navbar-nav .nav-link:hover,.navbar-light .navbar-nav .show>.nav-link{color:#fff}.navbar-light .navbar-nav .nav-link{font-size:16px;padding-left:7px;padding-right:7px}.nav-link:active,.navbar-light .navbar-nav .nav-link:focus,.navbar-light .navbar-nav .nav-link:hover{background:#18304c}.dropdown-item:focus,.dropdown-item:hover{background-color:#18304c;color:#fff;text-decoration:none}.dropdown-item-default:focus,.dropdown-item-default:hover{background-color:#f8f9fa;color:#16181b;text-decoration:none}.sm-menu{border:0;border-radius:0;box-shadow:1px 3px 4px 0 hsla(0,0%,68%,.2);top:97%}.dropdown-item_megamenu{max-width:32vw;white-space:normal}.dropdown-item>a,.dropdown-item>a:hover{color:#fff;font-size:16px;text-decoration:none}.dropdown-item.active,.dropdown-item:active{background-color:#18304c;color:#fff;text-decoration:none}.nav-item>.active{border-bottom:4px solid #f2bd56;color:#fff}.navbar-toggler{outline:none!important}.navbar-tog{color:#1ebdc2}.megamenu-li{position:static}.megamenu{left:0;padding:15px;position:absolute;right:0;width:100%}.megamenu h6{margin-left:21px}.megamenu i{width:20px}.outer{display:flex}.inner,.outer{width:-webkit-max-content;width:max-content}.inner{display:inline-block;float:left;margin:20px 0}.inner>ul{padding-left:0}.inner:nth-child(2n){border-left:1px solid #fff}.twtr-text-contrast{color:#e0e0e0}.dropdown-menu{background-color:#18304c;top:93%}.dropdown-menu-default{background-color:#fff;position:relative!important;transform:none!important;will-change:unset!important}.dropdown-toggle:after{background:0 0;background-color:#fff;background:url(data:image/svg+xml;base64,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) no-repeat 50%/1.3128205128ex .8ex;border:0;content:"";display:inline-block;height:.8ex;margin-left:.4em;vertical-align:middle;width:1.3128205128ex}.detdr-down:after{background:url(data:image/svg+xml;base64,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) no-repeat 50%/1.3128205128ex .8ex;margin-bottom:.2ex}.show .detdr-down:after{transform:scaleY(-1)}.wide-menu ul{zoom:1;display:inline-block;*display:inline;list-style-type:none;margin:0;padding:0}.dmenu:hover{background-color:#18304c}.dmenu:hover>.active,.dmenu>.active:hover{border-bottom:4px solid #18304c}@media (max-width:991px){.sub-hero-img{display:block}.desk-top-img{background-position:100%}.gry-txt-box{background:linear-gradient(90deg,rgba(0,0,0,.7) 0,rgba(0,0,0,.7) 95%,transparent 0,transparent);bottom:40px;margin-left:15px}.navbar{display:none}.gray-box-col{padding:25px 15px}}@media (min-width:992px){.sub-hero-img{display:none}.desk-top-img{background-position:50%}.navbar{display:block}.top-header-logo{padding-bottom:0}.navbar-light .navbar-nav .nav-link{font-size:16px;margin-left:28px;margin-right:28px;padding-left:0;padding-right:0}.gray-box-col{padding:25px 40px 25px 0}}@media (min-width:1200px){.navbar-light .navbar-nav .nav-link{font-size:16px;margin-left:50px;margin-right:50px;padding-left:0;padding-right:0}}body,html{background-color:#f0f0f0;font-family:Public Sans,sans-serif;height:100%;margin:0}.bgimg-1{background-color:#000;background-image:url(/static/Desktop_Hero-b23288cf949a300e4b9febe2a8145366.jpg);background-repeat:no-repeat;background-size:cover;max-width:100%;opacity:100%;position:relative}.caption{left:0;top:50%;width:100%}.caption,.title-h1-black,.title-h1-black a,.title-h1-black a:visited{color:#000}.title-h3-black,.title-h3-black a,.title-h3-black a:visited{color:#000;font-family:Public Sans,sans-serif;font-size:16px;letter-spacing:0;line-height:24px;margin-bottom:0;padding-top:0;text-decoration:none}.top-header-logo-home{background-color:#f0f0f0;background-color:hsla(0,0%,94%,.8);height:auto}.second-header-search-home{background-color:#828282}.hhs-logo-home{height:70px;width:70px}.top-logo-box-home{border-right:2px solid #6f7f92;margin:20px 10px 15px 0;text-align:right}.top-title-box-home{display:flex;flex-direction:column;height:auto;justify-content:center;padding-top:0}.top-title-box-home,.top-title-box-home:hover{text-decoration:none}.footer-bottom-home{color:#171717;font-size:16px;height:auto;line-height:35px;padding-top:30px;text-align:center}.home-body-middle{min-height:400px;width:100%}.home-body-main-title{width:100%}.home-body-title{color:#fff;font-size:60px;font-weight:500;line-height:71px;padding-bottom:15px}.h_title{font-size:50px!important;line-height:38.4px!important}.home-body-button{background-color:#f0f0f0}.home-body-button-txt{color:#15223b;font-size:30px;line-height:13px;padding:10px 15px 0}.img-credit{color:#fff;font-size:15px}.home-body-button{box-shadow:0 0 1px transparent;display:inline-block;overflow:hidden;padding:15px 20px;position:relative;transform:perspective(1px) translateZ(0);vertical-align:middle}.home-body-button:before{background:#065fa9;bottom:0;content:"";height:4px;left:0;position:absolute;right:100%;transition-duration:.3s;transition-property:right;transition-timing-function:ease-out;z-index:-1}.home-body-button:active:before,.home-body-button:focus:before,.home-body-button:hover:before{right:0}.home-body-button-txt{font-size:24px;font-weight:500;line-height:32px;padding:5px 0 0}.logo-lockup-home,.logo-lockup-home:hover,.logo-lockup-home:visited{margin:20px 10px 15px 0;text-decoration:none}.menu-row{display:none;height:89px;padding-top:4px;position:relative;right:0;width:80px}.btn-mobile-menu-home{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgZmlsbD0iY3VycmVudENvbG9yIiBjbGFzcz0icHJlZml4X19iaSBwcmVmaXhfX2JpLWxpc3QiIHZpZXdCb3g9IjAgMCAxNiAxNiI+PHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBkPSJNMi41IDEyYS41LjUgMCAwIDEgLjUtLjVoMTBhLjUuNSAwIDAgMSAwIDFIM2EuNS41IDAgMCAxLS41LS41em0wLTRhLjUuNSAwIDAgMSAuNS0uNWgxMGEuNS41IDAgMCAxIDAgMUgzYS41LjUgMCAwIDEtLjUtLjV6bTAtNGEuNS41IDAgMCAxIC41LS41aDEwYS41LjUgMCAwIDEgMCAxSDNhLjUuNSAwIDAgMS0uNS0uNXoiLz48L3N2Zz4=);background-position:bottom 34px right -1px;background-repeat:no-repeat;background-size:42px;color:#171717}.btn-mobile-search-close-home{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNSIgaGVpZ2h0PSIxNSIgdmlld0JveD0iMCAwIDE1IDE1Ij48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiMwMDAiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSIyIiBkPSJNMSAxNC4wMzMgMTQuMDMzIDFtMCAxMy4wMzNMMSAxIi8+PC9zdmc+);background-position:bottom 24px right 4px;background-repeat:no-repeat;background-size:26px}.srch-Btn-dtop-home:hover{background-color:#0076d6}.srch-Btn-dtop-home{background:url(data:image/png;base64,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);background-color:#065fa9;background-position:50%;background-repeat:no-repeat;background-size:20px 20px;border:none;border-radius:0;box-shadow:none;cursor:pointer;float:right;outline:0;transition:all .3s;width:50px}.srch-Btn-mobile-home{background:url(data:image/png;base64,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) 0 no-repeat;background-position-y:27px;background-size:31px}.navbar-nav li:hover>.dropdown-menu-home{display:block;min-width:100%;min-width:-webkit-fill-available;min-width:-moz-available}.menu-col{padding:0}.navbar-home,.navbar-home>.container{padding-left:0}.navbar-home{padding-bottom:0;padding-top:0}.navbar-home .navbar-light,.navbar-home .navbar-light .navbar-brand,.navbar-light .navbar-brand:focus,.navbar-light .navbar-brand:hover,.navbar-light .navbar-nav .nav-link-home,.navbar-light .navbar-nav .nav-link-home:focus,.navbar-light .navbar-nav .nav-link-home:hover{color:#000!important}.nav-link-home:active,.navbar-light .navbar-nav .nav-link-home:focus,.navbar-light .navbar-nav .nav-link-home:hover{background:#fff!important;transition:0s}.dropdown-item-home:hover,.navbar-home .dropdown-item-home:focus{background-color:#fff!important;color:#000!important;text-decoration:none}.navbar-home .sm-menu{border:0;border-radius:0;box-shadow:1px 3px 4px 0 hsla(0,0%,68%,.2);top:97%}.dropdown-item-home>a:hover,.navbar-home .dropdown-item-home>a{color:#000!important;font-size:16px;text-decoration:none}.dropdown-item-home:active,.navbar-home .dropdown-item-home.active{background-color:#fff!important;color:#000!important;text-decoration:none}.navbar-home .nav-item>.active{border-bottom:4px solid #f2bd56;color:#000!important}.navbar-home .navbar-toggler{outline:none!important}.navbar-home .megamenu-li{position:static}.navbar-home .megamenu{left:0;padding:15px;position:absolute;right:0;width:100%}.navbar-home .megamenu h6{margin-left:21px}.navbar-home .megamenu i{width:20px}.navbar-home .outer{display:flex}.navbar-home .inner,.navbar-home .outer{width:-webkit-max-content;width:max-content}.navbar-home .inner{display:inline-block;float:left;margin:20px 0}.navbar-home .inner>ul{padding-left:0}.navbar-home .inner:nth-child(2n){border-left:1px solid #000}.navbar-home .dropdown-menu-home{background-color:#fff!important;top:93%}.navbar-home .dropdown-toggle:after{background:0 0;background-color:#fff;background:url(data:image/svg+xml;base64,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) no-repeat 50%/1.3128205128ex .8ex;border:0;content:"";display:inline-block;height:.8ex;margin-left:.4em;vertical-align:middle;width:1.3128205128ex}.navbar-home .wide-menu ul{zoom:1;display:inline-block;*display:inline;list-style-type:none;margin:0;padding:0}.navbar-home .dmenu:hover{background-color:#fff}.navbar-home .dmenu:hover>.active,.navbar-home .dmenu>.active:hover{border-bottom:4px solid #fff}@media (min-width:320px){.bgimg-1{background-image:url(/static/Mobile_Hero-eb667adb061c1d61adb052fdf46dc1fe.jpg)}.title-hide-br{display:block}.top-title-box-home{padding-top:0}.home-body-title{font-size:27px;line-height:35px}.h_title{font-size:22px!important}.home-body-middle{align-items:center;display:flex;padding:0;text-align:center}.img-credit{font-size:9px}}@media (min-width:346px){.home-body-title{font-size:30px;line-height:45px}.h_title{font-size:25px!important}.home-body-middle{text-align:center}}@media (min-width:480px){.home-body-title{font-size:40px;line-height:50px}.h_title{font-size:28px!important}.home-body-middle{text-align:center}.img-credit{font-size:10px}}@media (min-width:580px){.home-body-title{font-size:45px;line-height:59px}.h_title{font-size:32px!important}.home-body-middle{text-align:center}}@media (min-width:768px){.title-hide-br{display:none}.home-body-title{font-size:48px;line-height:61px}.h_title{font-size:36px!important}.home-body-middle{text-align:center}.img-credit{font-size:12px}}@media (max-width:991px){.navbar{display:none}.menu-row{display:flex}}@media (min-width:992px){.bgimg-1{background-image:url(/static/Desktop_Hero-b23288cf949a300e4b9febe2a8145366.jpg)}.home-body-title{font-size:48px;line-height:61px}.home-body-middle{align-items:center;display:flex;padding:0;text-align:left}.footer-bottom-home{height:200px}.img-credit{font-size:13px}.navbar{display:block}.navbar-home .navbar-light .navbar-nav .nav-link-home{font-size:16px;margin-left:28px;margin-right:28px;padding-left:0;padding-right:0}.top-title-row-home{padding-bottom:0}}@media (min-width:1200px){.navbar-home .navbar-light .navbar-nav .nav-link-home{font-size:16px;margin-left:50px;margin-right:50px;padding-left:0;padding-right:0}}@media screen and (max-width:1024px){.home-body-middle{justify-content:center;text-align:center}}@media screen and (max-width:767px){.hhs-logo-home{height:60px;width:60px}.title-h3-black{font-size:11px;line-height:14px}.top-logo-box-home{padding-right:0}.top-title-box-home{padding-left:7px}.home-body-button-txt{font-size:18px}.home-body-middle{min-height:350px}}@media screen and (max-width:361px){.hhs-logo-home{height:35px;width:35px}.title-h3-black{font-size:11px;line-height:14px}.top-logo-box-home{padding-right:0}.top-title-box-home{padding-left:0}}.hs_inner-box{padding-bottom:1.5rem}.hs_inner-box:last-child{padding-bottom:0}.hs_inner-box p{line-height:24px;margin-bottom:0}.hs_title{border-left:4px solid #fbbb3d;padding-left:.6rem}.hs_title a{text-decoration:none}.hs_title a:hover{text-decoration:underline}.hs_desktop-img{background:url(/static/COVID_GL_homepage_highlights-sm-5391040a02621c7f909782b05fcd69c6.jpg) no-repeat top;background-size:cover}.hs_desktop-left{border-right:1px solid #6f7f92;padding:0 1.5rem}.hs_desktop-right{padding:0 1.5rem}.hs_tablet-left{border-right:1px solid #6f7f92;padding-left:0;padding-right:1.5rem}.hs_tablet-right{padding-left:1.5rem;padding-right:0}</style><title data-react-helmet="true">Immunocompromised | COVID-19 Treatment Guidelines</title><link data-react-helmet="true" rel="canonical" href="https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/"/><link data-react-helmet="true" rel="icon" type="image/vnd.microsoft.icon" href="data:image/vnd.microsoft.icon;base64,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"/><link data-react-helmet="true" rel="apple-touch-icon" href="data:image/png;base64,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"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-NGV9HC2');</script><link crossorigin="" href="https://www.googletagmanager.com" rel="preconnect"/><link crossorigin="" href="https://www.google-analytics.com" rel="preconnect"/><link rel="sitemap" type="application/xml" href="/sitemap-index.xml"/></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NGV9HC2" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><header><a href="#content" class="sr-only skip-nav-color sr-only-focusable white-bg">Skip to main content</a><section class="container-fluid usa-banner" aria-label="Official website of the United States government"><div class="container-md usa-banner-container"><header class="usa-banner__header"><div class="usa-banner__inner"><div class="grid-col-auto"><img class="usa-banner__header-flag" src="data:image/png;base64,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" alt="U.S. flag" width="16" height="16"/></div><div class="grid-col-fill tablet:grid-col-auto usa-banner__header-top" aria-hidden="true"><p class="usa-banner__header-text">An official website of the United States government</p><p id="usa-alt-btn" class="usa-banner__header-action">Heres how you know</p></div><button class="usa-accordion__button usa-banner__button" id="btn-gov" data-toggle="collapse" data-target="#gov-banner-default-default" aria-controls="gov-banner-default-default" aria-expanded="false"><span class="usa-banner__button-text">Heres how you know</span></button></div></header></div></section><div class="container-fluid red-banner" role="alert"><div id="divArchiveBanner" class=" container-md archived-Status "><div class="row archive-banner-box"><div class="col-md archive-text-box"><div class="row no-gutters archive-text-banner"><div class="grid-col-fill tablet:grid-col-auto col-sx-12 usa-banner__header-second"><p class="usa-banner__header-text yellow-banner-text">The final update of the COVID-19 Treatment Guidelines was on February 29, 2024. PDFs of the Guidelines can be downloaded until August 16, 2024, when the website will be shut down.</p></div></div></div></div></div></div><div class="container-fluid top-header-logo"><div class="container-md top-header "><div class="row top-title-row"><div class="col-sx-2 top-logo-box"><a class="logo-lockup" href="/"><img src="data:image/png;base64,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" alt="NIH-logo logo-home" class="nih-logo" width="70" height="49"/></a></div><div class="col-sx-10 top-title-box"><a class="logo-lockup" href="/"><div class="title-h1 title-h1-white">COVID-19 Treatment <br class="title-nxt-line"/>Guidelines</div></a></div><div class="ml-auto"><div class="input-group srch-box-dtop"><label id="search-label" for="covid_search_header" class="d-none text-white">Search</label><input type="text" autoComplete="off" id="covid_search_header" name="search" class="form-control srch-txt-dtop" placeholder="Search" aria-label="Search" aria-describedby="search-label"/><div class="input-group-append" id="covid_search_header-btn"><button type="button" class="srch-Btn-dtop" id="desk-top-search" aria-label="Search"></button></div></div><div class="row mx-0 menu-row"><div class="col-6 p-0"><button class="srch-Btn-mobile srch-Btn-mobile" id="mobile-top-search" aria-label="Search"></button></div><div class="col-6 p-0"><button data-toggle="modal" class="btn-mobile-menu btn-mobile-menu" data-target="#menuModal" aria-label="Menu">MENU</button></div></div></div></div><div class="row"><div class="col menu-col"><nav class="navbar navbar-expand-lg navbar-light" aria-label="navigation menu"><div class="container"><ul class="navbar-nav navbar-light"><li class="nav-item dmenu dropdown"><a class="nav-link dropdown-toggle clk-menu" id="navbarDropdown0" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="About the Guidelines" href="/about-the-guidelines/">About the Guidelines</a><div class="dropdown-menu dropdown-menu-left wide-menu sm-menu" aria-labelledby="navbarDropdown0"><div class="outer"><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/whats-new/">What&#x27;s New</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/table-of-contents/">Table of Contents</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/guidelines-development/">Guidelines Development</a></li></ul></div><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/panel-roster/">Panel Roster</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/panel-financial-disclosure/">Panel Financial Disclosure</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/about-the-guidelines/guidelines-archive/">Guidelines Archive</a></li></ul></div></div></div></li><li class="nav-item dmenu dropdown"><a class="nav-link dropdown-toggle clk-menu" id="navbarDropdown1" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="Overview" href="/overview/">Overview</a><div class="dropdown-menu dropdown-menu-left wide-menu sm-menu" aria-labelledby="navbarDropdown1"><div class="outer"><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/overview/overview-of-covid-19/">Overview of COVID-19</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/overview/sars-cov-2-testing/">SARS-CoV-2 Testing</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/overview/prevention-of-sars-cov-2/">Prevention of SARS-CoV-2</a></li></ul></div><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/overview/clinical-spectrum/">Clinical Spectrum</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/overview/prioritization-of-therapeutics/">Prioritization of Therapeutics</a></li></ul></div></div></div></li><li class="nav-item dmenu dropdown"><a class="nav-link dropdown-toggle clk-menu" id="navbarDropdown2" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="Management" href="/management/">Management</a><div class="dropdown-menu  sm-menu" aria-labelledby="navbarDropdown2"><div class="outer"><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/management/clinical-management-of-adults/">Clinical Management of Adults</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/management/clinical-management-of-children/">Clinical Management of Children</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/management/critical-care-for-adults/">Critical Care for Adults</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/management/critical-care-for-children/">Critical Care for Children</a></li></ul></div></div></div></li><li class="nav-item dmenu dropdown"><a class="nav-link dropdown-toggle clk-menu" id="navbarDropdown3" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="Therapies" href="/therapies/">Therapies</a><div class="dropdown-menu dropdown-menu-right wide-menu sm-menu" aria-labelledby="navbarDropdown3"><div class="outer"><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/antivirals-including-antibody-products/">Antivirals, Including Antibody Products</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/immunomodulators/">Immunomodulators</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/antithrombotic-therapy/">Antithrombotic Therapy</a></li></ul></div><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/miscellaneous-drugs/">Miscellaneous Drugs</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/supplements/">Supplements</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/therapies/concomitant-medications/">Concomitant Medications</a></li></ul></div></div></div></li><li class="nav-item dmenu dropdown"><a class="nav-link dropdown-toggle clk-menu active" id="navbarDropdown4" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" aria-label="Special Populations" href="/special-populations/">Special Populations</a><div class="dropdown-menu dropdown-menu-right wide-menu sm-menu" aria-labelledby="navbarDropdown4"><div class="outer"><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a aria-current="page" class="" href="/special-populations/immunocompromised/">Immunocompromised</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/special-populations/cancer/">Cancer</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/special-populations/transplant/">Transplant</a></li></ul></div><div class="inner"><ul><li class="dropdown-item dropdown-item_megamenu"><a href="/special-populations/pregnancy/">Pregnancy</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/special-populations/influenza/">Influenza</a></li><li class="dropdown-item dropdown-item_megamenu"><a href="/special-populations/hiv/">HIV</a></li></ul></div></div></div></li></ul></div></nav></div></div></div></div></header><div class="container-fluid p-0  white-bg"><div class="container-fluid white-bg"><div class="top-breadcrumb container-md"><nav aria-label="Breadcrumb" class="bread-crumb"><ol><li><a href="/">Home</a></li><li><a href="/special-populations/">Special Populations</a> </li><li>Immunocompromised</li></ol></nav></div></div><div class="container-md"><div class="row"><div class="col-lg-4 p-0 nav-col-left"><div class="outer-box-menu"><nav id="sidebar"><ul class="list-unstyled components"><li><a id="side-nav-special-populations" aria-label="Special Populations" class="nav-item gl-parent" title="Special Populations" href="/special-populations/">Special Populations</a><div class="collapse show"><ul class="list-unstyled components"><li><a aria-current="page" id="side-nav-immunocompromised" aria-label="Immunocompromised" class="nav-item nav-item-active" title="Immunocompromised" href="/special-populations/immunocompromised/">Immunocompromised</a><div class="collapse show"></div></li><li><a id="side-nav-cancer" aria-label="Cancer" class="nav-item" title="Cancer" href="/special-populations/cancer/">Cancer</a><div class="collapse"></div></li><li><a id="side-nav-transplant" aria-label="Transplant" class="nav-item" title="Transplant" href="/special-populations/transplant/">Transplant</a><div class="collapse"></div></li><li><a id="side-nav-pregnancy" aria-label="Pregnancy" class="nav-item" title="Pregnancy" href="/special-populations/pregnancy/">Pregnancy</a><div class="collapse"></div></li><li><a id="side-nav-influenza" aria-label="Influenza" class="nav-item" title="Influenza" href="/special-populations/influenza/">Influenza</a><div class="collapse"></div></li><li><a id="side-nav-hiv" aria-label="HIV" class="nav-item" title="HIV" href="/special-populations/hiv/">HIV</a><div class="collapse"></div></li></ul></div></li></ul></nav></div><div role="complementary" aria-label="complementary"><div class="sidebar-card"><p class="sidebar-title">Guideline PDFs</p><ul class="guideline-pdf-list"><li><a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_188.pdf" target="_blank" rel="noopener noreferrer">Section Only (PDF | 358 KB)</a></li><li><a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf" target="_blank" rel="noopener noreferrer">Full Guideline (PDF | 6.1 MB)</a></li></ul></div><div class="sidebar-card"><p class="sidebar-title">Sign Up For Updates</p><form target="_blank" rel="noopener noreferrer" id="GD-snippet-form" action="https://public.govdelivery.com/accounts/USNIAID/subscribers/qualify" method="post"><input name="utf8" type="hidden" value=""/><input type="hidden" name="authenticity_token" value="OjXVX/6YDyUq8jApBckhDuTl8VOop5nwtQbjpYurqwPzbOWtoF4v95KuPAQVnoV6u9wEJ9anQI2yanp+GKt17w=="/><input type="hidden" name="topic_id" id="topic_id" value="USNIAID_182"/><fieldset><label for="sidebar-left-email" class="sidebar-label">Email Address *</label><input type="email" autoComplete="off" name="emailaddress" id="sidebar-left-email" class="long sidebar-input" placeholder="example@domain.com" required=""/><div class="button_panel"><button type="submit" name="commit" class="sr-button reverse sidebar-submit-button submit-button"><span class="sidebar-submit-button-text">Submit<span class="externalIcon"></span></span></button></div></fieldset></form></div><div class="sidebar-card"><p class="sidebar-title">Related Content</p><ul class="archive-list"><li><a href="/about-the-guidelines/guidelines-archive/">Guidelines Archive</a></li><li><a href="/how-to-cite/">How to Cite These Guidelines</a></li></ul></div></div></div><div class="col-lg-7 px-md-3"><div class="txt-chunk-wrapper"><main id="content"><h1>Special Considerations in People Who Are Immunocompromised</h1><p class="update-date">Last Updated: <!-- -->February 29, 2024</p><div class="row mx-0 sr-heading"><h2 class="th-heading-h2 sr-heading-h2">Summary Recommendations</h2></div><div class="sr-table-body overflow-auto"><div class="sr-td"><h3>Prevention of COVID-19</h3><ul><li>The COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination for everyone who is eligible, including those who are immunocompromised, according to the Centers for Disease Control and Prevention&rsquo;s Advisory Committee on Immunization Practices <strong>(<span id="rating_node_desc_14020_1">AI</span>)</strong>.</li><li>Vaccine response rates may be lower in patients who are moderately or severely immunocompromised. Specific guidance on administering vaccines to these individuals is provided by the Centers for Disease Control and Prevention. </li><li>Clinicians should strongly encourage all household members and close contacts of patients who are immunocompromised to be vaccinated against COVID-19 <strong>(<span id="rating_node_desc_14020_2">AI</span>)</strong>. </li><li>Currently, antibody tests are not recommended for assessing SARS-CoV-2 immunity following COVID-19 vaccination or for assessing the need for vaccination in a person who is unvaccinated.</li></ul><h3>Management of Patients With COVID-19 Who Are Immunocompromised</h3><ul><li>Clinicians should consult with the appropriate specialists when making decisions about stopping or adjusting the doses of immunosuppressive drugs in patients with COVID-19.</li><li>When selecting treatments for COVID-19, clinicians should consider factors such as the underlying disease; the specific immunosuppressants being used; the severity of COVID-19; and the potential for drug-drug interactions, overlapping toxicities, and secondary infections. </li><li>For nonhospitalized patients with mild to moderate COVID-19 who are immunocompromised, the Panel recommends prompt treatment with antiviral drugs at the doses and durations recommended for the general population <strong>(<span id="rating_node_desc_14020_3">AIII</span>)</strong>. For more information, see <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/">Therapeutic Management of Nonhospitalized Adults With COVID-19</a>.</li><li>For most hospitalized patients with severe or critical COVID-19 who are immunocompromised, the Panel recommends using antiviral drugs and immunomodulatory therapies at the doses and durations recommended for the general population <strong>(<span id="rating_node_desc_14020_4">AIII</span>)</strong>. For more information, see <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/">Therapeutic Management of Hospitalized Adults With COVID-19</a>.</li><li>For patients who are immunocompromised and have prolonged COVID-19 symptoms and evidence of ongoing viral replication, the optimal management is unknown. The data for these approaches are not definitive, but some Panel members would use 1 or more of the following treatment options:<ul><li>Longer and/or additional courses of ritonavir-boosted nirmatrelvir (Paxlovid)</li><li>Longer and/or additional courses of remdesivir</li><li>High-titer COVID-19 convalescent plasma from a vaccinated donor who recently recovered from COVID-19 likely caused by a SARS-CoV-2 variant similar to the variant causing the patient&rsquo;s illness</li></ul></li></ul><div></div></div><div class="sr-td">Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See <a href="https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/guidelines-development/">Guidelines Development</a> for more information.</div></div><div class="detail-page_content overflow-auto"><h2>Introduction</h2><p>Approximately 3% of people in the United States have immunocompromising conditions.<sup>1</sup> People who are immunocompromised are a heterogeneous population, and the severity of COVID-19 can vary significantly in this group. Some individuals who are immunocompromised may have a higher risk of hospitalization, complications, or death, and some may have outcomes that are comparable to those in the general population.&nbsp;</p><p>This section pertains to people who are moderately or severely immunocompromised, which includes those who:&nbsp;</p><ul><li>Are receiving active treatment for solid tumor and hematologic malignancies.</li><li>Have hematologic malignancies (e.g., chronic lymphocytic lymphoma, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) and are known to have poor responses to COVID-19 vaccines, regardless of the treatment status for the hematologic malignancy.</li><li>Received a solid-organ or islet transplant and are receiving immunosuppressive therapy.</li><li>Received chimeric antigen receptor T cell (CAR T-cell) therapy or a hematopoietic cell transplant (HCT) and are within 2 years of transplantation or are receiving immunosuppressive therapy.</li><li>Have a moderate or severe primary immunodeficiency (e.g., severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency disease).</li><li>Have advanced or untreated HIV infection (defined as people with HIV and CD4 T lymphocyte cell counts &lt;200 cells/mm<sup>3</sup>, a history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV).</li><li>Are receiving active treatment with high-dose corticosteroids (i.e., &ge;20 mg prednisone or equivalent per day for &ge;2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, or immunosuppressive or immunomodulatory biologic agents (e.g., B cell&ndash;depleting agents).</li></ul><p>Analyses have found a higher risk of hospitalization or death from COVID-19 in those with a variety of immunocompromising conditions, including rheumatic diseases, hematological malignancies, solid organ transplants, and HIV.<sup>2-7</sup> Factors that increase the risk of severe COVID-19 in the general population, such as older age, chronic kidney disease, cardiovascular disease, and other comorbidities, are significant drivers of risk in people who are immunocompromised. Moreover, some immunodeficiencies seem to increase the risk above and beyond traditional risk factors. For example, there is evidence that individuals who make autoantibodies to type I interferons (proteins that are critical to the protective immune response against viral infections) have a higher risk of severe COVID-19.<sup>8</sup> Similarly, certain classes of medications, such as T cell&ndash;depleting or T cell&ndash;suppressing agents (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, belatacept) and B cell&ndash;depleting agents (e.g., rituximab, ocrelizumab, obinutuzumab), have been associated with more severe disease and death.<sup>7,9,10</sup></p><p>Prolonged shedding of SARS-CoV-2 has been reported in patients who are immunocompromised. A systematic review found that replication-competent virus could be detected for a median of 20 days in these patients, compared to 11 days in the general population.<sup>11</sup> Prolonged viral shedding may affect SARS-CoV-2 testing strategies and isolation durations for this group of patients. Moreover, case reports suggest that prolonged infections can create evolutionary pressure for the emergence of variants that resist therapies or evade vaccine-induced immunity.<sup>12-14</sup>&nbsp;</p><p>For any person who is eligible, clinicians should prescribe therapies for the treatment of COVID-19 as recommended in these Guidelines. However, if logistical constraints limit the availability of therapies, the COVID-19 Treatment Guidelines Panel (the Panel) suggests prioritizing the treatment of patients with COVID-19 who are at the highest risk of clinical progression (see <a href="https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/">Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints</a>). Providers should use their clinical judgment when prioritizing patients for treatment and assess a patient&rsquo;s immunocompromised status, age, comorbidities, and vaccination status.&nbsp;</p><p>The sections below outline the Panel&rsquo;s rationale for the recommendations on preventing and managing COVID-19 in people who are immunocompromised. Some of the special considerations for patients who are immunocompromised include the timing of COVID-19 vaccination, the management of immunosuppressive medications, and the strategies for treating COVID-19.</p><h2>Prevention of COVID-19&nbsp;</h2><h3>Vaccination</h3><p>COVID-19 vaccination remains the most effective way to prevent serious outcomes and death from SARS-CoV-2 infection. The Panel recommends COVID-19 vaccination for everyone who is eligible, including those who are immunocompromised, according to the Centers for Disease Control and Prevention&rsquo;s (CDC) Advisory Committee on Immunization Practices <strong>(<span id="rating_node_desc_14021_1">AI</span>)</strong>.</p><p>Authorized or approved COVID-19 vaccines in the United States are not live-virus vaccines and can be safely administered to patients who are immunocompromised. However, in people who are immunocompromised, the immune response to vaccination may be blunted, and the timing of vaccination requires special consideration. Nevertheless, vaccination is still recommended, as it may confer partial protection, including the protection provided by vaccine-induced, cell-mediated immunity.<sup>15</sup></p><p>The Panel recommends following the <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised" target="_blank" rel="noopener noreferrer">CDC&rsquo;s COVID-19 vaccination guidance<span class="externalIcon"></span></a> for people who are moderately or severely immunocompromised. This guidance includes information on the use of the updated 2023&ndash;2024 mRNA vaccines, which target the SARS-CoV-2 Omicron variant lineage XBB.1.5. Current CDC guidance allows for the use of additional vaccine doses in people who are moderately or severely immunocompromised.<sup>16</sup> Data on the optimal timing for repeat vaccination in people who are immunocompromised are lacking; the CDC recommends an interval of at least 2 months after the last dose. Other considerations include the patient&rsquo;s current or expected level of immunosuppression, their age, comorbidities, and the time since their last vaccine dose. Clinicians should also account for the prevalence of SARS-CoV-2 infection in the community and whether the patient intends to travel.&nbsp;</p><p>A preprint of a large observational study from Israel suggests a potential benefit from administering COVID-19 boosters every 6 months in groups with the highest risk of COVID-19&ndash;related hospitalization or death.<sup>17</sup> The CDC-funded VISION Network evaluated the effectiveness of bivalent vaccines between September 13, 2022, and April 21, 2023, at 5 sites in 7 states.<sup>18</sup> Among adults who were immunocompromised, a lower vaccine effectiveness was observed for the bivalent booster, but vaccine effectiveness was sustained against critical COVID-19&ndash;associated outcomes, including intensive care unit admission and death. Vaccine effectiveness against hospitalization was 28% during the first 7 to 59 days after receipt of the bivalent dose and declined to 13% by 120 to 179 days; this indirectly supports using a 6-month interval for repeat vaccination.</p><p>The pivotal clinical trials that evaluated the safety and efficacy of the COVID-19 vaccines excluded people who were severely immunocompromised; therefore, the data for this population are less robust.<sup>19,20</sup> Observational data suggest that serological responses to vaccines may be blunted in patients who are immunocompromised.<sup>21,22</sup> However, the MELODY trial reported detectable immunoglobulin G spike protein antibodies in approximately 80% of a large cohort of individuals in the United Kingdom who were immunocompromised and had received at least 3 doses of COVID-19 vaccines.<sup>23</sup> Those who had received anti-CD20 therapies within the past year were less likely than other groups in the study to have detectable anti-spike protein antibodies. In another study conducted during the Omicron era, a fourth dose of an mRNA COVID-19 vaccine reduced the risk of SARS-CoV-2 infection and severe COVID-19 among patients receiving treatment for systemic autoimmune rheumatic diseases.<sup>24</sup></p><h4>Vaccination of Close Contacts</h4><p>Clinicians should strongly encourage all household members and close contacts of patients who are immunocompromised to be vaccinated against COVID-19 <strong>(<span id="rating_node_desc_14021_2">AI</span>)</strong>. Before Omicron became the dominant circulating variant, a large cohort study of health care workers in Finland reported that COVID-19 vaccines were associated with a reduction in SARS-CoV-2 infections not only among vaccinated individuals but also among unvaccinated adult household members.<sup>25</sup> A 2022 systematic review and meta-analysis of 96 studies reported that people who received a complete primary COVID-19 vaccine series had reduced susceptibility to SARS-CoV-2 infection and were less infectious if they become infected.<sup>26</sup></p><h4>Vaccination Timing and Immunosuppressive Therapies</h4><p>If possible, COVID-19 vaccines should be administered at least 2 weeks before initiating or resuming immunosuppressive therapies. The timing of the vaccination should be determined based on the patient&rsquo;s current or planned immunosuppressive therapies, as well as the patient&rsquo;s medical condition and predicted response to the vaccine. Guidance about the timing of COVID-19 vaccination in solid organ transplant, HCT, and cellular immunotherapy candidates can be found in <a href="https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant/">Special Considerations in Solid Organ Transplant, Hematopoietic Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients</a>. <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised" target="_blank" rel="noopener noreferrer">The CDC&rsquo;s guidance<span class="externalIcon"></span></a> allows the use of additional vaccine doses in people who are immunocompromised. Each additional dose should be administered at least 2 months after the last dose.&nbsp;</p><p>The CDC recommends that HCT and CAR T-cell recipients who received doses of COVID-19 vaccines before or during treatment with HCT or CAR T-cell therapy should be revaccinated with the currently recommended primary vaccine series at least 3 months after the transplant or CAR T-cell therapy.<sup>16</sup> The American College of Rheumatology also provides guidance for temporarily stopping immunosuppressive regimens during vaccination.<sup>27</sup>&nbsp;</p><h4>Polyethylene Glycol Allergies</h4><p>The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) mRNA vaccines contain polyethylene glycol (PEG), whereas the NVX-CoV2373 (Novavax) vaccine contains polysorbate 80. PEG and polysorbate are used in many products, including in agents used for cancer chemotherapy (e.g., PEG-asparaginase). PEG and polysorbate are structurally related, and cross-reactive hypersensitivity between these compounds might occur. The detection of PEG antibodies after vaccination was not associated with increased adverse reactions (such as delayed-onset reactions, including injection site rashes, or severe allergic reactions) to the mRNA COVID-19 vaccines.<sup>28</sup> Therefore, testing for anti-PEG antibodies should not be used as a screening tool to assess the risk of allergic reactions<sup>29</sup> and should not replace an assessment by a specialist in those rare individuals with a history of anaphylaxis.<sup>30</sup> The <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html" target="_blank" rel="noopener noreferrer">CDC has issued guidance<span class="externalIcon"></span></a> on triaging people with a history of allergies or allergic reactions to the components of COVID-19 vaccines.&nbsp;</p><h3>Pre-Exposure Prophylaxis</h3><p>As of February 2024, no biomedical intervention other than vaccines prevents COVID-19 disease. Previously, the Food and Drug Administration (FDA) authorized the use of the anti-SARS-CoV-2 monoclonal antibodies tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP) of COVID-19 in certain people who were not expected to mount an adequate immune response to COVID-19 vaccination and in people with COVID-19 vaccine contraindications. Because the current Omicron subvariants are not susceptible to tixagevimab plus cilgavimab, this combination is not currently authorized by the FDA for use as PrEP of COVID-19.<sup>31</sup></p><h3>Serologic Testing to Guide Vaccination Strategies</h3><p>Currently, antibody tests are not recommended for assessing SARS-CoV-2 immunity following COVID-19 vaccination or for assessing the need for vaccination in a person who is unvaccinated. More than 80 SARS-CoV-2 serologic tests, including quantitative, semiquantitative, neutralizing antibody, and point-of-care tests, have been issued Emergency Use Authorizations by the FDA to aid in detecting antibodies to SARS-CoV-2.<sup>32</sup> However, these tests are not currently authorized for routine use in making individual medical decisions, and their ability to assess a person&rsquo;s level of immunity or protection from SARS-CoV-2 infection has not been evaluated.<sup>33</sup> Most of these tests have not been calibrated to a reference standard, limiting the ability to compare and reproduce results from different tests.</p><h2>Management of Patients With COVID-19 Who Are Immunocompromised</h2><h3>Adjusting Chronic Immunosuppressive Therapies</h3><p>Clinicians should consult with the appropriate specialists when making decisions about stopping or adjusting the doses of immunosuppressive drugs in patients with COVID-19. When selecting treatments for COVID-19, clinicians should consider factors such as the underlying disease; the specific immunosuppressants being used; the severity of COVID-19; and the potential for drug-drug interactions, overlapping toxicities, and secondary infections.</p><p>Early in the clinical course of COVID-19, the disease is primarily driven by the replication of SARS-CoV-2. Immunosuppressive medications can reduce the host immune responses that suppress viral replication, increasing the risk of prolonged viral shedding and infection.<sup>34,35</sup> Clinicians should consider adjusting the doses of immunosuppressive medications or substituting certain immunosuppressive medications, if possible, to improve the patient&rsquo;s immune response to infection. When making decisions about stopping or reducing the dose of immunosuppressive drugs, clinicians should balance the potential benefit of enhancing the patient&rsquo;s immune response to COVID-19 with the risk of exacerbating the underlying condition. They should also consider the role of immunomodulation in the treatment of COVID-19.&nbsp;</p><p>Clinicians should be aware that many immunosuppressive drugs, particularly biologic agents, have long half-lives or prolonged periods of biologic activity. Patients may remain immunosuppressed long after the drugs are stopped. Care should be taken to not stop glucocorticoids abruptly, since this may result in adrenal insufficiency. For medications other than glucocorticoids, decisions about dose adjustments should be made on a case-by-case basis. For example, for some autoimmune diseases, temporary cessation of immunosuppression is often possible, and restarting medications 7 to 14 days after symptom resolution may be appropriate.<sup>27,36</sup> Observational data suggest that patients receiving tumor necrosis factor&ndash;alpha (TNF-alpha) inhibitors may be at lower risk of progressing to severe COVID-19 than those receiving treatment with other immunomodulators.<sup>37,38</sup> Therefore, some patients with mild COVID-19 may safely continue receiving treatment with TNF-alpha inhibitors.</p><p>For solid organ transplant recipients, adjustments to immunosuppressive regimens should be individualized based on disease severity, the risk of graft rejection, the specific immunosuppressants being used, the type of transplant, the time since transplantation, the concentration of immunosuppressants, and the potential for drug-drug interactions.<sup>39</sup> See <a href="https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant/">Special Considerations in Solid Organ Transplant, Hematopoietic Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients</a> for more information.</p><h3>Therapeutic Management of Nonhospitalized Patients With COVID-19</h3><p>For nonhospitalized patients with mild to moderate COVID-19 who are immunocompromised, the Panel recommends prompt treatment with antiviral drugs at the doses and durations recommended for the general population <strong>(<span id="rating_node_desc_14021_3">AIII</span>)</strong>. See <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/">Therapeutic Management of Nonhospitalized Adults With COVID-19</a> to review the Panel&rsquo;s recommendations. Some special considerations for using these therapies in people who are immunocompromised are outlined below.</p><h4>Ritonavir-Boosted Nirmatrelvir (Paxlovid)&nbsp;</h4><p>In the EPIC-HR trial, the use of ritonavir-boosted nirmatrelvir reduced the risk of hospitalization or death when compared with placebo in nonhospitalized, unvaccinated adults who had laboratory-confirmed SARS-CoV-2 infection and a high risk of progressing to severe COVID-19.<sup>40</sup> Because the trial did not enroll many participants who were immunocompromised, the efficacy of ritonavir-boosted nirmatrelvir was not established for this population. In subsequent retrospective studies, some potential benefits of using ritonavir-boosted nirmatrelvir in people with various immunocompromising conditions have been observed.<sup>41,42</sup></p><p>A retrospective study investigated the use of ritonavir-boosted nirmatrelvir for the treatment of COVID-19 in patients who were moderately or severely immunocompromised.<sup>43</sup> Among 3,188 patients, the use of ritonavir-boosted nirmatrelvir reduced the risk of death or hospitalization in extremely vulnerable patients, such as those with solid organ, bone marrow, or stem cell transplants; those with severe primary immunodeficiencies; and those receiving B cell&ndash;depletion therapy or treatment for hematologic malignancies.</p><p>Because ritonavir-boosted nirmatrelvir is the only highly effective oral antiviral therapy for COVID-19, it should be considered for patients who are immunocompromised if there are no potentially significant drug-drug interactions or if the interactions can be safely managed. Clinicians should be aware of drug-drug interactions that may be life- or organ-threatening (see <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/">Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir [Paxlovid] and Concomitant Medications</a>).<sup>44</sup> Notably, calcineurin inhibitors (e.g., tacrolimus, cyclosporine A) and mammalian target of rapamycin drugs (e.g., sirolimus, everolimus) have important drug-drug interactions with ritonavir. For this reason, the American Society of Transplantation recommends preferentially using other therapies, such as remdesivir, over ritonavir-boosted nirmatrelvir in people who are taking calcineurin inhibitors or mammalian target of rapamycin inhibitors.<sup>39</sup> Ritonavir can inhibit the metabolism of many cancer-directed therapies and should only be given after consulting with specialty pharmacists and other appropriate specialists. Remdesivir and molnupiravir are other antiviral options for individuals who cannot receive ritonavir-boosted nirmatrelvir because of drug-drug interactions.</p><p>Observational studies and the EPIC-HR and MOVe-OUT trials have described SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms in some patients who have completed treatment with ritonavir-boosted nirmatrelvir or molnupiravir.<sup>45-49</sup> However, viral rebound can also occur in patients who have not received treatment for COVID-19.<sup>50</sup> Some observational studies have reported that patients who were treated with ritonavir-boosted nirmatrelvir had a higher frequency of viral rebound and symptom recurrence than those who did not receive treatment.<sup>51,52</sup>&nbsp;</p><p>To date, virus detection and the recurrence of COVID-19 symptoms following the use of antiviral therapies have not been associated with progression to severe COVID-19.<sup>53,54</sup> Therefore, concerns about viral rebound or the recurrence of symptoms should not be a reason to avoid using antiviral therapies when their use is indicated.<sup>49,55-57</sup> A clinical trial that is evaluating the use of a second course of ritonavir-boosted nirmatrelvir to treat patients with viral rebound and symptom recurrence is underway (ClinicalTrials.gov Identifier <a href="https://clinicaltrials.gov/study/NCT05567952" target="_blank" rel="noopener noreferrer">NCT05567952<span class="externalIcon"></span></a>). See <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/">Ritonavir-Boosted Nirmatrelvir (Paxlovid)</a> for more information on rebound.</p><h4>Remdesivir</h4><p>Remdesivir was studied in nonhospitalized patients with mild to moderate COVID-19 who were at high risk of progressing to severe disease, and it was shown to be highly effective in reducing the risk of hospitalization and death.<sup>58</sup> However, this trial only included a small number of participants who were immunocompromised. Because remdesivir treatment for nonhospitalized patients requires an intravenous infusion for 3 consecutive days, there may be logistical constraints to administering this drug in many settings. It can be considered for patients who are immunocompromised if other options, such as ritonavir-boosted nirmatrelvir, are not appropriate or available.</p><h4>Molnupiravir</h4><p>In the MOVe-OUT trial, molnupiravir reduced the rate of hospitalization or death when compared with placebo in nonhospitalized patients with COVID-19.<sup>59</sup> However, this trial only enrolled a small number of participants who were immunocompromised. In a post hoc analysis of data from 55 patients who were immunocompromised, 2 of 24 patients (8%) who received molnupiravir were hospitalized or died through Day 29 compared with 7 of 31 patients (23%) who received placebo.<sup>60</sup> The PANORAMIC trial enrolled a larger population of people who were immunocompromised, but this population was heterogeneous and the results of the study were inconclusive.<sup>61</sup> Although the different treatment options have not been directly compared in clinical trials, the available evidence suggests that molnupiravir has a lower efficacy than ritonavir-boosted nirmatrelvir or remdesivir (see <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/">Molnupiravir</a>). Other COVID-19 therapies should be prioritized over molnupiravir in patients who are immunocompromised.&nbsp;</p><h4>COVID-19 Convalescent Plasma</h4><p>There is insufficient evidence for the Panel to recommend either for or against the use of high-titer COVID-19 convalescent plasma (CCP) for the treatment of COVID-19 in nonhospitalized patients who are immunocompromised.&nbsp;</p><p>The FDA issued an Emergency Use Authorization that allows the use of high-titer CCP for the treatment of COVID-19 in nonhospitalized or hospitalized patients who have immunosuppressive disease or are receiving immunosuppressive treatment.<sup>62</sup> However, the evidence generated from well-designed clinical trials that evaluated the use of CCP for the treatment of nonhospitalized patients with COVID-19 is conflicting; these trials only enrolled a small number of patients who were immunocompromised.<sup>63-66</sup>&nbsp;</p><p>For a discussion on the potential use of high-titer CCP in patients who are immunocompromised and have prolonged viral replication, see the Therapeutic Management of Patients With COVID-19 Symptoms and Prolonged SARS-CoV-2 Replication section below.</p><h4>Intravenous Immunoglobulin</h4><p>The Panel <strong>recommends against</strong> the use of <strong>intravenous immunoglobulin</strong> (IVIG) for the prevention or treatment of acute COVID-19 in adults and children, except in a clinical trial <strong>(<span id="rating_node_desc_14021_4">AIII</span>)</strong>.&nbsp;</p><p>Some individuals who are immunocompromised and have hypogammaglobulinemia are candidates for receiving supplemental antibodies in the form of IVIG for the prevention of a variety of infections and in the setting of acute infections, including COVID-19. IVIG can be administered as outpatient or inpatient therapy. However, outside these specific circumstances, the Panel&rsquo;s recommendation should not preclude the use of IVIG when it is otherwise indicated for underlying conditions. See <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/intravenous-immunoglobulin/">Intravenous Immunoglobulin</a> for more information.</p><h3>Therapeutic Management of Patients Who Are Hospitalized for COVID-19</h3><p>For most hospitalized patients with severe or critical COVID-19 who are immunocompromised, the Panel recommends using antiviral drugs and immunomodulatory therapies at the doses and durations recommended for the general population <strong>(<span id="rating_node_desc_14021_5">AIII</span>)</strong>. See <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/">Therapeutic Management of Hospitalized Adults With COVID-19</a> for more information. The optimal management strategies and treatments for COVID-19 in hospitalized patients who are immunocompromised are unknown since these individuals were either excluded from or poorly represented in major clinical trials. Nevertheless, clinical experience and retrospective data suggest that many patients who are immunocompromised have the expected responses to standard therapies for COVID-19.&nbsp;</p><h4>Remdesivir</h4><p>Case reports suggest that remdesivir can suppress, but does not always eliminate, viral replication in this population.<sup>67,68</sup> In a large retrospective study of hospitalized patients who were immunocompromised, including patients who did not require supplemental oxygen, patients who received remdesivir had a lower risk of mortality at 14 days and 28 days than patients who did not receive remdesivir.<sup>69</sup> The optimal duration of treatment with remdesivir in patients who are immunocompromised is unknown. Given the risk of prolonged viral replication in patients who are immunocompromised, some clinicians may choose to extend the course of antiviral therapy past 5 to 10 days. For patients receiving immunomodulatory therapy who have severe respiratory impairment due to COVID-19, clinicians may consider adding remdesivir treatment, although remdesivir has not been adequately studied in prospective clinical trials to determine whether there is a benefit in these patients.&nbsp;</p><h4>Corticosteroids</h4><p>The RECOVERY trial reported a survival benefit for dexamethasone in inpatients with COVID-19 who were receiving oxygen, high-flow nasal cannula oxygen, noninvasive ventilation, or mechanical ventilation; however, specific data regarding the subgroup of patients who were immunocompromised are not available.<sup>70</sup> Corticosteroids should not be used for the treatment of COVID-19 in patients who are not receiving oxygen. In the RECOVERY trial, no survival benefit was observed for dexamethasone among the subset of patients with COVID-19 who did not require supplemental oxygen at enrollment. In an observational cohort study of U.S. veterans, the use of dexamethasone was associated with higher mortality in hospitalized patients with COVID-19 who did not require supplemental oxygen.<sup>70,71</sup></p><p>Patients who are immunocompromised may experience delayed development of favorable adaptive responses and a prolonged period of viral replication, as discussed above. For patients who are immunocompromised, are receiving minimal levels of conventional oxygen, and are earlier in the course of COVID-19 (e.g., those with &lt;10 days of symptoms), the preferred approach may be emphasizing supportive care, using antiviral therapy, and avoiding corticosteroids. This strategy may reduce the duration of viral replication and the risk of secondary infections. Dexamethasone should be added if the patient has escalating oxygen requirements.&nbsp;</p><p>For patients who are immunocompromised and who were on chronic corticosteroids prior to hospitalization, the optimal dose of dexamethasone for the treatment of COVID-19 is unknown. The recommended dose of dexamethasone is 6 mg, which is equivalent to 40 mg of prednisone. This is the minimum dose of a steroid that should be used. Maintenance doses of corticosteroids should be discontinued while a patient is receiving dexamethasone, and the doses should be resumed as soon as possible after the patient recovers from COVID-19 or completes the course of dexamethasone.</p><h4>Other Immunomodulators&nbsp;</h4><p>Several randomized trials have shown that adding baricitinib or tocilizumab as a second immunomodulator to dexamethasone improves clinical outcomes in patients with severe or critical COVID-19.<sup>72-74</sup> Another randomized trial that examined the use of abatacept, cenicriviroc, or infliximab in combination with dexamethasone in hospitalized adults with COVID-19 reported no differences between the study arms in the primary endpoint of time to recovery.<sup>75</sup> However, patients who received infliximab or abatacept had a lower risk of mortality at 28 days. These trials generally excluded patients who were immunocompromised or only included small numbers of these patients. For patients who are immunocompromised, the use of these agents may provide a clinical benefit similar to the benefit seen in the general population. However, it is not clear whether augmenting immunomodulation in this population increases the risk of serious bacterial, invasive fungal, or parasitic infections.&nbsp;</p><p>The Panel currently recommends adding another immunomodulator to dexamethasone in hospitalized patients with COVID-19 who are hypoxemic and experiencing clinical progression (see <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/">Therapeutic Management of Hospitalized Adults With COVID-19</a>). This approach can also be used for most patients with COVID-19 who are immunocompromised. However, clinicians should consult with specialists to ensure that the risks of using additional immunosuppressive medications, including the risks of serious infections, do not outweigh the benefits. The patient should be closely monitored for secondary infections.</p><h4>COVID-19 Convalescent Plasma</h4><p>There is insufficient evidence for the Panel to recommend either for or against the use of high-titer CCP for the treatment of COVID-19 in hospitalized patients who are immunocompromised.&nbsp;</p><p>Three key randomized trials that evaluated the use of CCP for the treatment of COVID-19&mdash;RECOVERY, CONCOR-1, and REMAP-CAP&mdash;reported no evidence of a benefit of CCP in hospitalized patients with COVID-19. However, most of the patients enrolled in these trials were not immunocompromised.<sup>76-78</sup> Some of the subgroup analyses generated from clinical trials that enrolled patients who were immunocompromised suggested a potential benefit of CCP in this population,<sup>78-80</sup> but subgroup analyses need to be interpreted with caution (see <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/clinical-data/">Table 4c</a>). Other clinical data from case series, retrospective case-control studies, and meta-analyses have been cited as support for the potential benefit of CCP in patients who are immunocompromised.<sup>81-89</sup> However, the patient populations differed across studies, and the studies had design limitations, making the findings difficult to interpret.&nbsp;</p><p>The RECOVER trial was a small, randomized trial that evaluated the use of plasma from donors who were vaccinated against COVID-19 or convalescent after SARS-CoV-2 infection as a treatment for COVID-19 in hospitalized people with cancer, people with immunosuppression, people with lymphopenia and D-dimer levels &gt;1&thinsp;&micro;g/mL, and people aged &gt;75 years.<sup>79</sup> Only the subgroup of patients with cancer who received plasma treatment experienced a shorter median time to improvement and lower mortality when compared with the control arm.</p><p>For a discussion on the potential use of high-titer CCP in patients who are immunocompromised and have prolonged viral replication, see Therapeutic Management of Patients With COVID-19 Symptoms and Prolonged SARS-CoV-2 Replication below.</p><h3>Therapeutic Management of Patients Who Are Hospitalized for Reasons Other Than COVID-19&nbsp;</h3><p>People who are immunocompromised and have COVID-19 but were hospitalized for conditions other than COVID-19 should receive the same treatments as nonhospitalized patients <strong>(<span id="rating_node_desc_14021_6">AIII</span>)</strong>. See <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/">Therapeutic Management of Nonhospitalized Adults With COVID-19</a> for more information.</p><h3>Therapeutic Management of Patients With COVID-19 Symptoms and Prolonged SARS-CoV-2 Replication</h3><p>For patients who are immunocompromised and have prolonged COVID-19 symptoms and evidence of ongoing viral replication (e.g., those with a low cycle threshold value, as measured by a reverse transcription polymerase chain reaction result or with a positive rapid antigen test result) despite receiving a course of antiviral therapy, the optimal management is unknown. Case reports and case series have described the treatment of these patients with additional antiviral treatments, prolonged courses of antiviral treatments, high-titer CCP, or combination therapy.<sup>90-96</sup> The data for these approaches are not definitive, but some Panel members would use 1 or more of the following treatment options:&nbsp;</p><ul><li>Longer and/or additional courses of ritonavir-boosted nirmatrelvir</li><li>Longer and/or additional courses of remdesivir</li><li>High-titer CCP from a vaccinated donor who recently recovered from COVID-19 likely caused by a SARS-CoV-2 variant similar to the variant causing the patient&rsquo;s illness</li></ul><p>Clinicians should be aware that the drug-drug interaction potential of ritonavir may change based on the duration of treatment. Although the primary concern with the use of a 5-day course of ritonavir is cytochrome P450 (CYP) 3A4 inhibition, the induction properties of ritonavir may become clinically relevant when it is used for &ge;10 days.<sup>97</sup>&nbsp;</p><p>After longer courses of ritonavir-boosted nirmatrelvir are discontinued, drug-drug interactions caused by CYP3A4 inhibition are expected to resolve within 2 to 3 days.<sup>98</sup> Drug-drug interactions that are caused by induction (e.g., CYP2C9, CYP2C19, uridine diphosphate-glucuronyltransferase) resolve gradually and variably.</p><p>Clinicians should consult experts (e.g., pharmacists and physicians with HIV expertise) for guidance on drug-drug interactions when using extended courses of ritonavir-boosted nirmatrelvir. For more information, see <a href="https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/">Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications</a>. The <a href="https://covid19-druginteractions.org/checker" target="_blank" rel="noopener noreferrer">Liverpool COVID-19 Drug Interactions website<span class="externalIcon"></span></a> provides guidance on managing drug-drug interactions in patients who are receiving extended courses (i.e., &ge;10 days) of ritonavir-boosted nirmatrelvir.</p><h2>Considerations in Pregnant and Lactating People</h2><p>Multiple studies have found that pregnant individuals have an increased risk of severe COVID-19 compared to age-matched controls, with increased rates of intensive care unit admission, mechanical ventilation, extracorporeal membrane oxygenation, and death.<sup>99-101</sup> Although hormonally mediated immunomodulation occurs during pregnancy, pregnancy is not a state of systemic immunosuppression. Changes in the immune response to certain infectious pathogens during pregnancy may increase the severity of respiratory illness in pregnant individuals. Physiologic changes, such as reduced pulmonary residual capacity, may also contribute to respiratory disease severity.<sup>102-105</sup> Pregnant people who have underlying immunocompromising conditions or are receiving immunosuppressive medications likely have an even higher risk of severe disease. This patient group should be prioritized for the prevention and treatment of COVID-19.&nbsp;</p><h3>Prevention</h3><p>The Panel recommends COVID-19 vaccination for everyone who is eligible, including pregnant and lactating individuals, according to the CDC&rsquo;s Advisory Committee on Immunization Practices <strong>(<span id="rating_node_desc_14021_7">AI</span>)</strong>. COVID-19 vaccination is strongly recommended for pregnant individuals due to their increased risk for severe disease.<sup>106,107</sup> Vaccination is especially important for pregnant people with concomitant risk factors such as underlying immunocompromising conditions (including those who are receiving immunosuppressive medications), as the risk for severe disease is likely additive.<sup>100</sup></p><h3>Treatment</h3><p>Although pregnant patients have been excluded from the majority of the clinical trials that evaluated the use of COVID-19 therapeutics, pregnant patients with COVID-19 can be treated the same as nonpregnant patients, with a few exceptions. Pregnant patients who are immunocompromised or who have other risk factors likely have an even higher risk of severe COVID-19 and should be prioritized for treatment. Providers should refer to <a href="https://www.covid19treatmentguidelines.nih.gov/special-populations/pregnancy/pregnancy-lactation-and-covid-19-therapeutics/">Pregnancy, Lactation, and COVID-19 Therapeutics</a> for the Panel&rsquo;s guidance on treating COVID-19 in pregnant and lactating patients. Pregnant people who are immunocompromised are a heterogeneous group of patients, ranging from those who are mildly immunocompromised to those who are severely immunocompromised. Evaluating and managing pregnant patients require collaboration from a multidisciplinary team. This team should include a transplant or specialty provider, an obstetrician or maternal-fetal medicine specialist, a pediatrician or neonatology specialist, and a pharmacist.</p><h2>Considerations in Children&nbsp;</h2><p>Although the overall risk of critical illness and death related to COVID-19 is lower in children than in adults, severe disease does occur, particularly in children with risk factors such as moderate or severe immunocompromising conditions. See <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/special-considerations-in-children/">Special Considerations in Children</a> for a discussion of the risk factors for severe COVID-19 in children, and see <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/nonhospitalized-children-therapeutic-management/">Therapeutic Management of Nonhospitalized Children With COVID-19</a> for the Panel&rsquo;s framework for assessing a child&rsquo;s risk of progression to severe COVID-19 based on vaccination status, comorbidities, and age.&nbsp;</p><h3>Prevention</h3><p>The Panel recommends COVID-19 vaccination for everyone who is eligible, including children, according to the CDC&rsquo;s Advisory Committee on Immunization Practices <strong>(<span id="rating_node_desc_14021_8">AI</span>)</strong>.</p><h3>Treatment</h3><p>The majority of children with mild to moderate COVID-19 will not progress to more severe illness; therefore, the Panel recommends managing these patients with supportive care alone <strong>(<span id="rating_node_desc_14021_9">AIII</span>)</strong>. Few children, if any, have been enrolled in clinical trials of treatments for COVID-19. Among the children who were enrolled, very few were immunocompromised. Therefore, clinicians should be cautious when applying recommendations based on adult data to children. Clinicians need to consider the potential risks and benefits of therapy, the severity of the patient&rsquo;s disease, and underlying risk factors. See <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/hospitalized-children-therapeutic-management/">Therapeutic Management of Hospitalized Children With COVID-19</a> and <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/nonhospitalized-children-therapeutic-management/">Therapeutic Management of Nonhospitalized Children With COVID-19</a> for the Panel&rsquo;s treatment recommendations in these scenarios.</p></div><div class="ref-accord-box"><h2 class="ref-h2-title ref-h2-title-closed">References</h2><div class="ref-accord-list collapse"><ol><li>Wallace BI, Kenney B, Malani PN, et al. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018&ndash;2019. <em>JAMA Netw Open</em>. 2021;4(5):e214920. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34014329" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34014329<span class="externalIcon"></span></a>.</li><li>Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. <em>Blood. </em>2020;136(25):2881-2892. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33113551" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33113551<span class="externalIcon"></span></a>.</li><li>Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. <em>Arthritis Rheumatol</em>. 2022;74(5):766-775. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34807517" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34807517<span class="externalIcon"></span></a>.</li><li>Song Q, Bates B, Shao YR, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. <em>J Clin Oncol</em>. 2022;40(13):1414-1427. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35286152" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35286152<span class="externalIcon"></span></a>.</li><li>Ao G, Wang Y, Qi X, et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. <em>Transplant Rev (Orlando)</em>. 2021;35(3):100628. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34087553" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34087553<span class="externalIcon"></span></a>.</li><li>Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between HIV infection and COVID-19 mortality. <em>AIDS. </em>2021;35(11):1875-1878. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34397487" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34397487<span class="externalIcon"></span></a>.</li><li>MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. <em>Lancet Rheumatol</em>. 2022;4(7):e490-e506. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35698725" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35698725<span class="externalIcon"></span></a>.</li><li>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <em>Science.</em> 2020;370(6515):eabd4585. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32972996" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32972996<span class="externalIcon"></span></a>.</li><li>Strangfeld A, Sch&auml;fer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <em>Ann Rheum Dis</em>. 2021;80(7):930-942. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33504483" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33504483<span class="externalIcon"></span></a>.</li><li>Sharifian-Dorche M, Sahraian MA, Fadda G, et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review. <em>Mult Scler Relat Disord</em>. 2021;50:102800. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33578206" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33578206<span class="externalIcon"></span></a>.</li><li>Qutub M, Aldabbagh Y, Mehdawi F, et al. Duration of viable SARS-CoV-2 shedding from respiratory tract in different human hosts and its impact on isolation discontinuation polices revision; a narrative review. <em>Clin Infect Pract</em>. 2022;13:100140. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35190799" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35190799<span class="externalIcon"></span></a>.</li><li>Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. <em>Nature</em>. 2021;592(7853):277-282. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33545711" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33545711<span class="externalIcon"></span></a>.</li><li>Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. <em>N Engl J Med</em>. 2021;385(6):562-566. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34347959" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34347959<span class="externalIcon"></span></a>.</li><li>Leung WF, Chorlton S, Tyson J, et al. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. <em>Int <em>J Infect Dis</em></em>. 2022;114:178-182. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34757008" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34757008<span class="externalIcon"></span></a>.</li><li>Ku JH, Sy LS, Qian L, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. <em>Vaccine. </em>2023;41(24):3636-3646. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/37173268" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/37173268<span class="externalIcon"></span></a>.</li><li>Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States. 2024. Available at: <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html" target="_blank" rel="noopener noreferrer">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html<span class="externalIcon"></span></a>. Accessed February 13, 2024.</li><li>Yechezkel M, Samuel Faust J, Netzer D, et al. COVID-19 vaccine booster cadence by immunocompromised status. <em>medRxiv. </em>2023;Preprint. Available at: <a href="https://www.medrxiv.org/content/10.1101/2023.04.18.23288615v1" target="_blank" rel="noopener noreferrer">https://www.medrxiv.org/content/10.1101/2023.04.18.23288615v1<span class="externalIcon"></span></a>.</li><li>Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions&mdash;VISION Network, September 2022&ndash;April 2023. <em>MMWR Morb Mortal Wkly Rep</em>. 2023;72(21):579-588. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/37227984" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/37227984<span class="externalIcon"></span></a>.</li><li>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. <em>N Engl J Med</em>. 2021;384(5):403-416. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33378609" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33378609<span class="externalIcon"></span></a>.</li><li>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 Vaccine. <em>N Engl J Med</em>. 2020;383(27):2603-2615. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33301246" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33301246<span class="externalIcon"></span></a>.</li><li>Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. <em>JAMA.</em> 2021;325(21):2204-2206. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33950155" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33950155<span class="externalIcon"></span></a>.</li><li>Barri&egrave;re J, Chamorey E, Adjtoutah Z, et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. <em>Ann Oncol</em>. 2021;32(8):1053-1055. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33932508" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33932508<span class="externalIcon"></span></a>.</li><li>Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. <em>Lancet Rheumatol</em>. 2023;5(8):e461-e473. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/38251578" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/38251578<span class="externalIcon"></span></a>.</li><li>Hanberg JS, Fu X, Wang X, et al. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. <em>Lancet Rheumatol</em>. 2024;6(1):e21-e30. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/38258675" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/38258675<span class="externalIcon"></span></a>.</li><li>Salo J, H&auml;gg M, Kortelainen M, et al. The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers&rsquo; unvaccinated household members. <em>Nat Commun</em>. 2022;13(1):1162. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35246536" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35246536<span class="externalIcon"></span></a>.</li><li>Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. <em>JAMA Netw Open</em>. 2022;5(4):e229317. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35482308" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35482308<span class="externalIcon"></span></a>.</li><li>American College of Rheumatology. COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases. 2022. Available at: <a href="https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf" target="_blank" rel="noopener noreferrer">https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf<span class="externalIcon"></span></a>.</li><li>Carre&ntilde;o JM, Singh G, Tcheou J, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. <em>Vaccine. </em>2022;40(42):6114-6124. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36115801" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36115801<span class="externalIcon"></span></a>.</li><li>Bavli Y, Chen BM, Gross G, et al. Anti-PEG antibodies before and after a first dose of Comirnaty (mRNA-LNP-based SARS-CoV-2 vaccine). <em>J Control Release</em>. 2023;354:316-322. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36549393" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36549393<span class="externalIcon"></span></a>.</li><li>Brockow K, Mathes S, Fischer J, et al. Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis. <em>Allergy</em>. 2022;77(7):2200-2210. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34806775" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34806775<span class="externalIcon"></span></a>.</li><li>Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. 2023. Available at: <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us" target="_blank" rel="noopener noreferrer">https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us<span class="externalIcon"></span></a>. Accessed January 31, 2024.</li><li>Food and Drug Administration. EUA authorized serology test performance. 2022. Available at: <a href="https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance" target="_blank" rel="noopener noreferrer">https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance<span class="externalIcon"></span></a>. Accessed January 31, 2024.</li><li>Food and Drug Administration. Antibody (serology) testing for COVID-19: information for patients and consumers. 2023. Available at: <a href="https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers" target="_blank" rel="noopener noreferrer">https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers<span class="externalIcon"></span></a>. Accessed January 31, 2024.</li><li>Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. <em>N Engl J Med</em>. 2020;383(26):2586-2588. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33259154" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33259154<span class="externalIcon"></span></a>.</li><li>Tarhini H, Recoing A, Bridier-Nahmias A, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. <em>J Infect Dis</em>. 2021;223(9):1522-1527. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33556961" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33556961<span class="externalIcon"></span></a>.</li><li>Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. <em>Gastroenterology</em>. 2020;159(1):350-357. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32283100" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32283100<span class="externalIcon"></span></a>.</li><li>Curtis JR, Zhou X, Rubin DT, et al. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. <em>J Rheumatol</em>. 2022;49(3):320-329. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/34782447" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34782447<span class="externalIcon"></span></a>.</li><li>Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. <em>JAMA Netw Open</em>. 2021;4(10):e2129639. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/34661663" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34661663<span class="externalIcon"></span></a>.</li><li>American Society of Transplantation. COVID-19: FAQs for organ transplantation. 2023. Available at: <a href="https://www.myast.org/faqs-organ-transplantation" target="_blank" rel="noopener noreferrer">https://www.myast.org/faqs-organ-transplantation<span class="externalIcon"></span></a>. Accessed February 2, 2024.</li><li>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. <em>N Engl J Med</em>. 2022;386(15):1397-1408. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/35172054" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/35172054<span class="externalIcon"></span></a>.</li><li>Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. <em>Clin Infect Dis</em>. 2023;76(3):e342-e349. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/35653428" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/35653428<span class="externalIcon"></span></a>.</li><li>Qian G, Wang X, Patel NJ, et al. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. <em>Lancet Rheumatol</em>. 2023;5(3):e139-e150. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/36844970" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/36844970<span class="externalIcon"></span></a>.</li><li>Dormuth CR, Kim JD, Fisher A, Piszczek J, Kuo IF. Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications. <em>JAMA Netw Open</em>. 2023;6(10):e2336678. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37782496" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37782496<span class="externalIcon"></span></a>.</li><li>University Health Network. Management of nirmatrelvir/ritonavir (Paxlovid) drug-drug interactions in oncology. 2022. Available at: <a href="https://hivclinic.ca/wp-content/uploads/2023/12/Oncology-Related-Paxlovid-Drug-Interactions.pdf" target="_blank" rel="noopener noreferrer">https://hivclinic.ca/wp-content/uploads/2023/12/Oncology-Related-Paxlovid-Drug-Interactions.pdf<span class="externalIcon"></span></a>.</li><li>Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. <em>N Engl J Med</em>. 2022;387(11):1045-1047. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36069968" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36069968<span class="externalIcon"></span></a>.</li><li>Ritonavir-boosted nirmatrelvir (Paxlovid) [package insert]. Food and Drug Administration. 2023. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf<span class="externalIcon"></span></a>.</li><li>Anderson AS, Caubel P, Rusnak JM, EPIC-HR Trial Investigators. Nirmatrelvir-ritonavir and viral load rebound in COVID-19. <em>N Engl J Med</em>. 2022;387(11):1047-1049. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36069818" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36069818<span class="externalIcon"></span></a>.</li><li>Boucau J, Uddin R, Marino C, et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19). <em>Clin Infect Dis</em>. 2023;76(3):e526-e529. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35737946" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35737946<span class="externalIcon"></span></a>.</li><li>Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio (molnupiravir) capsules. 2023. Available at: <a href="https://www.fda.gov/media/155054/download" target="_blank" rel="noopener noreferrer">https://www.fda.gov/media/155054/download<span class="externalIcon"></span></a>.</li><li>Deo R, Choudhary MC, Moser C, et al. Symptom and viral rebound in untreated SARS-CoV-2 infection. <em>Ann Intern Med</em>. 2023;176(3):348-354. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/36802755" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/36802755<span class="externalIcon"></span></a>.</li><li>Edelstein GE, Boucau J, Uddin R, et al. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study. <em>Ann Intern Med</em>. 2023;176(12):1577-1585. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/37956428" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/37956428<span class="externalIcon"></span></a>.</li><li>Smith-Jeffcoat SE, Biddle JE, Talbot HK, et al. Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals. <em>Clin Infect Dis</em>. 2023;Published online ahead of print. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/37963102" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/37963102<span class="externalIcon"></span></a>.</li><li>Smith DJ, Lambrou A, Patel P. SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals. <em>MMWR Morb Mortal Wkly Rep</em>. 2023;72(51):1357-1364. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/38127665" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/38127665<span class="externalIcon"></span></a>.</li><li>Harrington PR, Cong J, Troy SB, et al. Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir/ritonavir treatment in randomized, double-blind, placebo-controlled trials&mdash;United States and international sites, 2021&ndash;2022. <em>MMWR Morb Mortal Wkly Rep</em>. 2023;72(51):1365-1370. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/38127674" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/38127674<span class="externalIcon"></span></a>.</li><li>Soares H, Baniecki ML, Cardin R, et al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. <em>Res Sq</em>. 2022;Preprint. Available at: <a href="https://www.researchsquare.com/article/rs-1720472/v1" target="_blank" rel="noopener noreferrer">https://www.researchsquare.com/article/rs-1720472/v1<span class="externalIcon"></span></a>.</li><li>Ranganath N, O&rsquo;Horo JC, Challener DW, et al. Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons. <em>Clin Infect Dis</em>. 2023;76(3):e537-e539. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35698452" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35698452<span class="externalIcon"></span></a>.</li><li>Centers for Disease Control and Prevention. COVID-19 rebound after Paxlovid treatment. 2022. Available at: <a href="https://emergency.cdc.gov/han/2022/han00467.asp" target="_blank" rel="noopener noreferrer">https://emergency.cdc.gov/han/2022/han00467.asp<span class="externalIcon"></span></a>. Accessed January 26, 2024.</li><li>Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. <em>N Engl J Med</em>. 2022;386(4):305-315. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34937145" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34937145<span class="externalIcon"></span></a>.</li><li>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. <em>N Engl J Med</em>. 2022;386(6):509-520. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34914868" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34914868<span class="externalIcon"></span></a>.</li><li>Johnson MG, Strizki JM, Brown ML, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the Phase 3 randomized, placebo-controlled MOVe-OUT trial. <em>Infection</em>. 2023;51(5):1273-1284. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36648627" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36648627<span class="externalIcon"></span></a>.</li><li>Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. <em>Lancet. </em>2023;401(10373):281-293. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36566761" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36566761<span class="externalIcon"></span></a>.</li><li>Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. Available at: <a href="https://www.fda.gov/media/141478/download" target="_blank" rel="noopener noreferrer">https://www.fda.gov/media/141478/download<span class="externalIcon"></span></a>.</li><li>Libster R, P&eacute;rez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. <em>N Engl J Med</em>. 2021;384(7):610-618. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33406353" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33406353<span class="externalIcon"></span></a>.</li><li>Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. <em>N Engl J Med</em>. 2021;385(21):1951-1960. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34407339" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34407339<span class="externalIcon"></span></a>.</li><li>Alemany A, Millat-Martinez P, Corbacho-Monn&eacute; M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. <em>Lancet Respir Med</em>. 2022;10(3):278-288. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35150610" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35150610<span class="externalIcon"></span></a>.</li><li>Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for COVID-19 with convalescent plasma. <em>N Engl J Med</em>. 2022;386(18):1700-1711. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35353960" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35353960<span class="externalIcon"></span></a>.</li><li>Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. <em>J Infect Dis</em>. 2020;222(7):1103-1107. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32702095" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32702095<span class="externalIcon"></span></a>.</li><li>Gandhi S, Klein J, Robertson AJ, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. <em>Nat Commun</em>. 2022;13(1):1547. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35301314" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35301314<span class="externalIcon"></span></a>.</li><li>Mozaffari E, Chandak A, Gottlieb RL, et al. Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice. <em>Clin Infect Dis</em>. 2023;77(12):1626-1634. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37556727" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37556727<span class="externalIcon"></span></a>.</li><li>RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. <em>N Engl J Med</em>. 2021;384(8):693-704. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32678530" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32678530<span class="externalIcon"></span></a>.</li><li>Crothers K, DeFaccio R, Tate J, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. <em>Eur Respir J</em>. 2022;60(1):2102532. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34824060" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34824060<span class="externalIcon"></span></a>.</li><li>Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled Phase 3 trial. <em>Lancet Respir Med</em>. 2021;9(12):1407-1418. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34480861" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34480861<span class="externalIcon"></span></a>.</li><li>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. <em>N Engl J Med</em>. 2021;384(9):795-807. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33306283" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33306283<span class="externalIcon"></span></a>.</li><li>RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <em>Lancet. </em>2021;397(10285):1637-1645. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33933206" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33933206<span class="externalIcon"></span></a>.</li><li>O&rsquo;Halloran JA, Ko ER, Anstrom KJ, et al. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial. <em>JAMA.</em> 2023;330(4):328-339. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37428480" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37428480<span class="externalIcon"></span></a>.</li><li>RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <em>Lancet. </em>2021;397(10289):2049-2059. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34000257" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34000257<span class="externalIcon"></span></a>.</li><li>B&eacute;gin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <em>Nat Med</em>. 2021;27(11):2012-2024. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34504336" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34504336<span class="externalIcon"></span></a>.</li><li>Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. <em>JAMA.</em> 2021;326(17):1690-1702. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34606578" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34606578<span class="externalIcon"></span></a>.</li><li>Denkinger CM, Janssen M, Sch&auml;kel U, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. <em>Nat Cancer</em>. 2023;4(1):96-107. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/36581734" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/36581734<span class="externalIcon"></span></a>.</li><li>Lacombe K, Hueso T, Porcher R, et al. Use of COVID-19 convalescent plasma to treat patients admitted to hospital for COVID-19 with or without underlying immunodeficiency: open label, randomised clinical trial. <em>BMJ Med</em>. 2023;2(1):e000427. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37920150" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37920150<span class="externalIcon"></span></a>.</li><li>Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. <em>JAMA Oncol</em>. 2021;7(8):1167-1175. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34137799" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34137799<span class="externalIcon"></span></a>.</li><li>Lanza F, Monaco F, Ciceri F, et al. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: an Italian retrospective study. <em>Hematol Oncol</em>. 2022;40(5):857-863. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35932208" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35932208<span class="externalIcon"></span></a>.</li><li>Lang-Meli J, Fuchs J, Math&eacute; P, et al. Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency. <em>J Clin Immunol</em>. 2022;42(2):253-265. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34893946" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34893946<span class="externalIcon"></span></a>.</li><li>Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. <em>Lancet Microbe</em>. 2021;2(4):e138. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33817676" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/33817676<span class="externalIcon"></span></a>.</li><li>Franchini M, Focosi D, Percivalle E, et al. Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients. <em>Viruses</em>. 2022;14(7):1443. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35891421" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35891421<span class="externalIcon"></span></a>.</li><li>Ljungquist O, Lundgren M, Iliachenko E, et al. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. <em>Infect Dis (Lond)</em>. 2022;54(4):283-291. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34878955" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34878955<span class="externalIcon"></span></a>.</li><li>Ripoll JG, Gorman EK, Juskewitch JE, et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. <em>Blood Adv</em>. 2022;6(23):5951-5955. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36156121" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36156121<span class="externalIcon"></span></a>.</li><li>Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. <em>Transfusion</em>. 2021;61(8):2503-2511. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34036587" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/34036587<span class="externalIcon"></span></a>.</li><li>Beraud M, Goodhue Meyer E, Lozano M, et al. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. <em>Transfus Apher Sci</em>. 2022;61(3):103355. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35063360" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/35063360<span class="externalIcon"></span></a>.</li><li>Huygens S, Gharbharan A, Serroukh Y, et al. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients. <em>J Antimicrob Chemother</em>. 2023;78(7):1644-1648. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/37248664" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/37248664<span class="externalIcon"></span></a>.</li><li>Brosh-Nissimov T, Ma&rsquo;aravi N, Leshin-Carmel D, et al. Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmatrelvir/ritonavir and tixagevimab/cilgavimab. <em>J Microbiol Immunol Infect</em>. 2024;57(1):189-194. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37805361" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37805361<span class="externalIcon"></span></a>.</li><li>Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients. <em>Clin Infect Dis</em>. 2023;77(2):280-286. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36976301" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36976301<span class="externalIcon"></span></a>.</li><li>Graziani L, Gori L, Manciulli T, et al. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19. <em>J Antimicrob Chemother</em>. 2023;78(2):555-558. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36544352" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36544352<span class="externalIcon"></span></a>.</li><li>Trottier CA, Wong B, Kohli R, et al. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. <em>Clin Infect Dis</em>. 2023;76(5):923-925. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/36281907" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/36281907<span class="externalIcon"></span></a>.</li><li>Focosi D, Maggi F, D&rsquo;Abramo A, Nicastri E, Sullivan DJ. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients. <em>Int <em>J Infect Dis</em></em>. 2023;137:55-59. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/37778409" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/37778409<span class="externalIcon"></span></a>.</li><li>Snell LB, McGreal-Bellone A, Nye C, et al. A multinational case series describing successful treatment of persistent severe acute respiratory syndrome coronavirus 2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir. <em>Open Forum Infect Dis</em>. 2024;11(1):ofad612. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/38269048" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/38269048<span class="externalIcon"></span></a>.</li><li>Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects on ritonavir: implications for drug interactions. <em>Ann Pharmacother</em>. 2008;42(7):1048-1059. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/18577765" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/18577765<span class="externalIcon"></span></a>.</li><li>Stader F, Khoo S, Stoeckle M, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <em>J Antimicrob Chemother</em>. 2020;75(10):3084-3086. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32556272" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32556272<span class="externalIcon"></span></a>.</li><li>Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status&mdash;United States, January 22&ndash;October 3, 2020. <em>MMWR Morb Mortal Wkly Rep</em>. 2020;69(44):1641-1647. Available at: <a href="https://pubmed.ncbi.nlm.nih.gov/33151921" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/33151921<span class="externalIcon"></span></a>.</li><li>Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status&mdash;United States, January 22&ndash;June 7, 2020. <em>MMWR Morb Mortal Wkly Rep</em>. 2020;69(25):769-775. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32584795" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32584795<span class="externalIcon"></span></a>.</li><li>Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. <em>BMJ. </em>2020;370:m3320. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32873575" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/32873575<span class="externalIcon"></span></a>.</li><li>Denney JM, Nelson EL, Wadhwa PD, et al. Longitudinal modulation of immune system cytokine profile during pregnancy. <em>Cytokine</em>. 2011;53(2):170-177. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21123081" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/21123081<span class="externalIcon"></span></a>.</li><li>Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. <em>N Engl J Med</em>. 2014;370(23):2211-2218. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/24897084" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/24897084<span class="externalIcon"></span></a>.</li><li>Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. <em>Am J Obstet Gynecol</em>. 2011;205(1):10-18. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21345415" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/21345415<span class="externalIcon"></span></a>.</li><li>Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. <em>JAMA.</em> 2010;303(15):1517-1525. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/20407061" target="_blank" rel="noopener noreferrer">https://www.ncbi.nlm.nih.gov/pubmed/20407061<span class="externalIcon"></span></a>.</li><li>Centers for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding. 2023. Available at: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html" target="_blank" rel="noopener noreferrer">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html<span class="externalIcon"></span></a>. Accessed January 31, 2024.</li><li>American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric-gynecologic care. 2023. Available at: <a href="https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care" target="_blank" rel="noopener noreferrer">https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care<span class="externalIcon"></span></a>. Accessed January 31, 2024.</li></ol><div></div></div></div><div role="complementary" aria-label="complementary mobile"><div class="sidebar-card-mobile"><p class="sidebar-title">Guideline PDFs</p><ul class="guideline-pdf-list"><li><a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_188.pdf" target="_blank" rel="noopener noreferrer">Section Only (PDF | 358 KB)</a></li><li><a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf" target="_blank" rel="noopener noreferrer">Full Guideline (PDF | 6.1 MB)</a></li></ul></div><div class="sidebar-card-mobile"><p class="sidebar-title">Sign Up For Updates</p><form target="_blank" rel="noopener noreferrer" id="GD-snippet-form-mobile" action="https://public.govdelivery.com/accounts/USNIAID/subscribers/qualify" method="post"><input name="utf8" type="hidden" value=""/><input type="hidden" name="authenticity_token" value="OjXVX/6YDyUq8jApBckhDuTl8VOop5nwtQbjpYurqwPzbOWtoF4v95KuPAQVnoV6u9wEJ9anQI2yanp+GKt17w=="/><input type="hidden" name="topic_id" id="topic_id_mobile" value="USNIAID_182"/><fieldset><label for="mobile_email" class="sidebar-label">Email Address *</label><input type="email" autoComplete="off" name="emailaddress" id="mobile_email" class="long sidebar-input" placeholder="example@domain.com" required=""/><div class="button_panel"><button type="submit" name="commit" class="sr-button reverse sidebar-submit-button submit-button"><span class="sidebar-submit-button-text">Submit<span class="externalIcon"></span></span></button></div></fieldset></form></div><div class="sidebar-card-mobile"><p class="sidebar-title">Related Content</p><ul class="archive-list"><li><a href="/about-the-guidelines/guidelines-archive/">Guidelines Archive</a></li><li><a href="/how-to-cite/">How to Cite These Guidelines</a></li></ul></div></div></main></div></div></div></div></div><footer class="footer-links"><div class="container-fluid footer-block-top"><div class="footer-top container-md"><div class="row"><div class="col-lg-1 align-self-center bottom-coloumn-logo"><span class="img-btm-logo"><a rel="noopener noreferrer" target="_blank" href="https://www.nih.gov/" id="anch_nlf"><img src="data:image/png;base64,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" alt="NIH logo" width="60" height="42" class="nih-logo-footer"/></a></span></div><div class="col-lg-11 bottom-col-texturl"><div class="col-xs-12"><span class="footer-site-url">www.covid19treatmentguidelines.nih.gov</span></div><div class="col-xs-12"><span class="footer-official">An official website of the <a class="footer-official-link" rel="noopener noreferrer" target="_blank" id="anch_nih_icon" href="https://www.nih.gov/">National Institutes of Health<span class="externalIcon"></span></a></span></div></div></div></div></div><div class="container-fluid footer-block"><div class="footer-bottom container-md  pr-lg-0"><div class="row"><div class="col-lg-3 pr-lg-0"><ol><li><a href="https://www.nih.gov/about-nih" rel="noopener noreferrer" target="_blank" id="anch_an">About NIH<span class="externalIcon"></span></a></li><li><a rel="noopener noreferrer" target="_blank" href="https://dpcpsi.nih.gov/oepr/performance_reporting" id="anch_npr">NIH Performance Reporting<span class="externalIcon"></span></a></li></ol></div><div class="col-lg-3 p-lg-0"><ol><li><a rel="noopener noreferrer" target="_blank" id="anch_fia" href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office">Freedom of Information Act<span class="externalIcon"></span></a></li><li><a rel="noopener noreferrer" target="_blank" id="anch_wpn" href="https://www.nih.gov/web-policies-notices">Web Policies and Notices<span class="externalIcon"></span></a></li></ol></div><div class="col-lg-3 p-lg-0"><ol><li><a rel="noopener noreferrer" target="_blank" id="anch_nfad" href="https://www.edi.nih.gov/no-fear-act">No FEAR Act Data<span class="externalIcon"></span></a></li><li><a rel="noopener noreferrer" target="_blank" id="anch_vdp" class="line-height-lg-22" href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">Vulnerability Disclosure Policy<span class="externalIcon"></span></a></li></ol></div><div class="col-lg p-lg-0"><ol><li><a href="https://oig.hhs.gov/" rel="noopener noreferrer" target="_blank" id="anch_oig">Office of Inspector General<span class="externalIcon"></span></a></li></ol></div><div class="col-lg-1 pl-lg-0 ml-lg-auto col-twitter_icon"><a rel="noopener noreferrer" target="_blank" id="anch_tb" class="btn twitter-button footer-twitter-btn" href="https://twitter.com/NIHCOVIDTxGuide?ref_src=twsrc%5Etfw"><span class="sr-only twitter-color">Twitter button</span></a></div></div><div class="row"><div class="col"><ol class="footer-date-list"><li>Looking for U.S. government information and services? </li><li><a rel="noopener noreferrer" target="_blank" id="anch_vug" href="https://USA.gov">Visit USA.gov<span class="externalIcon"></span></a></li><li>Site Updated: <!-- -->February 29, 2024</li></ol></div></div></div></div></footer><nav id="backtoTop" aria-label="Back to top"><button id="scroll_Top"><span id="div_arrow"></span><span id="div_bk">Back </span><span id="div_totop">to Top</span><span id="div_spacer"></span></button></nav></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/special-populations/immunocompromised/";/*]]>*/</script><!-- slice-start id="_gatsby-scripts-1" -->
          <script
            id="gatsby-chunk-mapping"
          >
            window.___chunkMapping="{\"app\":[\"/app-2da9c4018e55146e3f78.js\"],\"component---src-pages-404-js\":[\"/component---src-pages-404-js-bd2c75bf17a05a17c249.js\"],\"component---src-pages-about-the-guidelines-guidelines-archive-js\":[\"/component---src-pages-about-the-guidelines-guidelines-archive-js-c9dddfb52fa889140da3.js\"],\"component---src-pages-index-js\":[\"/component---src-pages-index-js-8e7fc8a2b0f75f2cc1ae.js\"],\"component---src-pages-search-js\":[\"/component---src-pages-search-js-82b37fdb7657f4b562b4.js\"],\"component---src-templates-custom-page-template-js\":[\"/component---src-templates-custom-page-template-js-b7c58302b60ab8f79806.js\"],\"component---src-templates-landing-page-template-js\":[\"/component---src-templates-landing-page-template-js-d0ada70567429d3851d8.js\"],\"component---src-templates-long-table-template-js\":[\"/component---src-templates-long-table-template-js-f117d613ec87d53ed755.js\"],\"component---src-templates-sidebar-main-template-js\":[\"/component---src-templates-sidebar-main-template-js-62cb52148e95b228c965.js\"]}";
          </script>
        <script>window.___webpackCompilationHash="dbe9da7b06581a82964a";</script><script src="/webpack-runtime-48cddce817eea0e085c9.js" async></script><script src="/framework-0db1d830d9ffcea4e65a.js" async></script><script src="/app-2da9c4018e55146e3f78.js" async></script><!-- slice-end id="_gatsby-scripts-1" --></body></html> contentType 9 text/html url 89 https://www.covid19treatmentguidelines.nih.gov:443/special-populations/immunocompromised/ responseCode 3 200 